Dual pH- and temperature-responsive magnetic nanocomposite for controlled drug delivery by Eslami, Parisa et al.
 
 
 Tesi di Dottorato in 
Scienze ed Ingegneria 
dei Materiali 
Ciclo XXXI                    
 
 
Dual pH and Temperature Responsive Magnetic 














DOTTORATO DI RICERCA IN 
INGEGNERIA INDUSTRIALE 





















Dual pH and temperature responsive magnetic 
nanocomposite for controlled drug delivery  
 
Dottorando 






















© Università degli Studi di Firenze – Faculty of Engineering Via di Santa Marta, 3, 50139 
Firenze, Italy 
 
Tutti i diritti riservati. Nessuna parte del testo può essere riprodotta o trasmessa in qualsiasi forma 
o con qualsiasi mezzo, elettronico o meccanico, incluso le fotocopie, la trasmissione fac-simile, la 
registrazione, il riadattamento o l’uso di qualsiasi sistema di immagazzinamento e recupero di 
informazioni, senza il permesso scritto dell’ editore . 
 
All rights reserved. No part of the publication may be reproduced in any form by print, 
















To my grandfather’s memory and beloved family for always supporting, 









“We must have perseverance and above all confidence in ourselves. We must 
believe that we are gifted for something and that this thing must be 










First and foremost, I have to express my heartful thanks to my inspiring parents and my 
brother for their love, endless support, and sacrifices. Their dedicated partnership 
encouraged me to achieve my goals. 
I would like to thank the director of Ce.Ri.Col (Research Center of Colorobbia 
Consulting S.r.l.), Dr. Giovanni Baldi, for the privilege of starting my research career; he 
gave me the great opportunity to gain invaluable experience in Materials Science & 
Nanotechnology. Under his guidance, I was given the freedom to pursue my research in 
my own way, and I greatly appreciate him for supporting and encouraging me through 
these years.  
I would like to express my deep appreciation to my supervisors, Prof. Andrea Caneschi 
and Dr. Claudio Sangregorio, for helpful discussions, valuable suggestions, their support 
during travels for conferences and hard work. I also would like to express extreme 
gratitude to Prof. Federica Chiellini and Dr. Andrea Morelli, who introduced me to the 
world of thermoresponsive polymers and broadened my research interests to this 
scientific field. They are gratefully acknowledged for helpful discussions during my PhD 
thesis work, interesting collaborations, and pleasant time. 
I am also appreciative of all the help from colleagues in our research group at Colorobbia, 
Dr. Saer Doumett, Dr. Costanza Ravagli, Luca Antonini, Laura Cappiello, Giada Lorenzi, 
Dr. Riccardo Rapini, Dr. Stefano Fedeli, Valentina Dami, Marco Trassinelli, Lucrezia 
Ballerini, and Andrea Cioni. In addition, I sincerely thank my friends in University of 
Florence: Dr. Andrea Guerrini, Dr. Michele Petrecca, Dr. Martin Albino, Dr. Claudia 
Innocenti, and Donella Rovai that helped me to carry out my thesis successfully. 
I am also grateful of the financial support provided by the Colorobbia Consulting S.r.l and 












Nanomedicine & Biomedical Application of Magnetic Nanoparticles..………………...9 
2.1. Superparamagnetic behavior......................................................................................9 
2.2. Basic principles of application of MNPs as heat mediators in magnetic 
hyperthermia………………………………………………………………………………..12 
2.2.1. Measurement of magnetic hyperthermia efficiency by a calorimetric 
method………………………………………………………………………………….14 
2.2.2. Dependence of magnetic hyperthermia efficiency on morpho-structural 
properties………………………………………………………………………………15 
2.2.3. Size dependence of the magnetic hyperthermia efficiency of superparamagnetic 
nanoparticles………………………………………………………………………….16 
2.2.4. Effect of shape anisotropy on magnetic hyperthermia 
efficiency……………………………………………………………….………………16 
2.2.5. Magnetic dipolar interactions: effect of nanochain and nanocluster formation 
on magnetic hyperthermia efficiency………………………………………………17 
2.3. Nanomedicine approach for cancer treatments………………………………………..18 
2.4. Superparamagnetic nanoparticles for biomedical application………………………19 
2.5. Magnetic nanoparticle stability…………………………………………………………..21 
2.5.1. Colloidal stability of iron oxide MNPs…………………………………………….21 
2.5.2. Shape, size, and size distribution…………………………………………………...21 
2.6. Nanoparticle delivery to the tumour site………………………………………………..22 
2.7. Magnetic hyperthermia……………………………………………………………………24 
2.8. Magnetic nanosystems for thermo-chemotherapy……………………………………..25 
2.9. Controlled drug delivery system…………………………………………………………26 
2.9.1. pH responsive polymer………………………………………………………………27 
2.9.2. Temperature responsive polymer…………………………………………………..29 
2.9.3. Thermoresponsive polymers based on poly N-vinylcaprolactam………………31 







Synthesis and Characterization of Magnetic Nanoparticles for Biomedical 
Application……………………………………………………………………………….44 
3.1. Iron oxides crystallographic structure (Fe3O4)………………………………………...45 
3.2. Preparation of magnetic nanoparticles………………………………………………….46 
3.3. Synthesis and characterization of Fe3O4-68 by polyol 
method……………………………………………………………………………………….48 
3.4. Magnetic measurement of Fe3O4-68 by SQUID………………………………………..52 
3.5. Magnetic heating capacity of Fe3O4-68…………………………………………………53 
References………………………………………………………………………………………….59 
Chapter 4 
Synthesis and Characterization of Poly (N-Vinylcaprolactam)-Based (Co)-
Polymers………………………………………………………………………………….61 
4.1. Living polymerization……………………………………………………………………...61 
4.2. Free radical polymerization………………………………………………………………62 
4.3. Synthesis of well-defined PVCL-based (co) polymers by controlled radical 
polymerization………………………………………………………………………………62 
4.4. RAFT polymerization and macromolecular design via the interchange of xanthates 
(MADIX) of NVCL………………………………………………………………………….63 
4.5. RAFT polymerization of PVCL and characterization…………………………………69 
4.6. RAFT polymerization and characterization of PVCL-b-PVPON……………………76 
4.7. Synthesis of poly(N-vinylcaprolactam)-b-poly(acrylic acid)…………………………84 
References………………………………………………………………………………………….96 
Chapter 5 
Encapsulation of Magnetic Nanoparticles by Thermoresponsive 
Polymers………………………………………………………………………………...100 
5.1. Modification of MNPs……………………………………………………………………101 
5.1.1. Anchoring of ligand with specific functional group…………………………….101 
5.1.2. Stabilization of MNPs using polymer chains…………………………………….102 





5.1.4. Stabilization of iron oxide MNPs using monofunctional polymer chains via 
exchange chemistry………………………………………………………………….104 
5.1.5. Stabilization of iron oxide MNPs using functional diblock polymers………...104 
5.2. Encapsulation of magnetic nanoparticles by poly N-vinylcaprolactam by post 
modification method……………………………………………………………………...105 
5.3. Encapsulation of magnetic nanoparticles by poly vinylcaprolactam-b-
vinylpyrrolidone by post modification method………………………………………..107 
5.4. Functionalization of Fe3O4-68 by in situ copolymerization of PVCL-b-PAA…….111 




Drug Loading & Drug Release………………………………………….………….….124 
6.1. Drug loading………………………………………………………………………………124 
6.2. Dual pH- and temperature-dependent in vitro drug release in the absence of 
AMF………..……………………………………………………………………………….126 
6.3. Drug release under the application of an AMF………………………………………129 
6.4. A smart hyperthermia with switchable drug release…………………………………131 
6.5. Cytotoxicity study...................................................................................................132 
References.......................................................................................................................135 
Chapter 7 
Conclusions and Perspectives………………………………………………………….136 
Appendix A 











Magnetic nanoparticles (MNPs) have emerged as promising nanomaterials for their 
potential use in biomedical applications such as magnetic resonance imaging (MRI) [1–3], 
cell separation [4,5], magnetic hyperthermia [6–8], and drug delivery [9-11]. Iron oxide 
MNPs have been greatly investigated for clinical trial due to their good biocompatibility, low 
toxicity, heat generation ability, and high chemical stability. In fact, MNPs are suitable for 
hyperthermia cancer treatment as a consequence of their heat generation potential under 
applying alternating magnetic field. Hyperthermia is known as a treatment where tumours are 
heated to temperatures between 40 

C and 45 

C [12] causing cancer cells to undergo 
apoptosis [13], while normal tissues are still alive as they are less sensitive to heat [14]. 
Hyperthermia therapy is also used as an auxiliary method to augment efficiency of standard 
cancer treatments such as chemotherapy or radiotherapy.  
Chemotherapy is a widely used treatment for cancer. However, the major drawback of 
chemotherapy is the non-specificity of the anticancer drugs, which may cause strong damage 
of healthy organs and cells during the therapy. Nanocarrier-based drug delivery system is a 
possible strategy that may improve therapeutic efficacy of chemotherapeutic agents and 
decreases their side effects in clinical trial. One of the major advantages of using 
nanoparticles (NPs) as drug carrier, especially MNPs, over conventional chemotherapy is that 
nanoparticles have possibility of targeting specific locations in the body, allowing the 
reduction of the chemotherapeutic dose to reach the concentrations needed in the tumour for 
an effective therapy. In addition, the concentration of drugs at non-targeted sites is reduced, 
minimizing undesirable side effects of chemotherapy [15].  
The advantages provided by the synergistic effect of the combined thermo-
chemotherapy by combining highly efficient magnetic hyperthermia with magnetothermally-
controlled drug release, make MNPs-based therapeutic agents a really promising candidate 
for the treatment of cancer; in fact, increased anti-cancer drug accumulation in tumour and 
thermal enhancement of drug cytotoxicity are among the most important mechanisms behind 
the synergistic effect of thermo-chemotherapy [16,17]. These are mainly caused by the 
improved intracellular uptake of drugs due to enhanced cell membrane permeability, 





acceleration of the cytotoxic chemical reaction. However, controlled drug release is still 
challenging, and there is an evident need to solve this issue particularly as concerns the 
control of the release rate. Indeed, the delivery of a drug is often problematic because the 
concentration of the released drug at the target area is either too low or too high and there is 
no possibility to control the delivery over time. Although the desirable-controlled drug 
release is not easily achievable, smart organic-inorganic nanohybrids have been proposed to 
provide multi-stimuli responsive platforms, which are able to optimize the efficiency of 
nanocarrier-based drug delivery system by allowing delivery and release of the drug at the 
right time and concentration by activation through external or internal stimuli such as 
temperature and pH. Among the many approaches proposed in the literature, particularly 
appealing method is the possibility to exploit the thermoresponsive drug nanocarriers, 
composed of a temperature-responsive polymer shell and a MNPs core to promote the 
effective controlled drug release only by response to an external AMF thanks to the heat 
generation ability of MNPs. To fulfil this aim the drug nanocarriers should ideally retain their 
load at body temperature (~ 37 °C), and release the drug within a locally heated tumour at the 
therapeutic temperature for magnetic hyperthermia (42.5 

C −46 °C) [18]. In this manner, the 
localized heat generated by the MNPs under AMF excitation can significantly raise the 
temperature of the thermoresponsive polymer shell above its critical solution temperature 
(CST), around which a sudden demixing from aqueous solutions occurs, leading the polymer 
to exhibit conformational transformation in response to change in temperature for remote-
controlled drug release. 
pH-responsive polymers can also be exploited for drug delivery applications because 
of the pH changes between healthy and tumour tissues. The pH in the tumour environment is, 
in fact, often more acidic than one that in the blood or healthy tissue. Therefore, if pH-
sensitive drug delivery systems target the tumour site, they can then release their payload due 
to the pH difference [19].  
The use of polymer sequences owning sensitivity to more than one stimulus such as 
pH and temperature can have even more advantages over one stimulus responsive polymers 
for regulating drug release since they can respond to a combination of external stimuli, which 
provides unique opportunities to advance medicine especially in controlled drug delivery 
strategies. An interesting example of this approach is represented by double pH- and 
temperature responsive polymer coated MNPs, which can release drug in a controlled way by 





endosome/lysosome microenvironments or either through the hyperthermia of 
superparamagnetic core of these nanocomposites under exposure of an external AC magnetic 
field (AMF) that can serve as the “trigger” to control the “on–off” of the thermo-sensitive 
polymer shell, which is capable of drug release in a controlled manner; thus, pH and 
temperature variations can simultaneously boost the drug release on tumour tissues, 
improving the efficacy of the therapy. 
The aim of this thesis is the development of a nanoencapsulation technology to 
produce highly effective smart multifunctional nanocomposites that have potential to be 
exploited as a multi-functional therapeutic agent for drug delivery and controlled drug release 
in combination with localized hyperthermia. To accomplish this ambitious goal, the thesis 
involves synthesis and characterization of smart nanohybrids made up of a 
superparamagnetic iron oxide core and a dual pH and temperature-responsive                               
poly (N-vinylcaprolactam-b-acrylic acid) shell, which are subsequently loaded with an 
anticancer drug, Doxorubicin. In fact, this dual stimuli-responsive magnetic nanocomposite 
offers spatial and temporal control over the release of the anticancer drug, which is triggered 
as a consequence of hyperthermia and tumour acidic pH at desired time without degradation 
or premature drug release, to enhance the effectiveness of the treatment. Moreover, the 
evaluation of this novel smart nanocomposite efficacy on selected pathological models in 
vitro is evaluated. To achieve this aim, the in vitro drug release of the drug-conjugated Fe3O4 
MNPs coated with the stimuli responsive polymer is investigated at physiological pH (7.4) 
and acidic pH (4.5-5.5, similar to the one found in tumour environment) under exposure to 
AMF at predetermined time interval, and the concentration of released drug is quantified 
using UV-VIS spectrophotometer. Finally, cytotoxic property of smart nanohybrids after and 
before drug loading is determined by incubation of magnetic nanohybrids on melanoma cell 
for 24 h at body temperature since nontoxicity of any material considered for therapeutic 
application is imperative. 
In order to grant for a multifunctional approach, it is essential to obtain MNPs with 
optimal heating characteristics that allow the clinical trials of hyperthermia technology in a 
safe manner, while being effective in cancer treatment. That means, MNPs that have potential 
to generate a large quantity of heat and thus a higher Spesific Absorption Rate (SAR) at their 
minimum concentration under low magnetic field amplitudes are clinically required. 
Therefore, engineering MNPs (control their physical and chemical properties using proper 
synthesis), which satisfy the above criteria, is highly desirable, and several synthetic 





and co-precipitation approaches are the most commonly synthetic methods used for MNPs 
preparation, we mainly focused on polyol synthetic procedure as this approach offers some 
advantages including: [20] (i) the high boiling point of polyol allows synthesis to proceed at 
relatively high temperature, ensuring that well crystallized materials are obtained, (ii) the 
reducing medium protects the as-prepared metal particles from oxidation as long as they 
remain in the medium, (iii) the ability of polyol to coordinate metal precursors as well as the 
particle surface, minimizing coalescence, (iv) the high viscosity of the medium favors a 
diffusion-controlled regime for particle growth [21], resulting in controlled structures and 
morphologies, (v) polyol process can be easily scaled up. Indeed, the polyol process was 
found to be particularly well-suited method as it can yield crystalline materials with a specific 
flower-like morphology i.e. aggregates of small NPs (10.0 nm or below in diameter) without 
subsequent thermal treatment, while allowing a fine control on particle size, shape and 
aggregate size. [20]. Importantly, flower-like MNPs show interesting magnetic behavior with 
extremely high heating power compared to isolated MNPs [22,23]. For instance, direct 
aggregation between 5.0 nm nanoparticles of manganese-doped magnetite (MnFe2O4) to form 
large spherical clusters of ca. 100.0 nm diameter was found to minimize the effect related to 
their characteristic magnetic dead layer at the surface. As a consequence, the clustering 
process provided nanostructures with high saturation magnetization (86 emu g
-1
) and very 
large specific absorption rate (SAR), which could be exploited for heat delivery [24]. 
In the following, pH and temperature responsive poly (N-vinylcaprolactam-b-acrylic 
acid) (PVCL-b-PAA) is prepared corresponding to free-radical polymerization by modifying 
some procedures previously reported in the literature for functionalization the surface of 
MNPs. In fact, poly N-vinylcaprolactam-based copolymers have been scarcely investigated 
for surface modification of MNPs, while the most of research being focused on poly 
isopropylacrylamide (PNIPAM). That is most probably because of the controlled radical 
polymerization of non-conjugated N-vinylcaprolactam monomers is inherently difficult; 
however, PVCL seems more promising biocompatible polymer as it has been shown to 
support higher cell viability and have lower cytotoxicity compared to PNIPAM. Importantly, 
the nitrogen atom in the caprolactam ring is directly connected to the chain backbone, so 
hydrolysis of PVCL if it occurs, will not produce a small toxic amide compound as PNIPAM 
does. This makes PVCL highly useful for biomedical applications including drug delivery 
and in vivo release systems [25]. Despite of the fact that synthesis of PVCL is challenging 
due to the high reactivity of vinyl monomers, and few works, in fact, have been done on 





smart polymer owing to the high biocompatibility, lower toxicity, and proper thermal 
sensitivity that PVCL shows respect to PNIPAM. Thanks to the presence of PAA blocks in 
copolymer backbone, the copolymer can be sensitive to pH as well. Moreover, the thermo-
responsive copolymer can be engineered so as to reveal reversible phase transition behavior 
at temperature above physiological temperature (~ 37
 
C) close to that which can be obtained 
by magnetic hyperthermia. In our case we perform for the first time surface modification of 
MNPs by this stimuli responsive PVCL-b-PAA polymer using a ’’grafting to’’ approach.  
To our knowledge, there is no previous work describing procedures for directly 
coating the magnetic nanoparticles using a temperature- and pH-sensitive poly                     
(N-vinylcaprolactam-b-acrylic acid) with a simple covalent ‘’grafting to’’ method. Previously 
published works [26–29], describing polymer-coated MNP, indeed, involve a polymerization 
step or covalent grafting reaction, which includes: (i) the use of initial reactants (monomers, 
initiators, catalysts, etc.), (ii) the need of an additional purification step to remove the non-
reacted reagents, (iii) longer preparation time and (iv) complex synthesis conditions (vacuum, 
inert atmosphere, high temperatures, etc.), i.e. a long list of issues, which can be overcome 
using the procedure developed in this work. In addition, we will show how one of the most 
challenging issues in drug delivery system, i.e. the long-time stability of colloidal suspension 
of NPs in aqueous media at physiological pH, can be solved by selecting this smart and 
biocompatible polymer.  
In the following, we will outline how with the proposed coating strategy, highly stable 
and monodisperse nanosystems with negative surface charge can be achieved, confirming 
strong adherence of polymer to the surface of the MNPs. Obtained results, in fact, 
demonstrated that we successfully fabricated nanosized drug delivery systems, which can be 
utilized as multimodal therapeutic agent in the tumour therapy by exploiting magnetic fluid 
hyperthermia and controlled drug release under exposure to AMF. 
Many magnetic nanoparticles-based drug delivery systems have been developed in the 
last decade. However, the major bottleneck for their clinical theranostic achievement has 
been the low drug loading capacity and poor controlled-drug release of the developed 
magnetic nanoparticles. Nevertheless, our nanocomposite exhibited exceptional drug loading 
capacity and controlled drug release triggered by the acidic tumour microenvironment in 





magnetic nanohybrids, which developed in this work as multifunctional nanocarriers, are able 
to have a dramatic impact in medicine and in the treatment of cancer. 
All the experimental work carried out to prepare and investigate this nanosystem is 
described in this thesis, which is organized as follows: 
Chapter 2 introduces drug delivery systems based on MNPs, strategies for their 
accumulation into cancer cells, and recent advances in cancer therapy. A brief summary of 
fundamental properties of MNPs and their potential for the combination of hyperthermia and 
chemotherapy are presented as well. Moreover, unique advantages of a double pH- and 
thermo-responsive magnetic nanohybrids drug carrier suitable for multi-modal cancer therapy 
by combining magnetic hyperthermia and controlled drug delivery are summarized. Chapter 
3 mainly focuses on synthesis and characterization of superparamagnetic iron oxide 
nanoparticles, prepared by polyol method; magnetic property and heat generation ability of 
MNPs are evaluated in terms of their potential application for hyperthermia performance in 
clinical trials. In Chapter 4 synthesis of temperature responsive (co)polymers based-PVCL 
with well-controlled molecular weights by applying sequential Reversible Addition 
Fragmentation Chain Transfer (RAFT) polymerization approach is discussed, and 
subsequently their temperature responsive behavior is evaluated. Development and 
characterization of a double pH- and thermo-responsive poly (N-vinylcaprolactam-b-acrylic 
acid) are reported as well. Chapter 5 is devoted to the encapsulation of superparamagnetic 
iron oxide nanoparticles by dual pH- and temperature responsive polymer to provide smart 
nanocomposite platform for triggered drug release. The effectiveness of surface modification 
approach is evaluated by employing some techniques including FT-IR, TEM, TG, and DLS 
analyses. Chapter 6 evaluates drug loading potential of stimuli responsive nanocomposite, 
and doxorubicin (DOX) as an anticancer drug is selected to explore drug delivery properties 
of this smart nanohybrids. Indeed, doxorubicin is a cationic chemotherapeutic drug with 
broad-spectrum antitumour activity that can be loaded on PVCL-b-PAA coated MNPs 
through electrostatic interactions. Moreover, the pH and temperature dependent drug release 
of DOX loaded on smart nanocomposite are assessed in the absence and presence of AFM. 
Finally, cytotoxicity of functionalized MNPs after and before drug loading is estimated as 
well. 
The final Chapter briefly summarizes the main conclusions obtained from the experimental 
work presented above and provides some hints about future work that needs to be done to 
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9 Nanomedicine & Biomedical Application of Magnetic Nanoparticles 
Chapter 2 
Since this thesis is focused on the fabrication and characterization of smart magnetic 
nanohybrids for magnetic hyperthermia therapy in conjunction with drug delivery, in this 
chapter the basic concepts relevant to physical behavior of superparamagnetic nanoparticles 
and, the importance of smart magnetic nanohybrids in nanomedicine are briefly overviewed. 
2.1 Superparamagnetic Behavior 
Among all types of nanoparticles, biocompatible superparamagnetic iron oxide 
nanoparticles with proper surface architecture and conjugated targeting ligands/proteins have 
attracted a great deal of attention for biomedical applications [1]. This is because their unique 
physical properties, among which superparamagnetism is undoubtedly the most notable one. 
Superparamagnetism is a form of magnetism that occurs in ferromagnetic or ferrimagnetic 
materials, when their size is lower than a critical size   , which varies between tens to few 
hundreds of nanometers, depending on the type of materials. The critical size    for a 
spherical particle can be estimated using the following equation (1) [2]. 
 
                                                               
    
 
 
                                      (1) 
  
where kB is the Boltzmann constant, T is the temperature, and K is the magnetic anisotropy 
constant, which is characteristic for each material. Depending on K, the critical size of 
nanoparticles can be 3–4 nm for very hard magnets and over ca. 130 nm for soft magnets 
including magnetite (Fe3O4) and maghemite (Fe2O3) [3]. 
Superparamagnetic nanoparticles are single-domain particles since the formation of 
magnetic domains is no longer energetically favoured, so they can be described by one giant 
magnetic moment, whose value equals the sum of all magnetic moments of the atoms 
forming the nanoparticles. The superparamagnetic behavior derives from the fact that a 
magnetic particle with size lower than dc prefers to be uniformly magnetized along one of its 
easy axes, the preferred crystallographic axes for the magnetic moment to point along, and 





10 Nanomedicine & Biomedical Application of Magnetic Nanoparticles 
magnetic anisotropy energy, which is related to the constant K. In a simple model for a non-
interacting single domain spherical particle with uniaxial anisotropy in zero magnetic field, 
the magnetic anisotropy energy, Ea, is given by equation (2) [4]. 
                                        Ea =KVSin
2
θ   (2) 
Where V is the volume of the particle and θ is the angle between the particle magnetization 
and the easy magnetization axis of the particle. According to equation (2), the magnetic 
anisotropy energy decreases when the volume of the particle becomes smaller. When Ea 
becomes comparable to or lower than the thermal energy (Ethermal = kBT) [5], the energy 
barrier for magnetization reversal can be thermally overcome (Figure 2.1), and the giant 
magnetic moment associated to the particle becomes free to fluctuate under the effect of 








Figure 2.1 Scheme representing the anisotropy energy barrier for magnetization [6] 
Superparamagnetism can be thus regarded as a thermally activated regime, which occurs 
above the so-called blocking temperature (TB), which is described by the equation (3),  
 
                    TB 
  
      
  
    
                          (3) 
   
where    is the measurement time, and    is the attempt time, which is typically 
approximated as 10
-9
 s for not interacting MNPs. Above TB, nanoparticles exhibit 
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magnetic moments, resulting in a zero averaged magnetization. Conversely, below TB the 
particles are in a blocked regime. That means, the magnetic moment has not the required 
energy to overcome the energy barrier, and thus magnetic irreversibility occurs (i.e. open 
hysteresis loop). The value of TB, associated with the energy barrier, depends on the 
characteristic measuring time, which can vary widely from 100 to 10
−8 
s, depending on the 
experimental techniques used [7]. The magnetic behavior observed, indeed, arises from the 
relative difference between the measuring time of the instrument and the intrinsic relaxation 
time of the system, i.e. the characteristic time needed for the magnetization reversal,   :  
        =    exp (
  
   
)                          (4) 
     
If the measuring time is greater than the relaxation time, the nanoparticles are in the 
superparagmagnetic regime. If, conversely, the measuring time is lower than the relaxation 
time, the nanoparticles are in a “blocked” regime [7], so note that the blocking temperature 
definition derives from the equality condition of these two characteristic times. 
Experimentally, the blocking temperature value can be estimated as the temperature of the 
“maximum” of the zero-field cooled (ZFC) magnetization curves [8]. In the standard 
experimental procedure of this magnetic characterization, the sample is cooled twice from 
room temperature to 10 K or lower, first with no applied magnetic field (ZFC) and then with 
a weak external field (field cooled, FC) Figure 2.2 shows the typical ZFC and FC 
magnetizations versus temperature curves and the TB position at the ZFC maximum. 
 
 
Figure 2.2 Magnetization versus temperature curves measured under ZFC and FC conditions, 
respectively. The maximum on the ZFC curve is commonly assumed to correspond to the blocking 
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As well known, ferromagnetic (or ferrimagnetic) nanoparticles show hysteresis loop 
with non zero coercivity field (Hc) and remanant magnetization (Mr). In the 
superparamagnetic regime, instead, Hc and Mr are zero as the magnetic moments of particles 
align themselves in the same direction as the applied external magnetic field, and revert to a 
random orientation state (zero magnetization remanence) when the external magnetic field is 




  can be easily magnetized to reach saturation, and the initial state can be 
easily restored by simply removing the external field. On the ground that superparamagnetic 
nanoparticles can be controlled by an external magnetic field, they are extremely 





















Figure 2.3 The magnetic response characteristic of nanoparticles in a superparamagnetic (red) and 
blocked (blue) state  
2.2. Basic Principles of Application of MNPs as Heat Mediators in Magnetic Hyperthermia  
Various models and experimental data have been employed to better understand the 
heating process in magnetic hyperthermia. In 2002, Rosensweig developed a model to 
explain the heating of colloidal magnetic fluids subjected to an alternating magnetic field 
[12]. He assumed that the heat generation was only due to the rotational relaxation of non-
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magnetic field (linear response theory, LRT). From the LRT model, the expression for the 
power dissipation (P) is given by the following equation [12] 
                                                      
     
                                              
Where    is the permeability of free space,  
   is the AC magnetic susceptibility,   and    
are the frequency and the amplitude of the applied AC magnetic field respectively. Beside, 
    can be expressed as:  
                          
  
       
                                         (6) 
Where      ,   is isothermal susceptibility and   is the effective relaxation time. 
Two mechanisms for the effective relaxation time, which is directly dependent on 
inversion of the magnetic moment, must be considered: Néel relaxation and Brownian 
relaxation. It is worth noting that the mechanisms of relaxation not only depends on the size 
of the NPs but also depends on the composition of magnetic materials owing to their specific 
anisotropy constant, K [13]. Nèel relaxation, which is strongly size-dependent (exponential 
dependence on the particle’s volume), comes from the internal rotation of the magnetic 
moment over the energy barrier in the same direction of the applied magnetic field with each 
field oscillation (Figure 2.4, a) [14,15], and the characteristic time  N for Néel relaxation is 
given by equation 4. On the other hand, Brownian relaxation is pertinent to the rigid rotation 
of the whole particle in a carrier liquid, and so it is absent when the particle cannot freely 
move (Figure 2.4, b) [14,15].  
 
 
Figure 2.4 a) Néel relaxation: rotation of the magnetization inside the particle, b) Brown relaxation: 
mechanical rotation of the whole magnetic particle [14,15].  
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                                                (7) 
Where  is the viscosity of the liquid carrier, VH is the hydrodynamic volume of the particle. 
The Brownian relaxation mechanism linearly depends on volume and viscosity [16]. A higher 
viscosity of the liquid medium will slow down the rotation of the particles. Generally, losses 
by Néel relaxation prevail for small MNPs, while the Brownian regime dominates for larger 
MNPs [14,17]. In fact, the Brownian losses are not exclusively found in superparamagnetic 
MNPs [18].  
For hyperthermia applications, it is better to have MNPs relaxing essentially through 
the Nèel mechanism because when internalized in the cells, a change in the viscosity medium 
and particle aggregation can happen, and free rotation of the particles can be prevented. As 
the two relaxation mechanisms take place in parallel, the overall effective relaxation time τ of 
the particles will be given by the combination of the two magnetic relaxation times [14]: 
 
                 
     
     
                                                    (8)                
 
2.2.1 Measurement of Magnetic Hyperthermia Efficiency by a Calorimetric Method 
 
The calorimetric approach is the most commonly adapted method for evaluating 
directly the magnetic hyperthermia efficiency of MNPs. In this method, the temperature 
increase in the sample is recorded over a period of time as the MNPs are exposed to an AMF 
field of a proper amplitude and frequency (Figure 2.5).  
 
Figure 2.5 (a) Experimental set-up used to evaluate the SAR of suspensions of nanopartciles, (b) 
scheme of the apparatus, (c) typical experimental temperature kinetics (blue curve), the green curve 
represents the ideal beahvior for a perfectly adiabatic apparatus, the SAR is estimated from the initial 
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The main apparatus is made by a magnetic induction heating system consisting of a water 
cooled coil connected to a high power rf generator, while an optical fiber optic is typically 
used to measure the temperature. 
Samples are placed in a thermally insulated container to avoid heat loss to the 
environment during measurement, and quantification of the power dissipation of magnetic 
nanoparticles in an AMF is usually done by evaluating the specific absorption rate (SAR), 
which is the power dissipated by mass unit and is expressed in W g
-1
 (also referred to as 
Specific Loss Power - SLP) according to the formula: 
 
    
      




                         (9) 
where    and     are the mass and heat capacity of the dispersion medium (4.18 J/g·K for 
water), respectively, while     is the mass of nanoparticles. As the system used is not 
adiabatic, the time derivative  
  
  
  of temperature is taken in the initial linear stage of heating 
(first 30 s). 
According to Eq. 9 the SAR value is also proportional to the applied AC magnetic 
field strength and frequency. Considering the equation of the heat dissipation value, it is clear 
that SAR values increase with the frequency f and the amplitude H of the applied field. 
However, in order to apply hyperthermia safely to patients and avoid any detrimental effect 
on healthy tissues due to electromagnetic radiation exposure, the Hf factor should not exceed 







2.2.2 Dependence of Magnetic Hyperthermia Efficiency on Morpho-Structural Properties   
 
The power dissipated during magnetic hyperthermia measurements depends on 
external parameters such as AC field and magnetic dipolar interaction effects in addition to 
the intrinsic magnetic properties of the MNPs, which influences their relaxation dynamics 
(Néel and Brownian). According to the LRT model, the heating efficiency is proportional to 
the square of the saturation magnetization of the MNP, but it can be maximized also by 
tuning the MNP size and magnetic anisotropy [12,20]. On the other hand, optimum MNP size 
and crystalline anisotropy vary, depending on the strength and frequency of the applied AC 
field. Magnetic dipolar interactions that promote the formation of nano-assemblies organized 
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following, the effect of size, shape, and aggregation of nano-assemblies on the heating 
efficiency of superparamagnetic nanoparticles will be discussed to provide a better 
understanding on how each of these parameters can be optimized for magnetic fluid 
hyperthermia applications. 
 
2.2.3 Size Dependence of the Magnetic Hyperthermia Efficiency of Superparamagnetic 
Nanoparticles  
Superparamagnetic NPs are governed by size dependent Néel and Brownian 
relaxation losses, which in turn directly affect the heat power dissipation process. To separate 
and understand the contributions of size dependent Néel and Brownian relaxation on the 
SAR, MNPs can be placed in solvents more viscous than water such as glycerol [21] or gel 
[22] to inhibit Brownian relaxation. Cobalt ferrite (CoFe2O4) NPs, for instance, placed in 
increasing amounts of glycerol showed a sharp change in SAR from 420 to 90 W g
-1
. 
Changing the size of MNPs dramatically alters its response to an applied AC field. 
That means, magnetization of MNPs decreases with decreasing particle size [23]. Owing to 
their small size, MNPs exhibit a reduced saturation magnetization due to surface and internal 
spin canting effects (spin canting or surface magnetic reconstruction is pertinent to different 
orientation of the surface spins with respect to the bulk ones) [20,21]. Spin canting gives rise 
to magnetically disordered spin glass-like layers on the surface of MNPs, which is not readily 
observed in bulk magnetic materials, causing decrease of magnetization [24,25]. Because the 
SAR value depends on magnetization and the relaxation time, for a given magnetic material, 
there is an optimum size to enhance hyperthermia effects by Vreeland et al. observed that 
under an AC excitation field of H = 36.5 kA m
-1
 and f = 341 kHz, the optimum size was 
around 22 nm, which matches the theoretical prediction of the LRT [12,26]. tuning these both 
parameters [23]. As an illustration, for superparamagnetic nanoparticles,  
 
2.2.4 Effect of Shape Anisotropy on Magnetic Hyperthermia Efficiency 
The heating efficiency of MNPs also depends on the magnetic anisotropy and so it 
can be enhanced by optimizing the shape anisotropy by developing MNPs with different 
morphologies. Along this line, MNPs with specific morphology such as nanoflowers have 
been reported to show higher SAR values compared to spherical MNPs [27]. The increase in 
the heating efficiency is attributed to the magneto-structural properties of the nanoflowers, 
which are composed of highly ordered smaller nanocrystals of few nanometers, that do not 
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coalescence and crystal ordering of the individual grains, while the spherical particles showed 
higher surface disorder and consequently, higher surface anisotropy.  
Superparamagnetic nanoparticles with novel and more complex shapes and structures 
such as hexagonal nanoplates, brick-like nanostructures, as well as nanoclusters of              
Mn-Zn-ferrite nanoparticles have also demonstrated enhanced SAR [28,29]. These results 
show the importance of shape anisotropy in improving the magnetic hyperthermia 
performance of iron oxide-based nanoparticles. 
 
2.2.5 Magnetic Dipolar Interactions: Effect of Nanochain and Nanocluster Formation on 
Magnetic Hyperthermia Efficiency 
 
Dipolar interaction effects on heating efficiency in magnetic hyperthermia have been 
shown to be positive [30,31] or negative [32,33]. It has been demonstrated that the reduction 
or enhancement in the heating efficiency of MNPs is as a result of the formation of nano-
assemblies during hyperthermia measurements. When MNPs exposed to an AC field, they 
can form linear aggregates of magnetically ordered structures such as chains (Figure 2.6) 
[34]. Several research groups have pointed out theoretically [35,36] and have shown 
experimentally [37,38] that chain-like structures can give rise to a strong increase in the 
heating efficiency of MNPs. [35,37]. This type of assembly leads to an enhancement of the 
effective anisotropy of the MNPs due to the unidirectional magnetization orientation as a 
result of the dipolar coupling along the chain [37].  
Conversely, negative effects on heating efficiency have been reported upon formation 
of cluster of MNPs due to an increase in particle concentration [38]. Modification of particle 
concentration has been employed to vary the strength of dipole-dipole interactions, and the 
structure of the particle assembly [33,39]. Coral et al. also arrived at the same conclusion, 
wherein nanoclusters were shown to have lower heating efficiency with increasing cluster 
size and increasing number of particles in the cluster [33]. Moreover, the negative effects of 
nanoclustering to the heat dissipated during magnetic hyperthermia have been reported by 
other groups, which confirms an increase in the intensity of dipolar interactions resulted in a 
decrease in magnetic susceptibility and a reduction in the SAR value [32,39]. On the other 
hand, it has been reported in the literature that favorable increase in heating effects were 
observed with clusters in the form of nanoflowers compared to cluster formed by individual 
particles [27]. These nanoflowers, in fact, contain single grains that have the same crystal 
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organization than clusters of individual particles where the anisotropy axes are randomly 
oriented [27,33,39].  
 
 
Figure 2.6 Schematic representation of the different nano-assemblies that could form during AC 
magnetic field excitation 
 
To summarize, magnetic hyperthermia is a promising therapeutic approach, but in 
order to move this treatment modality to the clinical setting, a better understanding of the 
behavior of MNPs during hyperthermia measurements is required. As a first step, it is 
imperative to develop a standardized method of reporting hyperthermia efficiencies, and to 
establish clinically acceptable AC magnetic field excitation conditions. Another key aspect is 
the development of optimized and well characterized magnetic iron oxide-based 
nanoparticles by tuning size, composition, shape, and exchange anisotropy to improve their 
heating performance as hyperthermia agents. Combining all these parameters is the challenge 
in the development of MNPs with unprecedented heating efficiencies to enable effective 
cancer treatment in vivo applications. 
2.3 Nanomedicine Approach for Cancer Treatments 
Cancers are traditionally treated with surgery, radiation, and chemotherapy. Each of 
these approaches bears the risk of killing normal cells or fatally damaging healthy tissues. 
Hence, treatment options are limited, and accurate diagnosis and prognosis are difficult in 
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capable of identifying anatomical location of tumour and surrounding tissues, their sensitivity 
is not high enough for detecting abnormalities at the cellular (microscopic) level. This fact 
seriously limits our ability to perform early cancer diagnosis. Owing to the above-mentioned 
pharmaceutical, diagnostic, and therapeutic constraints, cancer still remains one of the most 
challenging problems in modern medicine.  
Nanotechnology, an emerging interdisciplinary research field, has the great potential 
to offer solutions to current limitations in early detection and effective treatment of cancer. 
Currently, the development of a wide range of nanoscale materials such as biocompatible 
nanoparticles and nanorobots enable new scientific approaches in prevention, diagnosis, 
treatment, and monitoring diseases in clinical conditions. These technological innovations of 
nanotechnology within medicine are referred to as “nanomedicine”. In general, the major 
areas in which nanomedicine is being developed for treating cancer includes early detection, 
proteomics, multifunctional therapeutics (hyperthermia and drug delivery), or simultaneous 
therapeutic and diagnostic functions (theranostics). 
2.4 Superparamagnetic Nanoparticles for Biomedical Application 
As already mentioned in the previous sections, the properties of nano-sized materials 
due to their small size and their large surface-to-volume ratio can be strongly different from 
those of the corresponding bulk materials. In particular, nanoscale particles have attracted 
much attention as a consequence of their unusual electronic [40], optical [41] and magnetic 
[42] properties, which are particularly appealing for biomedical applications. Consequently, a 
broad range of nanocarriers with diverse sizes, architectures, and surface properties has been 
designed [43,44] including liposomes, polymer nanoparticles, micelles, dendrimers, and 
inorganic nanoparticles made of iron oxide, quantum dots, gold, or metal oxide frameworks. 
The dimensions of these systems (< 100 nm) make them ideal candidates for the production 
of functional nanostructures by nanoengineering of surfaces. The surface functionalization 
capability, indeed, allows their use in clinical trials for cancer diagnosis or treatment [45]. 
Iron oxide MNPs show interesting properties such as heat generation ability, high 
saturation field, extra anisotropy contributions, etc. [46]. Due to these unique properties, iron 
oxide MNPs have attracted widespread attention in nanomedicine especially for drug 
delivery. The optimization of iron oxide MNPs for this application continues today with the 
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the associated side effects, and (ii) to reduce the required dose by a more efficient localized 
targeting of the drug.  
The application of iron oxide MNPs in biology, medical diagnosis (i.e. as magnetic 
resonance imaging contrast agents (MRI) [47,48], magnetic particle imaging tracers, cell 
labeling, magnetic separation, bacteria detection [49]), and therapy (e.g. drug and gene 
delivery [50], specific release of drug [51], hyperthermia [52]) requires iron oxide MNPs to 
be stable in water at neutral pH and physiological salinity. Such colloidal stability depends on 
the dimensions of the particles, which should be sufficiently small, so to avoid precipitation. 
Another important factor is the charge and surface chemistry, which allow stabilization 
through steric and coulombic repulsions. To control the surface properties of iron oxide 
MNPs, they can be coated with a biocompatible polymer during or after the synthesis process 
in order to prevent the formation of large aggregates, changes from the original structure, and 
biodegradation when exposed to the biological system. The coating acts to shield the 
magnetic particle from the surrounding environment and can also be functionalized with 
targeting agent by attaching carboxyl groups, biotin, avidin, carbodiimide, folic acid, and 
other molecules [53–55]. These molecules then act as attachment points for the coupling of 







Figure 2.7 Nanoparticle possessing various ligands to enable multifunctionality from a single 
platform. [56] 
The biocompatibility and toxicity of iron oxide MNPs are other important criteria to 
take into account for their in vivo applications. The most important parameters determining 
biocompatibility and toxicity of NPs contain (i) the nature of the magnetically responsive 
component (for instance, magnetite, iron, nickel, cobalt, neodimium–iron–boron or 
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2.5 Magnetic Nanoparticle Stability 
One of most promising applications of colloidal superparamagnetic nanoparticles is 
the use as carriers of drug for site-specific drug delivery to minimize side effect of 
chemotherapy. Ideally, they could bear on their surface a pharmaceutical drug that could be 
driven to the target organ and released there. For these applications, the size, surface charge, 
and colloidal stability of the magnetic nanoparticles are particularly important, and strongly 
affect both the blood circulation time as well as bioavailability of the particles within the 
body [57].  
2.5.1 Colloidal Stability of Iron Oxide MNPs 
The stabilization of MNPs in biological suspension is a critical issue to employ them 
as drug carriers. The stability of MNPs in suspension is controlled by three principal forces: 
(a) hydrophobicity–hydrophilicity, (b) magnetic and (c) Van der Waals forces. MNPs tend to 
aggregate to sub-micron size clusters in suspension due to the magnetic interactions between 
the nanometric size particles. Moreover, they can also aggregate because of the attractive Van 
der Waals forces in order to minimize the total surface or interfacial energy. Such 
aggregation can hamper the efficacy of MNPs in drug delivery (less drug loading) as a result 
of their low surface area and larger sizes, so surface modification approaches of MNPs can 
prevent aggregation and can be carried out either during their synthesis or in a post-synthesis 
process. The ideal molecules used for stabilization of MNPs should be biocompatible and 
biodegradable polymers or surfactants [58]. As an illustration, one of the most important and 
widely employed functionalities for the modification of MNPs surfaces is the carboxylic acid 
group, which can interact with the surface of nanoparticles by coordination processes [59-63]. 
Phosphonic acid and dopamine also improve MNPs stability over a large range of pH and 
temperature [64]. In addition, biocompatible polymer such as cysteine-terminated 
polyethylene glycol (PEG) anchors to the surface of MNPs to provide highly stable ferrofluid 
for biological applications [65]. 
2.5.2 Shape, Size, and Size Distribution 
The main advantage of using particles of sizes smaller than 100 nm is their higher 
effective surface areas (larger number of attached ligands), lower sedimentation rates (i.e. 
high stability in suspension), and improved tissular diffusion. Indeed, particles should be 
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the blood circulation after injection, and to be capable of passing through the capillary 
systems of organs and tissues avoiding vessel embolism. When the drug-loaded MNPs are 
injected systemically into the bloodstream, the size, morphology, and surface charge are the 
three important parameters, which determine their behavior. As a case in point, tissue 
macrophages (i.e. Kupffer cells in the liver) are highly sensitive to invading micro-organism 
and MNPs with diameter of 200 nm [66]. The plasma proteins (opsonins) can easily adsorb 
on the surface of invading MNPs, depending on their sizes and surface charge. Hence, 
particles with sizes above 200 nm are not suitable due to their uptake by the RES, whereas 
the NPs between 10 and 100 nm are most effective for drug delivery purposes because they 
can evade the RES [67]. 
2.6 Nanoparticle Delivery to the Tumour Site 
Magnetic nanoparticles (MNPs) loaded drug must be delivered specifically to the 
cancer site and should be retained in the tumour in order to reach a sufficient concentration 
for effective hyperthermia cancer therapy as well as controlled drug release. Three main 
approaches for the delivery of nanoparticles can be distinguished: direct injection, systematic 
passive, and active delivery. The direct injection method consists of injecting directly the 
magnetic fluid into the tumour. In fact, the intratumoural injection is the simplest way to 
administer the MNPs, and is the most widely used method for in vivo studies [68,69]. This 









Figure 2.8 Scheme representing active and passive targeting of NPs. Reprinted from Ref [72] 
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The main advantage of this technique is the ease of achieving a high and localized 
concentration of MNPs in the tumour. However, direct injection results in a non-
homogeneous MNP distribution in the tumour, which makes the complete regression of the 
tumour more difficult [73]. 
Passive delivery is achieved by injecting MNPs intravenously. The MNPs will 
accumulate preferentially in tumour tissue due to the enhanced permeability and retention 
(EPR) effect [74-76]. The EPR effect rests on the fact that solid tumours exhibit a defective 
vascular architecture and the lymphatic clearance from the interstitium of tumour tissue is 
impaired. The former that results in an enhanced vascular permeability, facilitating nutrient 
and oxygen supply to satisfy the demand of growing tumours, while the latter, resulting in the 
retention of macromolecules in the tumour. The EPR effect originates from the fact that solid 
tumours possess a leaky vasculature compared to normal tissues, which facilitates the 
extravasation of nanoparticles (Figure 2.8). To take advantage of the EPR effect, the 













Figure 2.9 Once nanoparticles have extravasated in the target tissue, the presence of targeting ligands 
(e.g. proteins) on the nanoparticle surface can result in active targeting of nanoparticles to receptors 
that are present on target cell or tissue resulting in enhanced accumulation and cell uptake through 
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However, the principal disadvantage of this method is the difficulty to reach high enough 
concentration of nanoparticles for effective treatment because the amount of nanoparticles 
injected cannot be further increased in order to avoid non-negligible MNPs toxicity. In order 
to achieve higher deposition and improve tumour uptake of the nanoparticles, they can be 
driven magnetically inside the body via an external magnetic field and/ or can be 
functionalized with a targeting ligand for active delivery. Active delivery consists of 
improving the specificity of the nanoparticles by functionalizing their surface with a targeting 
moiety that binds to cell receptors. It usually results in a higher nanoparticle accumulation 
and cellular uptake in the targeted cancer cells (Figure 2.9). Among the most commonly used 
targeting agents, we can find antibodies [78,79], antibody fragments [80,81], receptor ligands 
[82,83], peptides [84,85], and aptamers [86,87]. The superiority of targeted MNPs in cancer 
treatments has already been proven many times [88]. 
2.7 Magnetic Hyperthermia  
During the 19
th
 century, it was observed that high fever can cause tumour regression 
[84], and scientific study was performed on hyperthermia to treat cervical cancer. The use of 
hyperthermia as a treatment for cancer was considered more seriously in the 1970s, and 
controlled clinical trials on induced hyperthermia began to be conducted. It was then 
discovered that cancer cells have greater sensitivity to hyperthermia as compared to normal 




C, in contrast to 
cancer cells, which undergo apoptosis at those temperatures [89,90]. 
Recently new technology has been developed to provide local hyperthermia using 
superparamagnetic nanoparticles as heating source, which is called Magnetic Fluid 
Hyperthermia (MFH). Upon excitation with an AC field, these unique materials can 
transform part of electromagnetic energy into heat, and the heat generated can raise the 




C, which is mortal for cancer cells and pathogenic microbes. 
This treatment is currently adopted in conjunction with chemotherapy or radiotherapy, as it 
also renders the cells more sensitive [91]. A high heating potential is crucial for the clinical 
use of MFH since it would require a smaller amount of MNPs to be administered into the 
body patient as well as to treat smaller tumours, which are not surgically addressable. The 
latter, indeed, have a larger dissipation capability and thus require larger amount of heat to be 
destroyed. Therefore, engineering MNPs (control their physical and chemical properties 
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2.8 Magnetic Nanosystems for Thermo-Chemotherapy 
The potential of MFH as a treatment for cancer is clear, but can even be improved by 
designing MNPs with multiple therapeutic functions, i.e. hyperthermia and drug delivery. 
The major drawback of chemotherapy is the non-specificity of the drugs, which may strongly 
damage healthy organs and cells during the treatment. With MNPs, the possibility of 
targeting to the specific locations in the body allows the lower dosage of chemotherapeutic 
drug to be administered into the patient to reach to the needed concentrations in the tumour 
area for an effective therapy. In addition, the concentration of drugs at non-targeted sites is 
reduced, therefore, minimizing undesirable side effects of chemotherapy[93]. Besides, the 
synergistic effect of the combined thermo-chemotherapy can strongly enhance the effect of 
chemotherapy for the same amount of drug available. The enhancement of chemotherapy 
effects with application of concurrent hyperthermia is called thermo-chemosensitisation. 
Several mechanisms are involved in this thermal enhancement such as increased 
antineoplastic drug accumulation in tumours and enhanced drug cytotoxicity (improved 
intracellular uptake of drugs and increased sensitivity of cells to drugs) [94,95]. The first one 
is due to the physiological effect of mild hyperthermia on tumour vasculature, including an 
increased blood flow, perfusion, and blood vessel pore size of the already leaky tumour 
vasculature. All these factors facilitate drug extravasation in tumour tissues. The mechanisms 
responsible for the enhanced drug cytotoxicity are not yet fully understood, but several 
studies have demonstrated that the thermal enhancement of the cytotoxic activity of many 





Increased drug cytotoxicity generally involves improved intracellular uptake of drugs as a 
result of increased cell membrane permeability, inhibition of DNA repair of the chemically 
induced lethal or sublethal damage, and acceleration of the cytotoxic chemical reaction in the 
case of alkylating or platinum-based antineoplastic agents at elevated temperatures [97]. 
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Figure 2.10 Mechanisms responsible for the synergistic effect of the combined thermo-chemotherapy  
 
2.9 Controlled Drug Delivery System 
It is known that the drug concentration levels in the blood plasma depend on the 
quantity of drug released from the carrier. The delivery and release of a drug at target area, in 
fact, are often problematic since the concentration of the released drug at the target cell is 
either too low or too high, and is not delivered for the desirable amount of time. In the view 
of the fact that desirable drug release (that is often characteristic of a zero-order kinetic rate) 
is not easily achievable, controlled drug release technique has been proposed to solve this 
problem. The main advantages of the use of controlled drug delivery systems include: (1) 
sustained constant concentration of therapeutically active compounds in the blood with 
minimum fluctuations; (2) predictable and reproducible release rates over a long period of 
time; (3) protection of bioactive compounds having a very short half-life; (4) elimination of 
side-effects, waste of drug and frequent dosing; (5) optimized therapy in addition to better 
patient compliance; and (6) solution of the drug stability problem [98]. Hence, smart 
polymers, responding to external stimuli, represent a very attractive choice of polymer 
coating for drug delivery to achieve a controlled release of the drug. Using polymers for 
controlled drug delivery requires complete control over the architecture of the polymer 
microstructure, especially when synthesizing materials such as multi-stimuli responsive 
polymers [99].  
Temperature-responsive soft materials used in conjunction with localized heating 
(e.g., via hyperthermia) are, therefore, prime candidates for biomedical applications to 
remotely trigger the release of the drug [100]; in fact, at physiological temperature the drug is 
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retained in the polymeric matrix, and when the surrounding temperature rises above the 
LCST, which is the temperature at which polymers undergo a reversible conformational 
change from a swollen hydrophilic state to a shrunken hydrophobic one, triggers the release 
of the drug in a temporal control manner. Other stimuli such as pH, glucose, stress or strain, 
and electromagnetic fields can be combined with thermal stimulus to create a multi-stimuli-
responsive system. [101]. 
2.9.1 pH Responsive Polymer  
Different parts of the human body have different pH levels. The saliva and blood are 
neutral, but the gastric juices inside the stomach are acidic [102, 103]. Specifically, tumours 
have an acidic environment at around 5.5-6.75, which is below the pH (7.4) of normal tissues 
[104–107]. When being internalized into the cells, NPs will encounter more acidic 








Table 2.1 pH values from several tissues and cell compartments [108] 
Based on these pH variations, researchers have developed various pH-responsive 
nanohybrids, which are constituted by metal nanoparticles core and pH-responsive polymer 
shell [109–117] to deliver drugs, genes, and proteins to enhance the curative effect in tumour 
sites and specific organs [118–122]. pH-responsive polymers share the common feature of 
being polyelectrolytes, which include in their structures weak acidic or basic groups that 
either accept or release protons in response to a change in the environmental pH. Such an 
ionic/non-ionic transition, or hydrophobic/hydrophilic characteristic changes of polymeric 
surfaces, or swelling/deswelling behavior of nanogel (crosslinked polymeric network) allow 






























28 Nanomedicine & Biomedical Application of Magnetic Nanoparticles 
to tune their nature (hydrophilicity, self-assembly polyelectrolyte nature), in the aqueous 
phase (Figure 2.11).  
 
Figure 2.11 pH-responsive polymers with different architectures: (a) unimer–micelle, (b) nanogels or 
microgels [123] 
Two main strategies exist to pH-trigger cargo release: a) the use of polymers 
(polyacids or polybases) with ionizable groups that undergo conformational and/or solubility 
changes in response to environmental pH variation (Figure 2.12); as an example, 
polyhistidine-based micelles could respond to acidic tumour microenvironments by efficient 
exposure of the transactivating regulatory protein (TAT) sequence (Figure 2.12) [124], which 
is essential for micelle translocation into the cells. The micelle surface hides TAT during 








Figure 2.12 pH-sensitive nanocarriers for efficient TAT-peptide exposure. Polyhistidine (PHis)-based 
micelles responding to acidic tumour microenvironments by an efficient TAT-sequence exposure 
following ionization of the polyhistidine segments [124] 
b) The design of polymeric systems with acid-sensitive bonds, whose cleavage, enables the 
release of molecules anchored at the polymer backbone, the modification of the charge of the 
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decorated liposomes comprising an acidic hydrolyzable polyethylene glycol (PEG) shell, 
allowing improved exposure of the TAT sequence at low pH to enhance cellular uptake of the 
TATp-containing immunoliposomes as shown in Figure 2.13 [125]. For this purpose, a 
degradable pH-sensitive hydrazone bond between a long shielding PEG chains was 
introduced by modifying the structure of PEG. At normal pH, surface TATp moieties are 
"hidden" by the long PEG chains, while upon the exposure to lowered pH, this 
multifunctional carrier exposes TATp moieties due to the degradation of the hydrazone bond 






2.13 pH-sensitive nanocarriers for efficient TAT-peptide exposure. TAT-peptide-decorated liposomes 
comprising a hydrolyzable PEG shell allowing improved exposure of the TAT sequence at low pH 
[125] 
Among pH-responsive polyacids, poly acrylic acid (PAA) has attracted widespread 
attention [126] as a result of its unique properties. Acrylic acid can be easily polymerized via 
various polymerization techniques and is inexpensive. Importantly, one of the most widely 
employed functional groups for anchoring ligand to the MNPs surfaces is the carboxylic acid 
units. PAA surface grafted-MNPs is a favorable candidate to be utilized as a smart 
nanocomposite for intracellular pH-triggered drug release [127]. 
2.9.2 Temperature Responsive Polymer 
Thermoresponsive polymers exhibit a temperature-dependent phase transition in 
solution across a critical temperature, which is known as the critical solution temperature 
(CST). The polymers, which are water soluble below a certain temperature and turn to be 
phase separated above that temperature, are defined to have a lower critical solution 
temperature (LCST), whereas the polymers exhibiting the opposite behavior are defined to 
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solution below the LCST is clear and homogeneous solution, while above the LCST appears 











Figure 2.14 Scheme showing phase transition phenomenon. (a) Lower critical solution temperature 
(LCST) and (b) upper critical solution temperature (UCST) phase transition behaviors of thermo-
responsive polymers in solution [129] 
 
 
Figure 2.15 LCST transitions (cloud point) of poly (N-vinylcaprolactam) solution at different 
temperatures: (a) at 25

C, (b) 38 





This conformational transition can be described by taking into account the 
thermodynamics of polymer in solution. For a process to be favored, it is required that the 
Gibbs free energy (ΔG) ((ΔG) = ΔH−T·ΔS) is negative. Dissolution of polymer in solvent 
involves a variety of interactions between the polymer and solvent. For polymers showing 
LCST behavior, Gibbs free energy for the dissolution in water is negative at room 
temperature, thus they dissolve in water. The water molecules from the solvent form a thin 
layer surrounding the hydrophilic part of the polymer, and this hydration process gives 
negative enthalpic contribution to the dissolution process. However, there is formation of a 
structured arrangement of water molecules around the hydrophobic part of the polymer, 
where there is formation of extensive hydrogen bonding among the surrounding water 
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temperature of the aqueous polymer system is increased, entropy (ΔS) of the system 
increases; indeed, hydrogen bonds break, leading to collapse of the hydration shell formed by 
the water molecules. The entropic term becomes greater than the enthalpic one, providing 
positive value of ΔG of the dissolution process. Breakage of hydrogen bonds and loss of 
hydration shell lead to increased hydrophobic interactions between hydrophobic parts of the 
same or different polymer molecules [131]. This leads to chain collapse and intermolecular 
aggregation (Figure 2.16) [132], and thereby separation into two phases, which ultimately 
leads to suppression in conformation changes of polymer chains [133-136]. Polymers that 







Figure 2.16 Temperature-induced phase transitions in thermo-responsive polymer chains. Extended 
chains-to-globules-to-aggregate transition is shown [137] 
 
2.9.3 Thermoresponsive Polymers Based on Poly N-vinylcaprolactam 
 
Poly N-vinylcaprolactam (PVCL) is a non-ionic polymer and exhibits LCST behavior 




C [138]. The growing interest in PVCL-based copolymers is 
driven by its thermoresponsive essence, the hydrophilic/hydrophobic transition temperatures 
close to the body temperature, as well as its complexation capability [139]. Additionally, 
PVCL is stable against hydrolysis and is highly biocompatible [140,141], so all these 
strengths make it an interesting candidate for biomedical applications. In addition, PVCL is a 
typical polyvinylamide, bearing both hydrophilic amide groups and hydrophobic          
carbon–carbon backbones. In fact, PVCL has been shown to support high cell viability and 
low cytotoxicity especially in the hydrophobic state above the LCST [142]. Importantly, the 
nitrogen atom in the caprolactam ring is directly connected to the chain backbone, so the 
hydrolysis of PVCL, if it occurs, will not produce a small toxic amide compound [143,144]. 
Some basic physicochemical properties of N-vinylcaprolactam (NVCL) monomer and PVCL 














N-vinylcaprolactam Poly (N-vinylcaprolactam)  
 
Figure 2.17 Structure of N-vinylcaprolactam and poly (N-vinylcaprolactam) 
Like NVCL monomer, PVCL also shows a good solubility in many organic solvents such as 
aromatic hydrocarbons, alcohols, ketones, dioxane, chlorinated aromatic, and aliphatic 
hydrocarbons, etc. The solubility decreases with the increase of molar mass of PVCL. On the 




C, and high concentrations, e.g., 
40 wt %, can be achieved. The lack of popularity among researchers for PVCL compared to 
other thermoresponsive polymers can be ascribed to the difficulty of polymerizing NVCL in 
a controlled fashion. The polymerization kinetics of these monomers is very different, and the 
controlled copolymerization of NVCL with other monomers is more difficult to achieve. 
 
NVCL  NVCL PVCL  PVCL 
Tb (
C)  128 in 22 mm Hg T g (C)  147 (dry polymer)-17-38 (aqueous solution) 
Tm (
C)  32-36 LCST (C)  30-45 
D (g mL-1)  1.029 Tc or Tm (C)  None 
Tf (
C)  101 Good solvents  Aromatic/aliphatic hydrocarbons/ alcohols, dioxane 






























Table 2.2 Physic-chemical parameters of NVCL monomer and PVCL polymer 
               
T b : boiling temperature; T m : melting temperature; d : density; T f : flash point; T g :  glass 
transition temperature 
 
Up to now, PVCL-containing materials such as micelles, nanogels, microgels, and 
core/corona hybrids, which have been explored for cell immobilization, [145] tissue 
engineering, [146] anticancer drug delivery [147,148], and protein separation, [149] to be 
cited a few. More specifically, multifunctional PVCL-based micelles, hydrogels, and 
nanohybrids are now developed and investigated for biomedical applications, notably for 












Figure 2.18 Thermo-induced global-coil transition of poly (N-vinylcaprolactam) (PVCL), well-
defined PVCL-based homopolymer, block copolymer, random copolymer, and brush copolymer via 
controlled radical polymerization, as well as their corresponding topological self-assembly structures, 
like micelles, hydrogels, organic/inorganic nanohybrids, functional surface via surface-initiated 






34 Nanomedicine & Biomedical Application of Magnetic Nanoparticles 
2.10 Multistimuli-Responsive Drug Delivery 
Sensitivity to more than one stimulus can further improve drug delivery efficiency 
[150]. One of the biggest advantages of an ideal stimuli-responsive drug delivery system is 
the precise control of drug release in response to exogenous or endogenous stimuli such as 
temperature and pH [151]. In the past year, polymers with unique sensitivity are mostly used 
for the construction of dual pH and temperature-responsive drug delivery nanocarriers. In 
general, to obtain a temperature and pH sensitive polymer, it is only necessary to integrate 
temperature sensitive monomers (as an example, N-vinylcaprolactam) with pH sensitive 
monomers (for example, acrylic acid) [152-154]. Combination of pH and temperature 
sensitivity in polymeric backbone, indeed, offers a way to control the polymer phase behavior 
[155]. That is to say, the presence of pH-responsive segments modifies the 
hydrophilicity/hydrophobicity balance in polymeric structure, leading to LCST changes at 
desired temperature range. For instance, the LCST of copolymers increases over 
physiological temperature by increasing acrylic acid comonomer contents at all pH ranges 
due to its high hydrophilicity [156]. 
Recently, integration of iron oxide superparamagnetic nanoparticles (Fe3O4) and 
smart cross-linked polymers such as poly (N-vinylcaprolactam-b-acrylic acid) nanogel into a 
composite/hybrid core-shell system resulted in a smart platform, responding to both 
temperature and pH [157]. This double pH- and thermo-responsive magnetic nanocarrier is 
suitable for multi-modal cancer therapy, by combining magnetic hyperthermia and controlled 





C), the drug will be retained by nanocarrier at physiological temperature, and 
remotely released under magnetic hyperthermia performance and tumour acidic pH [158].  
  
Figure 2.19 Smart magnetic nanocomposites-loaded drug provides advanced features for dual pH and 
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The objective of this thesis moves in this complex scenario and is schematized in 
Figure 2.19. In fact, our work reports fabrication and characterization of a smart 
nanocomposite composed of a superparamagnetic core and dual pH-temperature sensitive 
shell containing an anticancer drug (doxorubicin) for multimodality cancer therapy 
corresponding to this mechanism: (i) the magnetic core produces heat in response to harmless 
AC magnetic field enhancing temperature up to 45 

C (above LCST of polymer), (ii) heat 
generated is simultaneously conducted from core to the thermoresponsive polymer shell, 
which shrinks and triggers the fast release of the drug. The increase of the temperature up to 
45 

C, and the pH decreasing from 6 to 4 (due to the acidic pH of cancer cell) boost the 
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Chapter 3 
Synthesis and Characterization of Magnetic Nanoparticles for 
Biomedical Application 
Magnetic iron oxide nanoparticles have been the subject of great interest in recent 
years due to their various potentials in biological applications such as MRI [1-3], cell 
tracking [4,5] hyperthermia [6], and drug delivery [7,8]. Currently iron oxide nanoparticles as 
magnetite (Fe3O4) and maghemite (Fe2O3) with their remarkable magnetic properties are the 
most frequently investigated nanomaterials in biological systems owing to their 
biocompatibility, non-toxicity, and non-immunogenicity [9]. In almost all applications the 
preparation method of the nanomaterials represents one of the most important tasks as it will 
determine the particle size, shape, size distribution, surface chemistry of the particles, and 
consequently their magnetic properties. Therefore, the production of such nanoparticles 
should be directed towards the achievement of a material, which is suitable for therapeutic 
and/or diagnostic applications. In general, the effectiveness of the therapeutic magnetic 
nanoparticles (MNPs) requires:  
(a) High magnetic susceptibility and high saturation magnetization [10]  
(b) Tailored surface chemistry for specific biomedical applications [11] 
(c) An average hydrodynamic size of 10–100 nm with the proper coating and ζ-potential 
values below -30 or above +30 mV [12] 
(d) Capability to incorporate chemotherapeutic drugs  
Despite of the many attempts to develop processes and techniques, which are able to yield 
monodisperse nanoparticles to satisfy these criteria [13], their preparation is still challenging.  
To accomplish the objective of this thesis, MNPs that have high heating potential 
even at their low concentrations under AC excitation, must be prepared [14] because 
extremely huge SAR implies smaller amount of NPs to be required for injection into the 
patient for clinical trials. Regarding to the fact that using proper synthesis approach can 
control physical and chemical properties of NPs to obtain a desirable SAR value, we mainly 
focused on polyol method to fulfil this goal. Indeed, bottom-up liquid-phase techniques such 




      
 
45 Superparamagnetic Nanoparticles 
fine control of the structure, chemical nature, and morphology of the particles [15], herein we 
present and discuss the synthesis of iron oxide magnetic nanoparticles, prepared according to 
this technique, together with their extended chemical and physical characterizations including 
evaluation of size distribution, morphology, magnetic property, and heat dissipation ability. 
3.1 Iron oxides Crystallographic Structure (Fe3O4) 




 ions, within a spinel crystal structure. The 






 with the oxide anions 
arranged in a face center cubic (fcc) crystal structure and the metal cations occupying 
interstitial sites. These interstitial sites are of two types: tetrahedral, Td, and octahedral, Oh as 
shown in Figure 3.1. The spinel structure was named for the mineral MgAl2O4, in which the 
trivalent aluminum cations occupy the 16 Oh sites, and the 8 Td sites are occupied by the 













Figure 3.1 Basic spinel structure illustrating the octahedral and tetrahedral sites relative to the position 
of oxygen [18] 
 
Spinel phases are called normal or inverse according to the arrangement of cations in 
the cavities. If Oh sites are solely occupied by trivalent atoms, and the Td sites are occupied 
by the divalent atoms, it is called normal spinel structure as displayed in Figure 3.2; 
conversely, in inverse spinel structure trivalent ions are equally distributed among Td and Oh 
sites, while divalent ions are placed in Oh cavities. 




 = 1/2, the divalent irons can be partly or fully 
replaced by other divalent ions such as Co, Mn, Zn, etc. The general formula for ferrites can 
then be expressed as (M1-iFei)[MiFe2-i]O4, where round parentheses and brackets denote Td 
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varies between 1 (totally inverted spinel) and 0 (normal spinel). The nature of the divalent 
metal cation and the magnetic ordering in the crystal lattice influence the magnetic 
hyperthermia property of ferrite nanoparticles. For instance, spherical (Zn0.4Fe0.6) Fe2O4 
nanoparticles were demonstrated to have higher magnetization, and heat generation ability 
twice larger compared to the undoped Fe3O4 nanoparticles of similar size (438.6 and         
189.6 W g
-1









Figure 3.2 Structure of magnetite [20] 
3.2 Preparation of Magnetic Nanoparticles 
The preparation of iron oxide nanoparticles was described by Khallafalla [21] and 
Massart [22] in 1980 for the first time. After that, especially during the last decade, many 
publications have been describing efficient synthetic routes to prepare shape/size controlled, 
highly stable, monodisperse, and biocompatible iron oxide nanoparticles.  
The co-precipitation synthesis is a very simple method for the preparation of MNPs, 





 salts by addition of a base (usually ammonia or NaOH). Magnetic phase and particle 




 ratio, temperature, pH, and the type of 
base used [23].  
The thermal decomposition of organometallic compounds in boiling organic solvents 
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narrow size distribution. Usually, iron carbonyls or iron acetylacetonates are used as 
precursors and oleic acid or fatty acids serve as surfactants. By variation of the proportion of 
precursors to the starting agents (surfactants and solvents), the size and morphology of the 
resulting particles can be controlled [24]. 
Micro-emulsion synthesis is a two-phase method for the production of nearly 
monodisperse MNPs. For this purpose, a water-in-oil microemulsion is prepared by 
dispersion of nanosized water droplets (10.0–50.0 nm) in an oil phase, stabilized by 
surfactant molecules at the water/oil interface [25]. 
Hydrothermal synthesis is commonly used to prepare MNPs under specific 
conditions. In fact, hydrothermal synthesis performed in aqueous media at temperatures 
above 200 

C, and usually achieved in autoclaves at pressures above 2000 psi. This route 
exploits the ability of water to hydrolyze and dehydrate metal salts at high temperatures. Due 
to the low solubility of the obtained metal oxide particles in water at such temperatures 
[26,27] a precipitation takes place, and particle size in addition to morphology can be 
controlled by variation of concentration, temperature, and autoclaving time. 





in a polyol mixture (e.g., poly-ethylene glycol (PEG)/diethylene glycol or                              
N-methyldiethanolamine) is a promising approach for MNPs preparation. Size and structure 
of the resulting MNPs can be tuned either by modifying the reaction conditions or changing 
the solvent [28]. Despite of the fact that the obtained particles are not always monodisperse, 
the technique is appealing for magnetic hyperthermia therapy since under certain reaction 
conditions, “flower-shaped MNPs” can be synthesized. [28] As discussed in the previous 
chapter, particles with this shape, show excellent heating performance for hyperthermia [29].  
Moreover, the polyol method offers other advantages that motivated us to use this 
method for MNPs synthesis including: 
i) Due to the polarity of the polyols (ε > 30), inorganic compounds/salts are often well 
soluble in polyol mixture [30].  
ii) Because nucleation and growth of particles can be performed at temperatures up to 
the boiling point of the polyol (e.g., glycol: 197 C, diethylene glycol: 246 C, 
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iii)  The chelation of the solid nuclei by the polyol is simultaneous to its formation, which 
limits the particle growth, and prevents agglomeration of particles [32,34].  
iv) As the polyols are normally low-weight molecules, they may act as weak stabilizers, 
which can be removed from the particle surface under certain experimental conditions 
[32]. Consequently, solvent exchange as well as controlled precipitation of 
nanomaterials are possible by this approach.  
v)  In principle, the synthesis is easy to perform, and suited for a preparation of larger 
quantities of ferrofluid.  
 
Particle size and shape can be controlled through temperature, amount of metal 
precursors, and the application of an external magnetic field (often used during the synthesis 
of ferromagnetic metals). For instance, if the temperature is increased, the size of the particle 
normally decreases as more nuclei are formed in a shorter nucleation time, allowing the 
intermediate oxide phase to diffuse more rapidly [35]. When the ratio of metal precursor to 
polyol is increased, the particle size increases due to the fact that the number of nuclei formed 
during the short nucleation step at a certain temperature is independent of the amount of 
metal salt introduced in the system. If the number of particles is constant, but more metal is 
available, the mean particle size will increase [35]. Moreover, the polyol-mediated method 
employs relatively mild conditions, and starting materials are much less toxic than those used 
in other preparation techniques.  
As it will be shown, in this thesis we adapted the polyol synthesis at high temperature 
condition, which allowed us to obtain MNPs with good magnetic properties and controlled 
morphology.  
3.3 Synthesis and Characterization of Fe3O4-68 by Polyol Method 
The nanoparticles were prepared following a procedure previously published [36], 
and patented by Colorobbia Italia S.p.A. [37]. In a typical synthesis stoichiometric quantities 
of Fe(CH3COO)3 and FeCl2 were solubilized in diethylene glycol (DEG) for 1 h at 150 C, 
and kept heating at 170 C for 19 h. After this time, dark brown stable suspensions were 
obtained (Figure 3.3). For further growth of average size of MNPs, and to obtain a flower-
like structure, synthesis was repeated using the NPs formed in the first step as seeds for 5 h at 
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Figure 3.3 Image (left) and scheme (right) of the experimental apparatus used for the synthesis of 
Fe3O4-68 MNPs by the polyol method 
The obtained nanoparticles (sample Fe3O4-68) are ready to be employed for further 
modifications without any need of purification procedure. Crystalline phase, morphology, 
and size distribution of the MNPs were evaluated by XRD, TEM, and DLS analyses.  
In order to verify the formation of crystalline iron oxide magnetic nanoparticles, 
Powder X-Ray Diffraction (XRD) pattern was recorded for the Fe3O4-68 sample. As shown 
in Figure 3.4, all diffraction patterns show the formation of a single crystallographic phase, 
which can be indexed as the cubic structure of Fe3O4 spinel ferrite. The average crystallite 
size was estimated by the well-known Scherrer equation as well. According to this law, once 
instrument broadening has been taken into account, the crystallite size <D> can be easily 
calculated from the full width at half maximum peak intensity according to this formula: 
       
  
      
 
where θ is the diffraction angle, λ is the wavelength of the incident X-ray beam, B is the line 
broadening at half the maximum intensity (FWHM) after subtracting the instrumental line 
broadening in radians, and K, which called Scherrer constant, is a dimensionless unit cell 
geometry dependent constant that has a typical value between 0.85 and 0.99; however, for 
spinel ferrites K can be taken as 0.89.  
By using the 5 main diffraction peaks, the average crystallite size of magnetite was 
determined 14.0 nm. Moreover, the lattice parameter was found 0.840 nm
 
in accordance with 
the value expected for magnetite, suggesting oxidation of Fe
2+
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Figure 3.4 Powder X-ray diffraction pattern of Fe3O4-68. Evaluation of the particle size by using the          
Scherrer formula gave an average diameter of 14.0 nm. 
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In Figure 3.5 a typical TEM micrograph of the dispersion of Fe3O4-68 in ethanol 
deposited over a 200 mesh carbon-coated copper grids, is shown. The sample consists of a 
dispersion of almost flower-like nanoparticles with a narrow size distribution. The average 
diameter obtained from a statistical analysis over 500 nanoparticles gave a mean diameter of 
18.0 nm. The measured value is larger than that obtained from XRD measurements as, 










Figure 3.6 Size distribution of Fe3O4-68 dispersed in DEG 
The average particle size was evaluated by DLS measurement corresponding to three 
independent runs (almost 15 measurements each run). DLS measurement demonstrated that 
Fe3O4-68 MNPs have uniform size with average particle size of 32.0 nm and PDI ~ 0.124 as 
shown in Figure 3.6. Although the particle size is slightly larger than that determined by 
TEM analysis, which points out the presence of small aggregates in the suspensions, this 
phenomenon does not have any effect on the stability of the NPs suspension. Moreover, ICP-
AES analysis indicated a mean concentration of magnetic nanoparticles (Fe3O4-68) dispersed 
in DEG was about 1.33 wt % respect to the Fe3O4. 
 
In next step, magnetization measurements of Fe3O4-68 nanoparticles were performed 
using a superconducting quantum interference device (SQUID) magnetometer with a helium 
flow, and measurements were carried out on pressed powder of sample. 
 
 






















      
 
52 Superparamagnetic Nanoparticles 
3.4 Magnetic Measurement of Fe3O4-68 by SQUID 




























































































Figure 3.7 Magnetization vs. temperature curves recorded after ZFC-FC procedures (A) hysteresis     
cycles recorded at 10 K (B,C) and room temperature (B,D) for Fe3O4-68 
 
The magnetic properties of powders were measured, and results are summarized in table 3.1.  
 
 
Table 3.1 magnetic properties of Fe3O4-68 
 
The zero-field-cooled (ZFC) and field-cooled (FC) curves were measured in a 
magnetic field of 50 Oe in the temperature range of 10 – 300 K. As shown in Figure (3.7, A) 
the ZFC curve of Fe3O4-68 nanoparticles shows a broad maximum around 300 K, which 
suggested blocking of the nanoparticles occurs close to room temperature. At low 
Sample Ms (emu g-1) 
10K 
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temperature the magnetic moment aligns along the energetically favorable axis, and cannot 
align with the field due to the anisotropy energy barrier. The net magnetization is low 
because of the random axis orientation of nanoparticles. As the temperature increases, 
thermal fluctuations switch the magnetic moment of nanoparticles to the direction of the 
applied field, leading to a growing magnetization. At room temperature the thermal energy 
equals the anisotropy energy barrier, and randomizes the magnetic moment. Thus, the 
nanoparticles appear almost superparamagnetic behavior, as requested for the magnetic fluid 
hyperthermia application. The feature observed in both the ZFC and FC curve at around      
100 K can be attributed to the Verway transition. This is a first order structural phase 
transition unique of magnetite (for bulk Fe3O4 occurs at 125 K) [38] connected to charge 
ordering. The transition is known to shift to lower temperature, and eventually to disappear 
upon oxidation of Fe
2+
 ions and size reduction [39]. The presence of this transition is, thus, a 
solid confirmation that our particles consist of high crystalline magnetite nanocrystals.  
 
Figure (3.7, B) shows the hysteresis loops of Fe3O4-68 nanoparticles at 10 K and      
300 K. At 10 K, the hysteresis loop indicates a typical ferromagnetic behavior with coercivity 
(Hc) of 115 Oe and remanence (Mr) of 29 emu g
-1 
as displayed in Figure (3.7, C). Consistent 
with the ZFC-FC measurements, the nanocrystals are superparamagnetic at 300 K, and the 
hysteresis loop shows neither remanence nor coercivity (Figure 3.7, D). Furthermore, as seen 
in Figure (3.7, C, D) the saturation magnetization (Ms) of Fe3O4-68 nanoparticles at 10 K and 
300 K are 80 emu g
-1
 and 75 emu g
-1
, respectively. Since the SAR value is dependent on the 
magnetization, the high magnetization saturation observed here should result in enhanced 
hyperthermia effects [40].  
 
3.5 Magnetic Heating Capacity of Fe3O4-68 
The heating efficiency of Fe3O4-68 with average particle size of 18.0 nm was 
measured by calorimetric method, i.e. by measuring the temperature increase in the sample 
over a period of time under application of an AMF field with a particular amplitude and 
frequency. A fiber optic temperature probe was used to measure sample temperature as well. 
For SAR measurement, 300 µL Fe3O4-68 dispersed in DEG, containing 1.33 wt % Fe3O4 was 
exposed to an alternating magnetic field generated by inductive coils at a fixed frequency       
(f ~ 340 kHz) and amplitude (H ~ 21 kA m
-1
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measured as a function of time, and the slope of the heating profiles was used to calculate the 
SAR according to the formula:  
 
    
      




     
 
Where md and      are the mass and heat capacity of the dispersion medium, while     is 
the mass of nanoparticles. The Fe3O4-68 raised the solution temperature to 40 

C within 10 
seconds, and up to 140 C during 150 min as displayed in Figure 3.8.  












 in DEG, 1.33 wt % MNPs
















Figure 3.8 Temperature evolution of a suspension containing the Fe3O4-68 dispersed in DEG                
(1.33 wt % MNPs) under application of an AMF (H = 21 kA m
-1
, f = 340 kHz) 
 
 









Fe3O4-68 0.0033 g 0.00456g 2.401 21 340 613.0 444.0 
 
Table 3.2 SAR value of ferrofluid containing Fe3O4-68 dispersed in DEG (13.0 mg mL
-1
) under AMF           
(f ~ 340 kHz, H ~ 21 kA m
-1
) 
                         
According to the table 3.2 the Fe3O4-68 flower-like nanostructure showed significantly 
high SAR of 613.0 W g
-1
 (Fe), (444.0 W g
-1 
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those commonly observed for spherical magnetite MNPs with similar volume                        
(SAR ~ < 50.0 W g
-1 
under applying same magnetic field) [41, 28]. This effect can be 
ascribed to the morphology of Fe3O4-68 nanoparticles as already discussed in chapter 2; 
indeed, nanoflowers are composed of highly ordered nanocrystals that do not behave like 
isolated grains [28], and they exhibit lower anisotropy due to coalescence and crystal 
ordering of the individual grains. Conversely, spherical particles display higher surface 
disorder, and consequently higher surface anisotropy, which all these factors together make 
the former NPs to behave as more efficient heat mediators for magnetic fluid hyperthermia.  
 
As discussed in the previous chapter, the SAR value is also proportional to the applied 
AMF magnetic field strength and frequency. In order to evaluate the influence of frequency 
and amplitude of the applied AMF on heat dissipation ability of Fe3O4-68, the SAR value of 
the same ferrofluid was measured by calorimetric method under applying AMF with lower f 
(183 kHz) and H (17 kA m
-1
) for 3 min, which are more suited for clinical application, and 
results are reported in table 3.3.  
 
Table 3.3 SAR value of ferrofluid containing Fe3O4-68 dispersed in DEG (13.0 mg mL
-1
) under AMF             




Temperature variation versus time is shown in Figure 3.9. Temperature of solution 
was raised to 40 

C within 14 seconds, and increased up to 187 

C during 170 min. In order 
to estimate reproducibility of the method, measurement was performed two times and 
average SAR value was calculated, obtaining SAR = 357.0 W g
-1
 (Fe), (258.0 W g
-1
 (Fe3O4)).  
 
The capability of heat dissipation of MNPs was still very high under milder condition 
(weaker magnetic field), demonstrating once again the selected morphology of nanoparticles 
is particularly suited for this kind of application. A high heating potential, in fact, implies 
lower time of residence of nanoparticles in the human body, and also lower dosages to be 
administered to the patient. Therefore, these nanoparticles are promising candidate for in vivo 
hyperthermia therapy.  
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 in DEG, 1.33 % wt MNPs

















Figure 3.9 Temperature evolution of a suspension containing the Fe3O4-68 MNPs dispersed in DEG           
(1.33 wt % MNPs) under application of an AMF  
 
As discussed before, single-domain NPs can dissipate heat through two mechanisms, 
Néel relaxation or Brownian relaxation. In order to figure out which mechanism mainly 
contributes to heat release, the SAR measurements were repeated after dispersing the MNPs 
in media with different viscosity, water and agar. To this aim, first, surface modification of 
DEG coated Fe3O4-68 nanoparticles was performed by polyacrylic acid (PAA) encapsulation, 
to prepare stable aqueous suspension. This was realized by precipitating Fe3O4-68 
nanoparticles from DEG suspension, washing 3 times with ethanol/acetone to completely 
remove DEG, and then mixing the precipitate to an aqueous solution of PAA under 
sonication. Finally, MNPs were separated via magnetic decantation, washed, and re-dispersed 
in distilled water (the surface modification procedure is fully discussed in Appendix A.9.1). 
DLS analysis of the obtained water dispersed NPs indicated that the PAA coating was carried 
out successfully since MNPs were found to preserve the high monodispersity (PDI ~ 0.154), 
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Table 3.4 Hyperthermia efficiency of MNPs (~18.0 nm) dispersed in water and agarose gel 
 
Besides, the zeta potential value of -42 mV confirmed the presence of carboxylic acid on the 
surface of Fe3O4-68. Afterward, samples contain Fe3O4-68/PAA (0.091 wt % Fe3O4 as 
determined by ICP analysis) were dispersed in agar media with different weight percentage 
ranging from 0.25 wt % to 5.0 wt % to provide media with diverse viscosity. All samples 
were subjected to AMF with frequency 183 kHz and amplitude 17 kA m
-1 
for 5 min. The 
obtained SAR values are reported in table 3.4. 
It appears that SAR of PAA coated Fe3O4-68 decreases when viscosity of media 
increases, reaching an almost constant value of ca. 85.0 W g
-1
(Fe) when the MNPs are 
completely blocked. This value corresponds to the heat released by just Néel relaxation 
mechanism since this relaxation will be presumably the only one operating once the MNPs 
will be internalized in tumour cells, so this is the value, which should be actually considered 
to evaluate the hyperthermic efficiency of our nanoparticles. Although the SAR obtained in 
agar at 5.0 wt % is considerably smaller than that measured on water dispersion, it is still 
very high if compared to that of other magnetite suspensions measured under the same 
viscosity conditions. We can, therefore, conclude that our particles are extremely appealing 
for application as heat mediators for magnetic fluid hyperthermia.  
To summarize, superparamagnetic nanoparticles of magnetite (Fe3O4) were 
successfully synthesized using the polyol method. Crystal size, morphology, and size 
distribution of Fe3O4-68 NPs were controlled by XRD, TEM, and DLS analyses. XRD 












 in water 17 183 250.0 176.0 




, 0.25 wt % Gel 17 183 148.0 107.0 




, 0.5 wt % Gel 17 183 148.0 107.0 




, 1.0 wt % Gel 17 183 120.0 87.0 




, 2.0 wt % Gel 17 183 104.0 76.0 




, 3.0 wt % Gel 17 183 98.0 71.0 




, 4.0 wt % Gel 17 183 84.0 60.0 
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patterns exhibited crystalline phase of magnetite with spinel structure, and TEM images 
indicated a well-defined and uniform crystalline flower-like structure of magnetite with 
average particle size ~ 18.0 nm, while DLS confirmed stable suspensions of NPs was 
obtained. The magnetic behavior of Fe3O4-68 and the heating efficiency in an alternating 
magnetic field were studied, and the iron oxide nanoparticles revealed a high heating power 
and saturation magnetization at low dosage as a result of their size and specific morphology, 
which resulted from the polyol method adopted. We can, thus, conclude that this technique 
fulfilled our goal to provide MNPs with high SAR value, that have potential to be employed 
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Chapter3  
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Chapter 4 
Synthesis and Characterization of Poly (N-vinylcaprolactam)-Based 
(Co)polymers 
In this chapter we report the synthesis and characterization of thermoresponsive 
homopolymer poly (N-vinylcaprolactam) (PVCL) and smart copolymers-based PVCL such 
as poly (N-vinylcaprolactam-b-vinylpyrrolidone) (PVCL-b-PVPON) and dual pH and 
temperature responsive poly (N-vinylcaprolactam-b-acrylic acid) (PVCL-b-PAA) by 
Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization and free radical 
polymerization methods respectively with the purpose of designing and developing a suitable 
and novel drug delivery system, which is composed of the stimuli responsive (co)polymers 
shell and magnetic nanoparticles core. 
4.1. Living Polymerization 
A living polymerization is strictly a chain propagation reaction that, after full 
monomer conversion, is still capable of propagation via addition of further monomer [1]. In 
an ideal case this occurs in polymerization reactions without any chain transfer and 
termination [2,3]. Furthermore, the rate of initiation should be fast compared to the rate of 
propagation, which results in the synthesis of polymer chains with an overall similar degree 
of polymerization [4]. 
The main living polymerization techniques are: 
 Living anionic polymerization 
 Living cationic polymerization 
 Living ring-opening metathesis polymerization 
 Living free radical polymerization 
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In this thesis we mainly focused our research activity on living radical polymerization 
to prepare poly N-vinylcaprolactam (PVCL) and (PVCL)-based copolymers containing 
PVCL-b-PVPON and PVCL-b-PAA as demonstrated in Figure 4.1, which will be then used 
to realize smart magnetic nanohybrids.  
Figure 4.1 Representative schemes of the homopolymer and PVCL-based copolymers 
4.2. Free Radical Polymerization 
Free-radical polymerization is a method of polymerization by which a polymer forms 
through the successive addition of free-radical building blocks. Free radicals can be created 
by involving separate initiator molecules. Following its generation, the initiating free radical 
adds nonradical monomer units to grow the polymer chain. 
4.3. Synthesis of Well-Defined PVCL-Based (Co)polymers by Controlled Radical 
Polymerization 
N-vinyl caprolactam (NVCL) belongs to the family of un-conjugated monomers, and 
can be polymerized up to high molar mass by a conventional free radical polymerization 
process by using 2,2ˊ-Azobis (2-methylpropionitrile) (AIBN) for instance as the free radical 
initiator in the bulk at 65 

C [5,6]. However, this process leads to highly polydisperse 
polymer, and does not allow accessing to more complex structures such as block copolymers. 
During the past decade, Controlled Radical Polymerization (CRP) techniques have been 
widely developed to give access to (co)polymers with precise molecular weight, low 
dispersity, and well-defined architectures that are specifically designed to fit the targeted 
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controlled polymerization method with virtually any desired distribution of monomer units 
along the polymer backbone, or within any specific segment in a copolymer, called well-
defined (co)polymer [7-9]. The most useful CRP strategies to prepare well-defined 
(co)polymers consist of Nitroxide-Mediated Polymerization (NMP) [10], Atom Transfer 
Radical Polymerization (ATRP) [11], Single-Electron Transfer polymerization (SET) [12], 
Reversible Addition–Fragmentation Chain Transfer polymerization (RAFT) [13], and 
Organometallic Mediated Radical Polymerization (OMRP) [14]. Up to now, a great variety of 
thermoresponsive macromolecules have been synthesized using CRP strategies [15,16]. 
However, CRP of un-conjugated monomers, such as NVCL, is not an easy task, since the 
highly active radical species derived from those monomers might result in significant 
retardation and/or completed inhibition of the polymerization [17,18]. Moreover, it is difficult 
to find a suitable reagent or catalyst, which induces the fast interconversion between the 
highly active radical and the dormant species. That is why even though PVCL has a long 
history, information on the precise synthesis of PVCL via CRP is relatively scarce. Since 
then, ATRP [19,20], OMRP [14,21] and RAFT [22-26] techniques were successively used to 
provide more sophisticated NVCL-based materials, and opened new doors in the precise 
design of thermoresponsive polymers for biomedical applications. In this section, the RAFT 
technique, used for controlling the NVCL polymerization, is discussed, and the preparation of 
advanced PVCL structures is highlighted. 
4.4. RAFT Polymerization and Macromolecular Design via the Interchange of 
Xanthates (MADIX) of NVCL 
Because NVCL is an un-conjugated vinyl monomer that leads to highly reactive 
growing radicals, the choice of the RAFT/Macromolecular Design via the Interchange of 
Xanthates (MADIX) controlling agent is of prime importance for the reactivation of the 
dormant PVCL chain and successful control over the polymerization [27]. RAFT/MADIX is 
based on a degenerative transfer mechanism due to the presence of a chain transfer agent 
(CTA) with the general structure RSC(=S)Z. The CTA is typically a thiocarbonyl thio 
compound featuring two substituents that are usually abbreviated as R- and Z-group. These 
two substituents, R (radical leaving group) and Z (stabilizing group) have a profound 
influence on the reactivity of the CTA and on the RAFT process [28], so their appropriate 
choice is a key point for a RAFT polymerization. Various thiocarbonylthio compounds 
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                        Figure 4.2 Structures of chain transfer agents used for RAFT polymerization 
The mechanism of the RAFT process is depicted in Figure 4.3. The RAFT process 
can be divided into five distinct reaction sequences: (I) Initiation, (II) pre-equilibrium, (III) 
reinitiation, (IV) main-equilibrium, and (V) termination. The initiation occurs via the 
formation of primary radicals, I, that form during the decay of a radical initiator, I2, with the 
rate coefficient kde. The formed radicals react with monomers to form short oligomeric chains 
P
•
m with the rate coefficient kini until a radical reacts with a CTA molecule in pre-equilibrium 
step. The initiator derived chain (P
•
m), adds to a CTA molecule with the rate constant kadd. 
Subsequently the thiocarbonyl centered radical, undergoes β-fragmentation with the rate 
coefficient kβ, which leads to the formation of a free radical (R
•
) and a thiocarbonyl thio 
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Figure 4.3 Mechanism of RAFT polymerization 
As depicted in Figure 4.3 the formed R
•
 radical should reinitiate the polymerization 
effectively with rate constant kre-in to provide macroradical P
•
1. Whenever a fragmentation 
takes place, the macroradical can add new monomers with the propagation rate constant kp. 
Afterward, the main equilibrium starts when CTA molecules-chain end adds macroradical p
•
n 
again with rate coefficient kaddP, and subsequently β-fragmentation with the rate coefficient 
kβp takes place. Finally, termination reactions occur intrinsically by free radical 
polymerization, or radical recombination with ktc. 
The RAFT process is the most useful controlled radical polymerization technique 
involving a large variety of monomers to synthesize well-defined water-soluble (co)polymers 
[30]. This technique is especially attractive as it is compatible with almost all common vinyl 
monomers, and it can be performed under mild reaction conditions. Additionally, chain-end 
transformation of prepared polymer after RAFT polymerization is comparably simple, which 
qualifies this technique for further polymer functionalization [31,32]; therefore, newly 
developed RAFT polymerization method allows to prepare NVCL-based materials with 
tunable size (from nm to μm), with a large variety of structures (e.g., hydrogels, micelles, 
core/coronahybrids), and surface functionality that can be used for the accommodation of 
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catalysts, it is well suited for synthesis of polymers, in particular smart polymers, which are 
appealing for medical applications. 
Smart polymers or stimuli-responsive polymers have been widely investigated as a 
building block to realize therapeutic agent for smart drug delivery since they can undergo 
relatively large physiochemical changes in response to external and internal stimuli, such as 
variation in temperature, pH, or ionic strength [33]. On the ground that some disease 
microenvironments manifest themselves with a remarkable change in some specific 
physiological factors such as temperature, the potential in vivo application of temperature-
sensitive polymers is significantly evidenced. In fact, thermoresponsive polymers in aqueous 
medium exhibit a critical temperature, around which a sudden change in the solvated state 
occurs. Polymers, which undergo a hydration/dehydration transition in aqueous medium upon 
heating, possess a so-called lower critical solution temperature (LCST) [34]. As shown 
schematically in Figure 4.4, thermoresponsive polymer can show a coil–globule transition in 
water at temperature above LCST, or reversible conformational change from a swollen 
hydrophilic state to a shrunken hydrophobic one, resulting in a volume decrease due to 
expelling of the aqueous content from its chains. So the polymer solution above the LCST is 







Figure 4.4 Hydration/dehydration behavior of thermoresponsive polymer upon heating  
Importantly, the thermo-induced hydration/dehydration transition of this type of polymers 
can be utilized to trigger the drug release just by response to the temperature variation. For 
smart drug release using heat as a trigger, the smart drug carriers, which is usually made up 
of magnetic nanoparticles core and thermoresponsive polymer shell, should ideally retain 
their load at body temperature (~ 37 C), and release the drug within a locally heated tumour 
at the therapeutic temperature for hyperthermia 41 

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nanocarrier loaded with anti-cancer drug, is injected into the bloodstream, and targeted to the 
tumour using an external magnetic field gradient, or by chemical targeting. When an 
alternating magnetic field is applied after localization, the iron oxide magnetic cores of the 
composite particles generate heat, raising the temperature of the tumour and resulting in 
hyperthermia. At the same time, the heat generated is conducted from the core to the 
surrounding polymer and temperature increase of the polymer shell above the LCST, triggers 
the release of the drug [35]. To satisfy this requirement, thermoresponsive macromolecules 
should possess LCST slightly above the physiological temperature 38 C–48 C. Based on 
the type of polymer, LCST can be tuned via shifting the hydration/dehydration balance, 
basically by well-controlled RAFT polymerizing technique with another comonomer as well 
as by varying concentration, pH, and length of polymeric chain. 
Thermoresponsive poly (N-vinylcaprolactam) with its unique properties attracted our 
attention for development of novel drug nanocarriers, complying with main objectives of this 
thesis. As a case in point, PVCL is a water soluble and temperature-responsive polymer with 




C [36]. LCST value of PVCL varies with the polymer chain 
length and concentration corresponding to “classical” Flory-Huggins thermoresponsive 
behavior in water (Type I); that means, LCST of PVCL decreases with increasing polymer 
chain length and/ or concentration. [37]. Consequently, this unique feature allows modulating 
the LCST of a PVCL-based thermoresponsive system by controlling the molecular weight, 
without using any comonomer. Moreover, PVCL has been shown to support high cell 
viability and low cytotoxicity especially in the hydrophobic state above the LCST [38]. 
Importantly, the nitrogen atom in the caprolactam ring is directly connected to the chain 
backbone, so the hydrolysis of PVCL, if it occurs, will not produce a small toxic amide 
compound [39]. These merits make PVCL highly useful for biomedical applications such as 
controlled drug delivery and in vivo drug release [40]. 
In spite of the fact that synthesis and properties of PVCL and PVCL-based 
(co)polymers have been rarely investigated due to the synthetic challenges associated with 
high reactivity of vinyl monomers, we synthesized PVCL, poly (N-vinylcaprolctam-b-N-
vinylpyrrolidone) PVCL-b-PVPON, and poly (N-vinylcaprolactam-b-acrylic acid)           
PVCL-b-PAA in order to prepare novel nontoxic, biocompatible double-hydrophilic block 
copolymers with temperature-induced amphiphilicity near to 45 

C. Furthermore, poly acrylic 
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similar to PVCL, are both water soluble polymers, and broadly used for surface decoration of 
nanoparticles in biomedical field because of their hydrophilicity and biocompatibility [41]. 
Moreover, the structural similarity of those monomers gives a unique opportunity for fine 
tuning of temperature-induced transitions and copolymer assembly.  
Surface modification of magnetic nanoparticles with this type of (co)polymers, 
consequently, leads to the preparation of stimuli responsive interfaces, which reveal 
thermoresponsive behavior in response to small changes of environmental temperature, 
which is aim of this thesis. Besides, PAA units in copolymer backbone with a high binding 
capacity and a high density of reactive functional groups, providing a strong linkage between 


























































Scheme 4.1 Synthesis of PVCL, PVCL-b-PVPON, and PVCL-b-PAA via RAFT and free radical 
(co)polymerization 
In this work, we followed E. Kharlampieva's [42] and Jean-Daniel Marty's procedures 
[43] for the synthesis of temperature-responsive (PVCL) and (PVCL-b-PVPON) diblock 
copolymers with well-controlled molecular weights by applying sequential RAFT 
polymerization using a dithiocarbamate as the chain transfer agent (CTA) [44], and        
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in Scheme 4.1. Diblock copolymers were synthesized and successfully characterized using 
1
HNMR, Gel Permeation Chromatography (GPC), Dynamic Light Scattering (DLS), 
Transmission Electron Microscopy (TEM), UV spectroscopy, and Fourier Transform Infrared 
spectroscopy (FTIR). 
4.5. RAFT Polymerization of PVCL and Characterization  
RAFT CTA was prepared according to the literature [45] by reaction between methyl-
2-bromopropionate and O-ethyl xanthic acid potassium salt in methanol as displayed in 
Scheme 4.2. Structure of final product was assigned by
 1
HNMR (400 MHz, CDCl3) to 
determine the molecular formula of an obtained compound. The synthesis pathway and 
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Scheme 4.2 Synthesis of Chain Transfer Agent 
RAFT polymerization of vinylcaprolactam was performed according to the literature 
[43] by mixing NVCL, CTA, and AIBN as initiator in dioxane (Scheme 4.3). Moreover, 
1
HNMR analysis of polymer was conducted in order to access the structure of PVCL [46]. 
The synthesis approach in addition to 
1
HNMR spectrum are fully described in materials and 



















Scheme 4.3 RAFT Polymerization of NVCL 
The degree of polymerization (DP), or number of repeating units of PVCL, n, was 
determined from its 
1
HNMR spectrum by comparing the relative proton peak intensity of a 
known moiety (typically an end-group(s) with a known number of protons) to that of the 
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Where    (  ) are the area or intensity of the 
1
HNMR peak of moiety x and y,    (  ) are 
the number of repeating units and    (  ) are the number of protons. Consequently, the 
number average molecular weight (Mn) can be calculated by substituting for n in the 
equation: 
Mn = nM0 + Me 
M0 is the molecular weight of one repeating unit, and Me is the combined molecular weight of 
the end-groups.  
To calculate the number of repeating units (n) in the PVCL chain, the peak areas of 
CH3O-(OMe, δ 3.18) and Ha- (Ha−NCH−of the α position, δ 4.39) were obtained from the 
1
HNMR spectrum (Appendix A.4, Figure A.1), and appropriately substituted into the 
equation, obtaining n=72. 






Molecular weight distribution of the produced polymer was determined by gel 
permeation chromatography as shown in Figure 4.5 coupled with Waters 410 Differential 
Refractometer and A Plgel guard column and two PLgel Mixed D 5 μm columns. The eluent 
employed was THF at a flow rate of 1.0 mL min
-1
. Polystyrene standards were used for 




























Figure 4.5 GPC curve of PVCL (Mn ~ 10857 g mol
-1
) 
Number-average molecular weight (Mn), weight average molecular weight (Mw), and 
polydispersity index (Mw/Mn) of PVCL were determined by GPC analysis, and results were 
10857 g mol
-1
, 12160 g mol
-1
, and 1.12 respectively. In fact, Mn obtained by GPC is in good 
agreement with one obtained by 
1
HNMR analysis (Mn ~ 10216g mol
-1
). These results 
demonstrate that the RAFT polymerization of PVCL provided a polymer with well controlled 
Mw since the molecular weight distribution was relatively narrow with Mw/Mn 1.12, as 
evidenced by the GPC results. 
The FTIR analysis of the synthesized polymer was performed to confirm the desired 
product was obtained promisingly. FTIR spectrum of sample was in good agreement with 
published results [43], and confirmed that polymer was successfully achieved by RAFT 
polymerization. (FTIR spectrum is reported and discussed in materials and method section, 
Appendix A.4, Figure A.2 ). 
The mean particle size and particle size distribution of the aqueous solution of PVCL 
were determined by Dynamic Light Scattering (DLS) measurement on 2.0 mL of sample with 
concentration of 1.0 mg mL
-1
. DLS of the polymer solution showed narrow size distribution 
(PDI, 0.294) with the intensity-average hydrodynamic diameter of 59.0 nm, obtained from 
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Figure 4.6 Statistics intensity distribution of size for a PVCL nanosphere aqueous solution 
The TEM analysis of the polymer structure in aqueous solution was performed to 
investigate morphology of macromolecular chains. The TEM image, reported in Figure 4.7, 
shows spherical structure in solution with average diameter ranging from 52.0 to 132.0 nm as 
obtained from a statistical analysis over 50 nanoparticles, performed by platform software 
(Olympus).The polymer size results are in good agreement with the average hydrodynamic 
diameter of 59.0 nm obtained by the DLS. 
 
 
Figure 4.7 TEM images obtained from 1.0 mg mL
-1
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Turbidity and DLS measurements were carried out to illustrate the phase transition 
behavior of the smart polymer in aqueous solutions. For this purpose, the LCST of aqueous 
solution of PVCL at different concentrations from 0.25 mg mL
-1
 to 2.0 mg mL
-1
 was 
determined using a UV–Vis spectrophotometer equipped with a temperature controller, and 
the measurements were performed by monitoring change in transmittance as a function of 
temperature at 500 nm wavelength. The LCST value was taken as the inflection point of the 
transmittance curve versus temperature during heating cycle.  
As mentioned before in aqueous solution, PVCL exhibits phase transition behavior in 
the range from 31 

C to 50 

C depending on molecular weight and polymer concentration. In 
fact, LCST could be shifted towards lower value with increasing concentration              
(Flory–Huggins change phase behavior, (type I). As a result, LCST could be easily 
modulated in order to be applicable for effectively controlled drug delivery in vivo 
application.  






















 0.25 mg mL
 -1
 0.5 mg mL 
-1
 1.0 mg mL 
-1
 2.0 mg mL 
-1
 
Figure 4.8 Turbidimetric analysis of aqueous solution of PVCL at different concentrations 
The type I phase-change behavior of PVCL is well evidenced by data reported in      
Figure 4.8. The LCST of homopolymer PVCL, indeed, decreased to lower temperature when 
concentration increased (33 

C and 35 

C at 2.0 mg mL
-1
and 1.0 mg mL
-1




74 pH & Temperature-Responsive Polymer 
39 

C and 40 

C at 0.5 mg mL
-1
 and 0.25 mg mL
-1
 respectively). These results confirm that 
by varying the concentration of PVCL aqueous solution, the LCST of a given polymer can be 
simply tuned to obtain desired value. 
DLS analysis was performed to evaluate the size distribution of polymer solution 
above and below LCST. According to the Figure 4.9, DLS results reveal the hydrodynamic 
size of PVCL solution is highly temperature dependent. That means, the hydrodynamic size 
at the critical temperature is much larger than that one at temperature below LCST, and then 
begins decreasing with further raising the temperature by 5–10 

C. The onset of temperature 
at which the abrupt size increase occurred was considered as the LCST value.  
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Figure 4.9 Hydrodynamic sizes of aqueous PVCL solution with various concentrations as a function 
of temperature  
For instance, 2.0 mg mL
-1
 aqueous solution of PVCL gave a low hydrodynamic size around        
50.0-60.0 nm at 25 

C (below LCST); however, this size value highly increased from 31 

C 
upon the increase of temperature. The hydrodynamic size of the PVCL was found to be     
4000 nm at 39 

C, and began to decrease slightly to 3800 nm, with further raising the 
temperature to 40 

C. Thus, 31 

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observed also for less concentrated PVCL although the total size variation decreased by 
decreasing the concentration of polymeric solution. 
LCST values of PVCL solutions with various concentrations, measuring by two 






Table 4.1 LCST value of PVCL by DLS measurement and UV spectroscopy 
According to the data reported in table 4.1, the LCST values obtained from DLS analysis are 
in good agreement with those obtained from the turbidimetric studies, and demonstrate that 
the LCST can be well controlled, and increased from 31 

C to 43 

C, when the concentration 
of PVCL solution is decreased from 2.0 to 0.25 mg mL
-1 
respectively. 
As seen from DLS data, hydrodynamic size of polymer abruptly increases when the 
temperature is raised above LCST. This phenomenon is relevant to the formation of large 
aggregates that occurs as a consequence of gradual dehydration of PVCL after heating above 
the LCST. That is to say, at temperature ~ LCST polymer-bounded water molecules are 
released to the solvent as the polymer chains collapse, generating mesoglobules, (i.e. uniform 
spherical aggregates stable in solution), which are also stabilized against further aggregation 
via hydrophilic surface. Then, upon increasing temperature, this structure can further expel 
water molecules progressively, leading to the formation of aggregates of increasing size as 
displayed in Figure 4.10. With the further increase in temperature, larger aggregates 
dissociate into smaller polymer structure as a result of the crowding effect, i.e. when the 
configurational entropy of macromolecular chains decreases in a crowded environment due to 
excluded volume effects, the formation of much smaller structures is favoured, as indeed 
observed by DLS measurements. 
 
Concentration mg mL-1 LCST (oC)-UV LCST (oC)-DLS 
2.0 33 31 
1.0 35 33 
0.5 39 39 












Figure 4.10 Hydrophilic/hydrophobic transition of polymer solution above LCST leading to the size 
variation [48] 
4.6. RAFT Polymerization and Characterization of PVCL-b-PVPON  
Since the primary objective of this thesis is to fabricate thermoresponsive magnetic 
nanohybrids for hyperthermia cancer treatment with thermal response in the 41 

C−48 C 
range, it is essential to design polymer with phase transition temperature above physiological 
temperature up to hyperthermia range. The LCST of PVCL can be modulated by controlling 
the molecular weight of polymer segments, and thus by adding another comonomer in the 
polymer backbone. To this aim poly (N-vinylcaprolactam-b-N-vinypyrrolidone),               
(PVCL-b-PVPON) was prepared, and then systematically investigated.  
PVCL-b-PVPON was synthesized by RAFT polymerization according to the same 
procedure described previously in section 4.5 [44] (the synthesis procedure is described with 
more details in Appendix A, section A.5). NVCL, N-vinylpyrrolidone (NVPON), CTA, and 
AIBN as initiator were mixed in dioxane and kept under stirring for 24 h at 60 

C as 
exhibited in Scheme 4.4. 
1
HNMR and GPC were also employed to check the molecular 





















Scheme 4.4 RAFT polymerization of block copolymer PVCL-b-PVPON 
Hydrophilic Hydrophobic
Bond water
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The degree of polymerization (DP) of a PVCL-b-PVPON was determined from 
1
HNMR spectrum shown in materials and method section (Appendix A.5, Figure A.3) by 
using the same formula reported in section 4.5. For this purpose, the peak areas of CH3O-
(OMe, δ 3.54), Ha- (Ha−NCH−of the α position of caprolactam ring, δ 4.38), and of Haˊ      
(Haˊ–NCH–of the α position of pyrrolidone ring, δ 3.69), were used, and the number average 
molecular weight (Mn) was calculated by substituting for n and m in the formula: 
Mn = nM0 +mM1+Me 
Where n and m are the number of repeating units of PVCL and PVPON blocks, respectively. 
M0 is the molecular weight of PVCL repeating unit, M1 is molecular weight of PVPON block, 
and Me is the combined molecular weight of the end-groups. By calculation of    and    the 














Mn= 21610.21 g mol -1  
Gel permeation chromatography analysis was carried out to determine molecular 
weight distribution of the PVCL-b-PVPON by following the same procedure mentioned in 
section 4.5, and result is displayed in Figure 4.11. THF was employed as eluent at a flow rate 
of 1.0 mL min
-1
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Number-average molecular weight (Mn), weight average molecular weight (Mw), and 
polydispersity index (Mw/Mn) of PVCL-b-PVPON obtained by GPC analysis were               
20857 g mol
-1
, 19460 g mol
-1
, and 1.08 respectively. Mn estimated by GPC analysis is in 
accordance with Mn obtained by 
1
HNMR analysis. These results reveal that the                
PVCL-b-PVPON obtained by RAFT copolymerization has a narrow molecular weight 
distribution with Mw/Mn value 1.08 as evidenced by the GPC results. 
FTIR spectrum, which is reported in Appendix A.5, Figure A.4 demonstrated that 
copolymer was successfully prepared, and the polymerization proceeded correctly.  
Dynamic Light Scattering (DLS) measurement was performed through three 
independent runs (15 measurements) to determine mean particle size and particle size 
distribution of PVCL-b-PVPON aqueous solution on 2.0 mL of sample with concentration of 
1.0 mg mL
-1
. The obtained result shows that the copolymer has an average hydrodynamic 
diameter of 86 nm with narrow size distribution (PDI, 0.187), as shown in Figure 4.12. 

















Figure 4.12 Size distribution of PVCL-b-PVPON 
In order to investigate morphology of macromolecular chains, TEM analysis of the 
copolymer structure in aqueous solution was performed. The TEM image in Figure 4.13 
demonstrates PVCL-b-PVPON has spherical shape with the average diameter ranging from 
20.0 to 89.0 nm as obtained from a statistical analysis over 80 nanoparticles, performed by 
platform software (Olympus). The copolymer size is in good agreement with the average 
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Figure 4.13 TEM images of PVCL-b-PVPON aggregates in water 
Turbidity, dynamic 
1
HNMR, and DLS measurements were carried out to determine 
the critical temperature of copolymer in aqueous solutions. 
As mentioned previously, the presence of the hydrophilic component in the 
thermosensitive polymer with a certain LCST value (denoted as cloud points, Tc) is known to 
shift the temperature at which the collapse of the hydrophobic backbone occurs to higher 
values [49,50]. The effect of the hydrophilic PVPON block on the LCST values was studied 
using turbidimetry measurements performed with a UV–Vis spectrophotometer equipped 
with a temperature controller. The measurements were carried out by monitoring change in 
transmittance as a function of temperature at 500 nm wavelength, and results are plotted in 
Figure 4.14. The cloud point was taken as the inflection point of the transmittance curve 
versus temperature during heating cycle.  
Corresponding to this technique, the diblock copolymer solutions were slowly heated 
from 25 

C to 51 

C. When the solution temperature reached the cloud point of                
PVCL-b-PVPON, the copolymer solution became turbid, and became clear again when the 
solution was cooled to T < Tc, demonstrating the transition is reversible. Moreover, the cloud 
point values of the diblock copolymers were compared with those of PVCL at the same 
concentration, and results are summarized in table 4.2.  
Figure 4.14 shows that the transmittance of PVCL-b-PVPON with different 
concentration ranges between 0.25 mg mL
-1
 to 2.0 mg mL
-1
 started decreasing at a higher 
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Figure 4.14 Plot of transmission vs. temperature for the PVCL-b-PVPON copolymer aqueous 
solutions with different concentrations from (2.0 mg mL
-1
 to 0.25 mg mL
-1






In fact, the presence of hydrophilic PVPON component shifted the LCST value of the diblock 
copolymer of about 6-9 

C in comparison with PVCL homopolymer due to the augmentation 
of hydrogen-bonding capabilities of the constituent monomer units. Consequently, the LCST 
of a given copolymer can be ‘‘tuned’’ as desired by variation in hydrophilic comonomer 
(NVPON) content and concentration of polymeric solution owing to the phase transition 








Table 4.2 LCST of PVCL-b-PVPON in comparison with PVCL 
Concentration of 
PVCL ( mg mL-1) 
LCST 
(C) 
Concentration of  
PVCL-b-PVPON ( mg mL-1) 
LCST  
(C) 
2.0 33 2 39 
1.0 35 1 42 
0.5 39 0.5 44 
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Nowadays, proton nuclear magnetic resonance (
1
HNMR) spectroscopy method is 
widely used for investigation of the changes in the chain structure and dynamics during 
temperature-induced phase separation in polymer solutions and hydrogels [51]. The            
coil-globule transition leads to a pronounced decrease of the integral intensity of the polymer 
groups in the NMR spectra, indicating the formation of more compact structures. It allows 
estimation of the phase transition temperature (determined as an onset temperature of the 
collapse) and the fraction of mobile component in polymer network.  
In the following, the temperature-induced collapse of PVCL segment in                
PVCL-b-PVPON diblock copolymer was investigated by 
1
HNMR spectroscopy. Figure 4.15 
displays 
1





C with the concentration of 1.0 mg mL
-1
. At the lower temperature, the diblock 
copolymer is molecularly dissolved in water and all peaks from PVCL and PVPON segments 
are present in the spectrum (Figure 4.15 (a)). The structures of PVCL and PVPON are similar 
with peaks in the region 1-3.5 ppm (Figure 4.15 (a)). The resonance band at 4.4 ppm (25 

C) 
is due to the proton (HX) in α-position of PVCL carbonyl group. The peaks of the proton (HY) 
at α-position of PVPON carbonyl group are in the range of 3.5–4.0 ppm. However, increasing 
temperature to 45 

C causes the collapse of PVCL blocks and self-assembly of the              
PVCL-b-PVPON copolymer chains as evidenced by the attenuated peaks from PVCL block, 
which are present between 4 and 5.5 ppm, whereas the peaks from PVPON (3.5–4.0 ppm) 
segment, which are still soluble at this temperature, are observed in the spectrum           
(Figure. 4.15 (b)). Noticeably at 45 

C, the PVCL resonance peak intensity is significantly 
lowered than one at 25 

C because of the highly restricted motions of the PVCL segments 
due to the PVCL collapse. Thus, dynamic 
1
HNMR results confirmed that aqueous polymer 
solution at concentration of 1.0 mg mL
-1
 has LCST over 40 











HNMR spectra of PVCL-b-PVPON in D2O (1.0 mg mL
-1
) at 25 

C (a) and 45 

C (b) 
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For further investigation on temperature-triggered self-assembly of PVCL-b-PVPON 
diblock copolymer in water, DLS analysis was performed, and evolution of hydrodynamic 
sizes of PVCL-b-PVPON diblock copolymers as a function of temperature is plotted in 
Figure 4.16. 
The hydrodynamic size (diameter) of the aqueous copolymers solution with different 
concentrations was around 80.0 nm below 40 

C (below LCST). However, at the 
temperatures close to the LCST, the size increased to 230.0 nm and 1714.0 nm for the lowest 
(0.25 mg mL
-1
) and highest (2.0 mg mL
-1
) concentrations respectively. This phenomenon has 
been observed earlier for PVCL homopolymer shown in Figure 4.9, and was explained by the 
occurrence of large micelle aggregates. 
























 2.0 mg mL 
-1
 1.0 mg mL
 -1
 0.5 mg mL
 -1
 0.25 mg mL
 -1
 
Figure 4.16 Temperature size dependence of PVCL-b-PVPON in aqueous solution 
In fact, at temperature above LCST, hydrophilic structure of copolymer changed to 
hydrophobic, which caused clouding of the solution due to the hydrophobic interactions 
between the polymer chains followed by their aggregation. At the temperature above LCST, 
indeed, the formation of water-polymer hydrogen bonds becomes less favorable relatively to 
polymer-polymer interactions, so that monomer units of polymer first interact with their 
nearest neighbors on the same macromolecule, and then they associate with surrounding 
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concentrated solution, leading to the formation of bigger aggregates, and subsequently to the 
abrupt size increase; therefore, the evolution of hydrodynamic size of copolymer upon 
heating is extremely high, and is larger for more polymer concentrated solution. As an 
illustration, polymer solution with concentration of 2.0 mg mL
-1 
showed size variation from 
80.0 nm to 1714.0 nm, while polymer solution with 0.25 mg mL
-1
 revealed a less marked size 
variation from 80.0 nm to 230.0 nm. 
LCST of aqueous copolymer solution with different concentrations, measured by DLS 
and UV analyses, are compared and reported in table 4.3. As seen, the LCST values are in 
accordance with those obtained from the turbidimetric studies, and confirm Flory–Huggins 






Table 4.3 LCST of PVCL-b-PVPON by DLS and UV 
4.7 Synthesis of Poly (N-vinylcaprolactam)-b-poly (Acrylic acid)  
One of the fundamental prerequisite to employ nanoparticles for clinical diagnosis 
and treatment purpose is that a stable colloidal solution can be formed without any significant 
agglomeration over a desired time period. A range of different functionalities and approaches 
can be used to attain colloidal stability. For many applications in medicine, a polymer coating 
on the magnetic nanoparticles is preferred over simple functionalization with small organic 
compounds since polymer stabilizers offer several advantages: (i) they are more effective in 
generating steric effect, (ii) they provide abundant binding sites and (iii) less prone to 
dissociation. A polymer coating, indeed, can provide colloidal stability in water through 
steric stabilization, or through charged groups (often -COO
_
), and can provide surface 
functionality along with the encapsulation of a therapeutic agent.  
In order to encapsulate magnetic nanoparticles with smart polymer, poly                     
N-vinylcaprolactam-b-poly acrylic acid was prepared. In fact, the presence of carboxylic acid 
blocks in the structure of smart copolymer not only allows the anchoring of the polymer 
Concentration mg mL-1 LCST-UV (C) LCST-DLS (C) 
2.0 39 38 
1.0 42 42 
0.5 44 45 
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around the nanoparticles but also it yields stable nanoparticles in biological fluid. 
Furthermore, the incorporation of acrylic acid monomer units into polymer backbones has 
been investigated for therapeutic use [53] on account of their ability to swell reversibly upon 
pH variation, and to adhere to biological surfaces when partially protonated.  
A first attempt of preparing the diblock copolymer by RAFT polymerization [43] 
similar to PVCL-b-PVPON synthesis procedure, failed. This could result from the fact that 
controlled radical polymerization of N-vinylcaprolactam as an unconjugated monomer is a 
big challenge due to the highly reactive growing vinyl radical [54]. To overcome this 
problem, PVCL-b-PAA was synthesized by free radical polymerization method according to 
slightly modified procedure from literature [55], so as to improve the length of PAA blocks. 
 
The PVCL-b-PAA copolymers were synthesized by free radical copolymerization of 
NVCL with AA in the presence of AIBN as an initiator in three different solvents including 
DMF (sampler AA1), dioxane (sample AA2), and isopropanol (sample AA3) as shown in 
Scheme 4.5. 
1
HNMR and GPC were carried out to consider structures and molecular weights 














Scheme 4.5 Free radical copolymerization of PVCL-b-PAA 
The full description of synthetic procedure and 
1
HNMR assignment are reported in Appendix 
A.6, Figure A.5 respectively. Significantly, 
1
HNMR spectra were identical for the three 
copolymers, indicating solvent did not have any influence on the polymer structure. Besides, 
FTIR spectroscopy and titration methods were performed to consider the structure of       
PVCL-AA copolymers. IR measurements also confirmed the PVCL-b-PAA copolymers 
backbone as indicated in Appendix A.6, Figure A.6, and similarly, obtained results from 
FTIR measurement for all three copolymers were equal as expected. For titration method, the 
copolymers (200 mg) were dissolved in an excess of 0.1 M sodium hydroxide               
(NaOH, 10.0 mL) to deprotonate the carboxylic groups. The excess of NaOH was titrated 
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from the amount of NaOH required to deprotonate the carboxylic acid groups. The copolymer 
compositions and the content of acrylic acid in their structures, which was almost              
0.002 mol g
-1
 for all copolymers, are summarized in table 4.4. 
 
The molecular weight distribution of the copolymers was determined by gel 
permeation chromatography as exhibited in Figure 4.17 coupled with Waters 410 Differential 
Refractometer and two Ultrahydrogel TM linear 6–13 μm columns. The eluent employed was 
water (HPLC grade) at a flow rate of 1.0 mL min
-1
. Polyethylene oxide standards were used 







Figure 4.17 Molecular weight distribution of PVCL-b-PAA prepared in various solvents 
Although a detailed study of the copolymerization behavior of AA and NVCL as a 
function of solvent was not within the scope of this thesis, the data in table 4.4 demonstrated 
clear differences in the molecular weight (between 102580 and 378510 g mol
-1
) as well as 
polydispersity between these three samples. 
Table 4.4 Reaction parameters of PVCL-b-PAA 
 





PVCL-b-AA1 DMF 0.00261 378510 1.70 
PVCL-b-AA2 Dioxane 0.00202 271890 1.48 
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According to Kirsh et al, in the copolymerization of AA with similar vinyl monomers 
such as N-vinylpyrrolidone (NVPON) and N- vinylcaprolactam (NVCL), the reactivity of AA 
in polar environment (eg DMF) is much higher than that of NVPON and NVCL [55], which 
justifies the higher Mn with broad molecular weight distribution of the copolymer prepared in 
DMF. By making use of aprotic non polar solvent such as dioxane, the copolymerization 
parameter of NVCL increases, while that of AA decreases, leading to a medium Mn and 
medium molecular weight distribution. For the isopropanol, the reactivity of both AA and 
NVCL are almost equal, leading to a copolymer with low Mn and narrow molecular weight 
distribution. Consequently, Mw of copolymer could be tuned in accordance with the type of 
solvent selected for polymerization. 
The combination of acrylic acid (AA) as a pH sensitive monomer and         
temperature-responsive segment in a block copolymer leads to a system that responds to both 
pH and temperature stimuli (Figure 4.18). As reported previously, LCST of            
temperature-responsive copolymers is usually affected by a lot of factors including the block 
length, molecular weight distribution, chemical composition, nature of the comonomer, and 
polymer concentration. It is worth noting that for dual pH-temperature sensitive copolymers, 
pH has a great influence on LCST value as well. Therefore, LCST of temperature-sensitive 
polymer is expected to be altered by the attachment of acrylic acid chains, and it is expected 
to be raised if the acrylic acid block is hydrophilic, and lowered if it is hydrophobic. In some 
cases, LCST behavior can even be lost if the length of the acrylic acid block is too large [57]. 
 
 
Figure 4.18 Dual pH-temperature responsive behaviour of PNIPAM-b-PAA [58] 
 
As an illustration, Figure 4.18 describes the double pH-temperature responsive behavior of 
poly (N-isopropylacrylamide-b-acrylic acid) (PNIPAM-b-PAA) in aqueous solution. Clearly 
the solubility of the PAA blocks in aqueous solutions depends on the pH of the medium. That 
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and the less soluble this block becomes in aqueous media. At pH ~ 8.5 and higher pH, 
virtually all carboxylate groups are deprotonated, and the PAA segment is readily soluble in 
water. At pH between 7-8, and temperature above LCST, PNIPAM segment is insoluble in 
aqueous solution, and it is assumed that it forms the core of a micelle with PAA forming the 
corona [58]. At pH 4.5-5, when the temperature is raised above LCST, the formation of large 
aggregates occurs due to increasing insolubility of both protonated PAA corona and PNIPAM 
micellar core. These observations demonstrate diblock copolymer containing temperature- 
and pH-responsive segments self-assembled in water in response to both temperature and pH 
changes as clearly obvious in Figure 4.18. 
 
In order to assess pH responsive property of PVCL-b-PAA in aqueous solution, zeta 
potential as a function of pH was measured, and results are reported in Figure 4.19. 
 
pH responsive property of 1.0 mg mL
-1
 PVCL-b-PAA in buffer phosphate 10 mM 
was determined by zeta potential measurements as a function of pH as exhibited in Figure 
4.19 by using Zetasizernano series instrument. An equilibration time of 3 min was allowed 
before each measurement, and at least five replicate measurements were made for each 
sample. Figure 4.19 indicates that zeta potential of solution decreases from 0 to -30 mV by 
increasing pH. That is to say, PVCL and PAA are both water soluble (pH = 7) at room 
temperature in contrast to the PVCL-b-PAA copolymers. The lack of water solubility of the 
copolymer is attributed to complex formation by hydrogen bonding between the amide bonds 
of PVCL and carboxylic groups in the protonated form. Therefore, the pH-responsive 
polymer precipitated out of water below pH ~ 5 because of protonation of the carboxylic 
groups of the polymer (zeta potential near to 0), while they were water soluble above            
pH ~ 5 because of deprotonation of the acidic groups (zeta potential ~ -25 mV). 
Subsequently, the higher pH values of the solutions (pH ˃ 8) lead to the ionic dissociation of 
the carboxylic acid and therefore to less interactions between the AA and NVCL units of the 
PVCL-b-PAA copolymers. Consequently, these results clearly indicated a pH-dependent 
behavior of copolymer and evidenced PVCL-b-PAA can be exploited to control the delivery 
of drugs in specific organs or intracellular compartments (endosomes or lysosomes), which in 
principle allow for tailored drug release with excellent spatial, temporal and dosage control 
when subtle environmental changes are associated with pathological situations such as cancer 
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Zeta potential of PVCL-AAC 1.0 mg mL 
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Figure 4.19 Zeta potential of PVCL-b-AAC in buffer phosphate 10 mM with various pH values 
 
The influence of pH on the LCST of PVCL-b-PAA was investigated on 1.0 mg mL
-1
 
buffered aqueous solutions of copolymers (phosphate buffer 10 mM) with pH values ranging 
from 5.5 to 8.5 by a UV spectrophotometer equipped with a thermostatic bath. The heating 




 and before each measurement, the sample was left to thermalize at the 
desired temperature for 10 min. The obtained data are reported in table 4.5, and the 
turbidimetric curves of PVCL-b-PAA are shown in Figure 4.20.  
 
Table 4.5 LCST of PVCL-b-PAA1, PVCL-b-PAA2, and PVCL-b-PAA3 in buffer phosphate 10 mM, 
pH 5.5-8.5 
Table 4.5 demonstrates the presence of acid groups in polymeric backbone allows control of 
LCST by means of pH. At pH ~ 8.5 deprotonation of the carboxylic acid groups occurs, 
leading to increase hydrophilicity of copolymer, and subsequent enhance of LCST; on the 
Sample  Mn (g mol-1) LCST C), pH 5.5 LCST (C), pH 7.4 LCST (C), pH 8.5 
AA1 378510 35  35 40 
AA2 271890 40 45 50 
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other hand, in acidic pH (5-5.5) LCST shifts to lower values as a result of protonation of 
acidic group. 

















































































Figure 4.20 Transmission vs temperature curves for the PVCL-b-PAA copolymers in buffer phosphate 
10 mM (1.0 mg mL
-1
) at different pH. AA1 prepared in DMF (A), AA2 prepared in Dioxane (B), AA3 
prepared in Isopropanol (C) 
 
According to transmission versus temperature curves displayed in Figure 4.20, in all 
cases the transmission sharply reduced when the temperature was raised above the LCST of 
copolymers. This behavior can be explained considering that at T > LCST copolymer can 
form micellar structures with PVCL core and a PAA corona, in consequence of pH and 
temperature responsive behavior of copolymer in aqueous media [58]. 
Owing to the fact that the main purpose of this thesis is hyperthermia drug release at 
temperature above physiological body temperature (~ 37 

C), PVCL-b-PAA2 is the best 
candidate to fulfil this goal, in that its LCST is above 37 

C even at acidic pH (tumours pH). 
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Particle size and particle size distribution of aqueous solution of PVCL-b-PAA2 on      
2.0 mL of sample with concentration of 1.0 mg mL
-1
 was determined by Dynamic Light 
Scattering (DLS). Corresponding to the measurement, the copolymer has narrow size 
distribution (PDI, 0.8) with the intensity-average hydrodynamic diameter of 68.0 nm as 
exhibited in Figure 4.21. 




















Figure 4.21 Size distribution of PVCL-b-PAA2 
 
 
Figure 4.22 TEM image of PVCL-b-PAA2 
Morphology of PVCL-b-PAA2 was considered by transmission electron microscopy, 
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15.0-65.0 nm, which is in good agreement with the hydrodynamic diameter obtained by DLS 
characterization. A representative example of polymer morphology is reported in Figure 4.22.  
 
Micelle formation of PVCL-b-PAA2 in aqueous solution at elevated temperature 
above LCST was evaluated by dynamic 
1
HNMR and DLS analyses.  
 
In this step, 
1
HNMR spectroscopy as an experimental technique was employed to 
study the temperature-induced collapse of PVCL segment (micelle formation) in              
PVCL-b-PAA2 diblock copolymer as displayed in Figure 4.23. 
 
Figure 4.23 shows the 
1
HNMR spectra of PVCL-b-PAA2 in deuterium oxide with 




C (T < LCST) and 48 

C (T > LCST). At the lower 
temperature, the diblock copolymer is molecularly dissolved in water by addition of NaOD 
0.1M, and all peaks associated with PVCL and PAA segments are present in the 
1
HNMR 
spectrum as shown in Figure (4.23, a). On the other hand, increasing temperature to 48 

C 
causes the collapse of PVCL blocks and self-assembly of the PVCL-b-PAA2 copolymer 
chains (micelle formation) as evidenced by the pronounced decrease of the peak intensity of 
PVCL block at 4 ppm, while the peaks related to PAA segment (1.75–2.5 ppm), which is still 
soluble at this temperature, are observable in the 
1
HNMR spectrum according to Figure   
(4.23, b). Thus, at 48 

C, the PVCL resonance peak intensity is significantly lowered than one 
at 25 

C because of the highly restricted motions of the PVCL segments as a result of the 
PVCL collapse. Dynamic 
1
HNMR analyses results, therefore, confirmed that copolymer has 
LCST over 45 









HNMR spectra of PVCL-b-PAA2 in D2O (1.0 mg mL
-1
) at 25 

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Hydrodynamic diameter (Dh) of the PVCL-b-PAA2 buffer solutions (1.0 mg mL
-1
) at 
different pH is plotted against temperature according to DLS measurements as displayed in 
Figure 4.24. Results are summarized in table 4.6, and compared with ones obtained by 
turbidimetry method. Obviously, a dramatic increase in Dh within a very narrow temperature 
range is detected from Figure 4.24. This is attributed to the thermo-induced dehydration of 
the PVCL block above its LCST that caused generation of thermo-induced physically 
assembled micelles [58] as demonstrated in Figure 4.25.  
 
























 1.0 mg mL 
-1
, pH 5.5
 1.0 mg mL 
-1
, pH 7.4




Figure 4.24 Dependence of Dh on the temperature for the PVCL-b-PAA2 copolymer solutions with 
concentration of 1.0 mg mL
-1









Figure 4.25 Self-Assembly of PVCL-b-PAA2 diblock copolymer in solution above LCST 
 
Table 4.6 indicates that the obtained data are in good agreement with those obtained 
from turbidity method and 
1
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indicated a pH-dependent LCST behavior of copolymer, which can be tailored to fall just 
above the physiological temperature by simply adjusting hydrophilicity of the acrylic acid 









Table 4.6 LCST of copolymer solution in buffer phosphate 10 mM with concentration of 1.0 mg mL
-1 
 
To conclude, we have demonstrated the synthesis of PVCL homopolymer and block 
PVCL-b-PVPON copolymer via well-controlled RAFT (co)polymerization. Polymers were 
characterized by 
1
HNMR, GPC, TEM, and FTIR. The heat-induced behavior of the 
synthesized copolymers in solution was studied using 
1
HNMR, turbidimetry, and DLS. All 
(co)polymers dissolved in water at ambient conditions below their cloud point values, and 
micellar morphologies were demonstrated to form from the (co)polymers at temperatures 
above their LCST due to the temperature-triggered association of dehydrated PVCL 
segments. The association temperature can be decreased by increasing (co)polymer 
concentration, or increasing the polymerization degree with the hydrophilic PVPON segment.  
Diblock copolymers PVCL-b-PAA prepared according to free radical polymerization 
containing temperature- and pH-responsive segments at an appropriate composition self 
assembled in water in response to both temperature and pH changes. The cloud point 
temperatures of the buffered solutions of this copolymer has a maximum value at pH around 
8.5, which is determined by the counterbalance of the hydrophilic charged carboxylate groups 
and the destabilizing effect of the cations. Moreover, The the presence of carboxyl groups 
derived from poly acrylic acid units of the copolymer could offer the potential to build up 
multifunctional nanocomposite for effective drug delivery in therapeutic application. 
 
Buffer solution of PVCL-b-PAA2 with concentration of 1.0 mg mL
-1 
pH LCST (C)- UV LCST (C)- DLS 
8.5 50 45 
7.4 45 40 




96 pH & Temperature-Responsive Polymer 
Chapter 4 
References 
1. M. Szwarc. Advances in polymer science. 1983, 49, 1-177. 
2. HL. Hsieh.; RP. Quirk. Anionic polymerization: principles and practical applications. 
1996, 1st edn. Marcel Dekker, New York, 1-711. 
3. G. Moad.; E. Rizzardo.; SH. Thang. Acc Chem Res. 2008, 41, 1133. 
4. M. Szwarc. Ionic polymerization and living polymers. 1993, 1st edn. Chapman & Hall, 
New York. 
5. O. F. Solomon.; D. S. Vasilescu.; V. Tararescu. J. Appl. Polym. Sci. 1969, 13, 1. 
6. C. Wu.; A. C. W. Lau. Macromolecules. 1999, 32, 581. 
7. L. Shao.; M. Hu.; L. Chen.; L. Xu.; Y. Bi. React Funct Polym. 2012, 72, 407. 
8. Y. Deng.; S. Zhang.; G. Lu.; X. Huang. Polym. Chem. 2013, 4, 1289.  
9. M. Destarac. Polym. Rev. 2011, 51, 163. 
10. a) V. Sciannamea.; R. Jerome.; C. Detrembleur. Chem. Rev. 2008, 108, 1104, b) J. 
Nicolas.; Y. Guillaneuf.; C. Lefay.; B. Charleux. Prog. Polym. Sci. 2013, 38, 63. 
11. J. S. Wang.; S. G. Gaynor.; J. Matyjaszewski. Polym. Prepr. 1995, 36, 465. 
12. N. Zhang.; S. R. Samanta.; B. M. Rosen.; V. Percec. Chem. Rev. 2014, 114, 5848. 
13. a) J. Chiefari.; Y. Chong.; F. Ercole.; J. Krstina.; G. Moad. Macromolecules. 1998, 3, 
5559, b) M. J. Flanders.; W. M. Gramlich. Polym. Chem. 2018, 9, 2328. 
14. a) A. Debuigne.; R. Poli.; C. Jerome.; R. Jerome.; C. Detrembleur. Prog. Polym. Sci. 
2009, 34, 211, b) M. Hurtgen.; C. Detrembleur.; C. Jerome.; A. Debuigne. Polym. Rev. 
2011, 51, 188, c) L. E. Allan.; M. R. Perry.; M. P. Shaver. Prog. Polym. Sci. 2012, 37, 
127. 
15. Z. M. O. Rzae.; S. Dincer.; E. Piskin. Prog. Polym. Sci. 2007, 32, 534. 
16. H. Wei.; S. X. Cheng.; X. Z. Zhang.; R. X. Zhuo. Prog. Polym. Sci. 2009, 34, 893. 
17. M. Hurtgen.; J. Liu.; A. Debuigne.; C. Jerome.; C. Detrembleur. J. Polym. Sci. Polym. 
Chem. 2012, 50, 400. 
18. M. Beija.; J. D. Marty.; M. Destarac. Chem. Commun. 2011, 47, 2826. 
19. a) X. Y. Jiang.; Y. J. Li.; G. L. Lu.; X. Y. Huang. Polym. Chem. 2013, 4,1402, b) X. Y. 




97 pH & Temperature-Responsive Polymer 
20. a) P. Singh.; A. Srivastava.; R. Kumar. J. Polym. Sci. Polym. Chem. 2012, 50, 1503, b) 
I. Negru.; M. Teodorescu.; P. O. Stanescu.; C. Draghici.; A. Lungu.; A. Sarbu. Mater. 
Plast. 2010, 47, 35. 
21. A. Kermagoret.; C. A. Fustin.; M. Bourguignon.; C. Detrembleur.; C. Jérôme.; A. 
Debuigne. Polym. Chem. 2013, 4, 2575. 
22. C. Detrembleur.; M. C. De Pauw-Gillet.; S. Mornet.; E. Duguet.; C. Jerome. Polym. 
Chem. 2014, 5, 799. 
23. D. C. Wan.; Q. Zhou.; H. T. Pu.; G. J. Yang. J. Polym. Sci. Polym.Chem. 2008, 46, 
3756. 
24. S. perrier.; P. Takolpuckdee. J. Polym Sci. Part A. Polym Chem. 2005, 43, 5347.  
25. Y. C. Yu.; U. H. Kang.; J. H. Youk. Colloid Polym. Sci. 2012, 290, 1107. 
26. a) M. L. Tebaldi.; L. A. Fiel.; A. M. Santos.; S. S. Guterres.; A. Pohlmann. J. 
Macromol. Sci. Pure Appl. Chem. 2013, 60, b) S. M. Ponce-Vargas.; N. A. Cortez-
Lemus.; A. Licea-Claverie. Macromol. Symp. 2013, 56, 325. 
27. G. Moad.; E. Rizzardo.; S. H. Thang. Acc. Chem. Res. 2008, 41, 1133. 
28. J. Chiefari.; R. Mayadunne.; C. L. Moad.; G. Moad.; M. A. Skidmore. Macromolecules. 
2003, 36, 2273. 
29. N. A. Cortez-Lemus.; A. Licea-Claverie. Prog. Polym. Sci. 2016, 53, 1. 
30. A. B. Lowe.; C. L. McCormick. Prog Polym Sci. 2007, 32, 283. 
31. G. Moad.; E. Rizzardoand.; S. H. Thang. Polym. Int. 2011, 60, 9. 
32. H. Willcock.; R. K. O'Reilly. Polym. Chem. 2010, 1, 149. 
33. A. S. Hoffman. Adv. Drug Deliv. Rev. 2013, 65, 10. 
34. B. Jeong.; S. W. Kim.; Y. H. Bae. Adv. Drug Deliv. Rev. 2002, 54, 37. 
35.  E. C. Abenojar.; S. Wickramasinghe.; J. Bas-Concepcion.; A. C. S. Samia. Prog Nat 
Sci Mater Int. 2016, 26, 440. 
36. a) D. C. Wan.; Q. Zhou.; H. T. Pu.; G. J. Yang. J. Polym. Sci. Polym. Chem. 2008, 46, 
3756, b) J. Spevacek.; J. Dybal.; L. Starovoytova.; A. Zhigunova. Soft Matter. 2012, 8, 
6110. 
37. a) F. Meeussen.; E. Nies.; H. Berghmans.; S. Verbrugghe.; F. Du Prez. Polymer. 2000, 
41, 859, b) Y. Maeda.; H. Yamamoto.; I. Ikeda. Langmuir. 2001, 17, 6855. 
38. H. Vihola.; A. Laukkanen.; L. Valtola.; H. Tenhu.; J. Hirvonen. Biomaterials. 2005, 26, 
3055. 
39. J. Ramos.; A. Imaz.; J. Forcada. Polym. Chem. 2012, 3, 852. 




98 pH & Temperature-Responsive Polymer 
41. a) P. Arsula Rose.; P. K. Praseetha.; M. Bhagat.; P. Alexander. Technol Cancer Res 
Treat. 2013, 12, 463, b) L. M. Sanchez.; D. A. Martin.; V. A. Alvarez.; J. S.Gonzalez. 
Colloids Surf A. 2018, 543, 28. 
42. X. Liang.; E. Kharlampieva.; Y. Wang.; V. Kozlovskaya. J. Polym. Sci. part A: Polym. 
Chem. 2014, 52, 2725. 
43. M. Beija.; J. D Marty.; M. Destarac. Prog. Polym. Sci. 2011, 36, 845. 
44. X. Zhao.; O. Coutelier.; C. Delmas.; M. Destarac.; J. D. Marty. Polym. Chem. 2015, 6, 
5233. 
45. D. Wan.; Q. Zhou.; H. Pu.; G. Yang. J. Polym. Sci. Part A: Polym. Chem. 2008, 46, 
3756. 
46. M. Destarac.; C. Brochon.; J-M. Catala.; A. Wilczewska.; S. Z. Zard. Macromol. Chem. 
Phys. 2002, 203, 2281. 
47. J. U. Izunobi.; C. L. Higginbotham. J. Chem. Educ. 2011, 88, 1098. 
48. G. Vancoillie.; D. Frank.; R. Hoogenboom. Prog. Polym. Sci. 2014, 39, 1074. 
49. X. Liang.; V. Kozlovskaya.; Y. Chen.; O. Zavgorodnya.; E.Kharlampieva. Chem. 
Mater. 2012, 24, 3707. 
50. J. E. Chung.; M. Yokoyama.; T. Aoyagi.; Y. Sakurai.; T. Okano. J. Control. Release. 
1998, 53, 119. 
51. E. Yu. Kozhunova.; Q. Ji.; J. Labuta.; I. R. Nasimova. eXPRESS Polymer Letters. 2018, 
12, 1005.  
52. H. G. Schild. Prog. Polym. Sci. 1992, 17, 163. 
53. a) C. M. Lehr.; J. A. Bouwstra.; H. E. Bodde.; H. E. Junginger. Pharm. Res. 1992, 9, 
70, b) H. Brondsted.; J. Kopecek. ACS Symp. Ser. 1992, 480, 285, c) R. Kishi.; T. 
Miura.; H. Kihara.; T. Asano.; Yosomiya. J. Appl. Polym. Sci. 2003, 89, 75, d) D. 
Kuckling.; A. Richter.; K. F. Arndt. Macromol. Mater.Eng. 2003, 288, 144, e) V. T. 
Pinkrah.; M. J. Snowden.; J. C. Mitchell.; G. R. Fern. Langmuir, 2003, 19, 585, f) S. R. 
Lustig.; G. J. Everlof.; G. D. Jaycox. Macromolecules, 2001, 34, 2364, g) A. Hervault.; 
A. E. Dunn.; M. Lim.; C. Boyer.; D. Mott.; N. T. K. Thank. Nanoscale. 2016, 8, 12152, 
h) Y. Zheng.; L. Wang.; L. Lu.; Q. Wang.; B. C. Benicewicz. ACS Omega. 2017, 2, 
3399. 
54. S. M. Ponce-Vargas.; N. A. Cortez-Lemus.; A. Licea-Claverı´. Macromol. Symp. 2013, 
325-326, 56.  
55. N. I. Shtanko.; W. Lequieu.; E. J. Goethals.; F. E. Du Prez. Polym Int. 2003, 52, 1605. 




99 pH & Temperature-Responsive Polymer 
57. V. Bulmus.; Z. Ding.; C. J. Long.; P. S. Stayton.; A.S. Hoffman. Bioconjugate Chem. 
2000, 11, 78. 
58. C. M. Schilli.; M. Zhang.; E. Rizzardo.; S. H. Thang.; A. H. E. Muller. 


















100 Stimuli Responsive Magnetic Nanocomposite 
Chapter5 
Encapsulation of Magnetic Nanoparticles by Thermoresponsive 
Polymers 
The functionalization of magnetic nanoparticles (MNPs) surface is a useful method 
for tuning the overall properties of nanoparticles to fit targeted applications. The surface 
modification of MNPs by functional molecules/polymers has different tasks to fulfill [1]:       
(i) provide functional groups at the surface for further derivatization, (ii) enhance MNPs 
stabilization in various solvents extending their application possibilities, (iii) modify the 
capability to assemble the particles in specific arrays, or the ability to target desired chemical, 
physical, or biological environments, and (iv) reduction of their toxicity. Consequently, 
appropriate surface functionalization of MNPs, which makes them biocompatible and         
bio-specific, is a prerequisite for various nano-bio applications. 
Despite the potential benefits that functionalized MNPs have rendered to 
nanomedicine, some applications remains still challenging; for instance, in vivo efficient drug 
delivery inside the target cell. In this context, the decoration of MNPs with smart polymer 
could significantly improve already existing MNPs characteristics, and help to surmount this 
challenge. Therefore, in our work, with the aim of improving multi-modal cancer therapy, we 
propose a novel approach to obtain polymer coated magnetic nanoparticles as agents for 
combined drug delivery and hyperthermia. The composite nanoparticles (CNP) used in this 
work consisted of superparamagnetic iron oxide nanoparticles coated by thermo-responsive 
(co)polymers including poly-N-vinylcaprolactm (PVCL), poly (N-vinylcaprolactam-b-
vinylpyrrolidone) (PVCL-b-PVPON), and dual stimuli responsive poly (N-vinylcaprolactam-
b-acrylic acid). In the present chapter we will discuss the synthesis of the two building blocks 
of the core-shell nanosystems, and we will present the strategy adopted for encapsulation of 
Fe3O4-68 in the stimuli-responsive (co)polymers, performed via post modification         
‘grafting to’ and ‘grafting from’ methods. Moreover, we will show how the polymeric shell 
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5.1. Modification of MNPs 
Uncoated iron oxide MNPs are not stable in water at neutral pH or in physiological 
fluids, tending to agglomerate and precipitate quickly. Since nanoparticles (NPs) attract to 
each other due to magnetic dipolar interactions and weaker Van der Waals forces, surface 
modification of MNPs is often indispensable to make the NPs suspensions stable.  
There is a wide variety of functionalization methods for modification of the surface of 
magnetic nanoparticles including [2]: 
1. Anchoring of a functional group  
2. Stabilization of iron oxide MNPs using polymer chains 
 Grafting ‘onto’ versus ‘from’ 
 Stabilization of iron oxide MNPs using monofunctional polymer 
chains via exchange chemistry 
 Stabilization of iron oxide MNPs using functional diblock polymers 
3. Micelle and liposome encapsulation 
5.1.1 Anchoring of Ligand with Specific Functional Group 
 
Figure 5.1 Groups that can be used to anchor polymers on iron oxide MNPs surfaces [2] 
The presence of iron-derived positive charges on the surface of MNPs due to the lack 
of oxygen ions, which determine vacancies, provides a versatile synthetic handle, allowing 
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nanoparticles by exploiting electrostatic, hydrophobic, chelating, and covalent interactions as 
demonstrated in Figure 5.1. 
One of the most important and widely employed functional groups is the carboxylic 
acid, which can coordinate to the surface of iron oxide MNPs covalently. For instance, the      
–COOH group of oleic acid has been employed for iron oxide MNPs surface decoration 
during synthesis in organic solvents. Citric acid has been used commercially for the 
stabilization of iron oxide MNPs such as in the MRI contrast agent VSOP C184. However, 
the –COOH/MNPs coordination bond is labile and can be broken easily by increasing 
temperature or by exchange with another carboxylic acid compound [3-7].  
Phosphonic acid also shows a strong affinity for iron oxide MNPs surfaces through 
the formation of Fe–O–P– bonds [8]. These bonds are more stable than the carboxylic acid 
bond, and have shown stability for several weeks at neutral pH. Moreover, phosphonic acid 
has a higher grafting density than the carboxylic acid group [8]. 
Finally, dopamine can coordinate to the iron oxide MNPs surfaces as a result of 
improved orbital overlap of the five-member ring [9]. This approach has been widely used to 
attach a range of biologically important molecules such as peptides and amino acids to iron 
oxide MNPs [10]. However, problems with the stability of this bond in water and biological 
fluids have been reported by Carpenter et al. after long exposure periods [11]. Phosphonic 
acid and dopamine groups appear to improve iron oxide MNPs stability over a larger range of 
pH and temperature compared with carboxylic acid groups. 
5.1.2 Stabilization of MNPs Using Polymer Chains 
For many applications in medicine, a polymer coating on the iron oxide MNPs is 
preferred over simple functionalization with small organic compounds. A polymer coating 
provides colloidal stability in water through steric stabilization, and can provide surface 
functionality allowing the possibility of designing hybrid particles with capacity for 
multimodal tracking, targeting, delivery, and stimulated release of therapeutic agents such as 
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5.1.3 Grafting ‘to’ Versus ‘From’ 
Nanohybrids comprising a polymer and an inorganic support can be generally 
prepared by four main methods as schematized in Figure 5.2:  
(a) “in situ” preparation, in which the inorganic support is synthesized from a 
precursor in the presence of the polymer;  
(b) surface-initiated polymerization / “grafting from”, in which the inorganic surface 
is functionalized with an initiator or a chain transfer agent (CTA) and then polymerization of 
the desired monomer is carried out;  
(c) post-modification / “grafting to”, in which preformed polymer and inorganic 
support are mixed together, and the polymer chains physically adsorb onto                        
(post-modification) or covalently bind (“grafting to”) the inorganic surface; 
(d) “grafting through”, in which the polymerization of a given monomer is carried out 
in the presence of the support, previously modified with polymerizable moieties.  
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Each of these approaches has advantages and disadvantages. It is well known that 
grafting ‘from’ yields a higher grafting density than the grafting ‘to’ approach. However, 
grafting ‘to’ allows control of polymer architecture and functionality, and is therefore more 
versatile than the grafting ‘from’ method. In addition, grafting ‘from’ can present difficulties 
in maintaining the integrity of the hybrid nanoparticles in organic solvents. However, the use 
of living radical polymerization with a carefully designed protocol can facilitate the 
modification of iron oxide MNPs, using the grafting ‘from’ approach [12-17]. 
5.1.4 Stabilization of Iron Oxide MNPs Using Monofunctional Polymer Chains via 
Exchange Chemistry 
The attachment of polymer chains onto iron oxide MNPs can be achieved using 
polymers with functionality capable of binding to the iron oxide MNPs by exchange of 
surface ligands. State-of the- art of these methods is to prepare inorganic nanoparticles that 
are stabilized by alkyl phosphines, amines, thiol, or carboxylic acids. These groups have 
proven to be most efficient in controlling nanocrystal growth during synthesis, and to provide 
stability of the final particles in solution. The exchange of these surface ligands with 
polymers could be an attractive route for a flexible and versatile polymer attachment [18-20]. 
5.1.5 Stabilization of Iron Oxide MNPs Using Functional Diblock Polymers 
The attachment of polymer chains to iron oxide MNPs can also be achieved via 
multiple interactions between the polymer chains and the particle surface. This multiple 
attachment strategy should enhance the stability of the resultant hybrid nanoparticles, and can 
be achieved through the use of block or random copolymers. The insertion of several 
functional groups along the copolymer backbone increases the number of possible anchoring 
points on the iron oxide MNPs surface. However, the control of polymer architecture is a 
crucial factor influencing polymer aggregation. As a case in point, when statistical 
copolymers are used, the presence of multiple groups on the backbone can result in 
interactions with several particles leading to flocculation, so in the case of di- and multi-block 
polymers, the functional block should be kept relatively short (several units) to avoid 
flocculation. The introduction of several attachment points on a single chain can also reduce 
the packing density. Many examples exist of this multi-interaction approach, based on the use 
of different types of functionality, such as dopamine [21], carboxylic acid [22] and trimethyl 
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5.2 Encapsulation of Magnetic Nanoparticles by Poly N-vinylcaprolactam via Post 
Modification Method 
As a first attempt, Fe3O4 nanoparticles (Fe3O4-68) were encapsulated by                   
poly (N-vinylcaprolactam) via ‘’grafting to’’ method. Indeed, we expected that carbonyl 
group from thermo-responsive PVCL can make coordinate covalent bond by donating 
electrons to the empty d-orbital of the metal (Fe) to bond strongly on the surface of MNPs. 
To this aim, 13.5 mg of DEG-stabilized Fe3O4-68 was mixed with the 4.0 mL DEG 
containing 10.0 mg PVCL. The resulting suspension was sonicated and stirred for two hours 
at room temperature. Afterward, the obtained nanocomposite was precipitated by addition of 
acetone and recovered by magnet decantation. Then, final nanocomposite was dispersed into 
20.0 mL buffer phosphate (10 mM, pH = 7.4), and the concentration of the suspension was 
determined by ICP analysis. According to ICP-AES measurement, a mean concentration of 
magnetic nanocomposite dispersed in solution was about 0.11 wt % respect to the Fe3O4 
nanoparticles. Details of the encapsulation procedure of Fe3O4 coated PVCL is given in 
Appendix A.7.  
Morphological characteristics of magnetic nanoparticles with and without                
poly (N-vinylcaprolactam) coating are shown in the TEM micrographs of Figure 5.3. Figure 
(5.3, A), a typical TEM image of the MNPs after the coating, clearly shows that most of the 
nanoparticles are polycrystalline nearly spherical in shape, with an average diameter of          
18.0 nm, as evaluated from a statistical analysis over 300 iron oxide nanoparticles. For 
comparison, Figure (5.3, C) illustrates a TEM image of MNPs before polymer coating, with 
the same average size of 18 nm, so the comparison between these two images suggests that 
the most of nanoparticles are still uncoated or, alternatively the thickness of the polymer is 
very thin; moreover, Figure (5.3, D) displays the size distribution of a suspension of MNPs 
after polymer coating, which was obtained from three independent runs                                 
(15 measurements each). The average diameter of MNPs, was found 39.0 nm (PDI ~ 0.22), 
much larger than that found from TEM, indicating that the MNPs are largely aggregated due 
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Figure 5.3 TEM images of Fe3O4-68 after the polymer conjugation (A), PVCL nanosphere (B), Fe3O4-68 
before polymer conjugation (C), DLS histogram of hydrodynamic diameter of a Fe3O4-68@PVCL (D)  
 
To clarify this point the weight loss of the functionalized Fe3O4-68 was determined by 
using a thermogravimetric analyzer under a nitrogen atmosphere (60 cm
3
/min). The sample, 
which contains 30.6 mg of the thermoresponsive coated Fe3O4-68, was heated from room 
temperature to 1000 C with the heating rate set at 5 C/min. TGA curve for PVCL–MNPs as 
displayed in Figure 5.4 revealed weight losses occurred at two steps. The first step between      
100 

C and 190 

C was due to the loss of residual water in the sample. The pronounced 
weight loss between 200 

C and 600 

C was related to the degradation of PVCL [24]. There 
was no significant weight change between 600 

C and 1000 

C, implying the presence of only 
iron oxide within the temperature range. Figure 5.4 also exhibits TGA curve of Fe3O4-68 NPs 
before polymer coating. The first significant weight loss between 40 

C and 193 

C            
(0.54 wt %) can be attributed to the evaporation of water molecules on the surface. The sharp 
mass loss observed around 200 

C to 550 

C (3.1 wt %) corresponds to the combustion of 
diethylen glycol (DEG) in the sample. 
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Figure 5.4 Thermogravimetric analysis of PVCL functionalized Fe3O4-68 (red line) and uncoated 
MNPs (blue line) 
 
From the percentage of weight loss in the TGA curve, the composition of the       
Fe3O4-68 @ PVCL was estimated 91.0 wt % Fe3O4-68 and 9.0 wt % PVCL. These results 
indicated that Fe3O4-68 was not successfully encapsulated by PVCL.  
To conclude, according to TEM and TG analyses, the smart nanocomposite 
containing Fe3O4-68 core and PVCL shell did not fulfil our goal as we expected, likely due to 
the weak thermoresponsive polymer adherence on their surface. To overcome this drawback, 
MNPs were encapsulated by thermoresponsive copolymer PVCL-b-PVPON by          
‘’garfting to’’ approach to provide stable suspension usable for biological system.  
5.3 Encapsulation of Magnetic Nanoparticles by PVCL-b-PVPON by Post Modification 
Method 
The same procedure as that used for Fe3O4-68@PVCL preparation was employed to 
prepare Fe3O4-68 @PVCL-b-PVPON nanocomposite. The obtained product was suspended 
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stability problem. Preparation procedure of this nanocomposite is explained completely in 
Appendix A.8.  
Morphology of coated Fe3O4-68 was investigated by TEM as shown in                
Figure (5.5, A). In this case also from TEM images is not possible to distinguish 
encapsulation of MNPs by copolymer.  
 
Figure 5.5 TEM views of Fe3O4-68 after polymer conjugation (A) the PVCL-b-PVPON (B), DLS 
histogram of hydrodynamic diameter of a Fe3O4-68@PVCL-b-PVPON suspension (C), Fe3O4-68 NPs 
before the copolymer conjugation (D) 
Similarly, DLS analysis (Figure 5.5, D) was performed by six independent runs                   
(15 measurements each) on 1.0 mL of suspension, and results indicated that the 
hydrodynamic radius of the coated MNPs in suspension is 45 nm with PDI ~ 0.22, which is 
larger than that found from TEM, which could be as a result of aggregation.  
The organic content of the Fe3O4-68@PVCL-b-PVPON was determined using TGA 
in the temperature range from 25 

C to 1000 

C under a nitrogen atmosphere (60 cm
3
/min). 
Figure 5.6 reveals the weight loss of the functionalized MNPs as a function of temperature 
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occurs in two steps. The first step between 100 

C and 200 

C is attributed to the loss of 
residual water in the sample, while the second mass loss observed around 215 

C to 575 

C 
can be ascribed to the degradation of PVCL-b-PVPON. Moreover, according to the          
Figure 5.6, in the absence of a polymer coating, the weight loss is about 4.0 wt % for the 
whole temperature range, corresponding to the desorption of water and combustion of DEG 
from the surface of Fe3O4-68. 





























Figure 5.6 Thermogravimetric analysis of PVCL-b-PVPON functionalized Fe3O4-68 (blue line) and 
uncoated MNPs (red line) 
Based on the percentage of weight loss in the TGA curve, the composition of the             
Fe3O4-68@ PVCL-b-PVPON contained 85.0 wt % MNPs and 15.0 wt % PVCL-b-PVPON, 
indicating that the PVCL-b-PVPON was bound to the MNPs surface with low yield. 
Encapsulation of Fe3O4-68 with thermo-responsive PVCL-b-PVPON was also 
analyzed by FT-IR measurement, displayed in Figure 5.7. For the IR spectrum of                   
Fe3O4@PVCL-b-PVPON, the broad band (3000–3500 cm
-1
) centered around 3383 cm
-1
 can 
be originated from residual water. The aliphatic C-H stretching peaks, which located at      
2937 cm
-1
 and 2865 cm
-1
 with low intensity, suggesting the small quantity of copolymer shell 
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absorption bands at around 1661-1624 cm
-1 
correspond to characteristic carbonyl amide 
bonds (NHC=O) of PVCL-b-PVPON (Appendix A.5, Figure A.4), were not appeared in the 
FT-IR spectrum of polymer coated MNPs. 











































Figure 5.7 FTIR spectra of Fe3O4-68 coated with PVCL-b-PVPON (blue line) and Fe3O4-68 (red line) 
However, two characteristic absorption bands, assigned at 588 cm
-1
 and 418 cm
-1
, which are 
the characteristic peaks of the stretching vibration of Fe-O bonds from MNPs were clearly 
observed for both samples. Furthermore, the characteristic absorption band appeared at         
3390 cm
-1
 in the spectrum of MNPs was attributed to the water. 
To summarize, these data confirm that functionalization of Fe3O4-68 by            
thermo-responsive PVCL-b-PVPON through ‘’grafting to’’ approach did not proceed as 
expected. We, thus, decided to modify (co)polymer structure by grafting acrylic acid units in 
polymeric backbone to directly anchor the polymer on MNPs surface. In fact, as previously 
discussed, poly acrylic acid can easily bind to iron oxide MNPs and stabilize them, providing 
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carboxylate groups on the surface allows further modifications such as bioconjugation for in 
vivo application. 
5.4 Functionalization of Fe3O4-68 by In Situ Copolymerization of PVCL-b-PAA 
As alternative route, we explored in situ copolymerization, which is a well established 
technique to prepare magnetic nanocomposites. Indeed, this technique offers several 
advantages such as simplicity, (especially for the embedding of MNPs in cross-linked 
nanogel or microsphere) [25], having control on polymer chain length and molecular weight 
with high drug loading capacity [26].  
As demonstrated in Scheme 5.1, the decoration of Fe3O4-68 surface by PVCL-b-PAA 
temperature sensitive copolymer was performed directly in situ on Fe3O4-68 (0.2 mol % with 
respect to NVCL) by free radical copolymerization between N-vinylcaprolactam              
(NVCL, 90.0 mol %), acrylic acid (AA, 10.0 % mol), and 2.0 mol % of AIBN (initiator) 
dissolved in 15.0 mL DMF. The obtained functionalized Fe3O4-68 NPs were dispersed in      









5 h, 70 C
 
 
Scheme 5.1 Encapsulation of Fe3O4-68 by thermo-responsive copolymer PVCL-b-PAA 
Particle size and size distribution of encapsulated Fe3O4-68 (0.011 wt % of Fe3O4 
according to ICP analysis) were determined by DLS measurement on 2.0 mL of suspension 
as shown in Figure 5.8, and average particle size was estimated corresponding to three 
independent runs (15 measurements each run). DLS result indicated that particles are nearly 
uniform in size with PDI ~ 0.247 and with average hydrodynamic diameter of 128.0 nm. 
Moreover, negative surface charge of -17.0 mV was obtained consistently with the presence 
of carboxylate group on the surface of the nanosystems. However, for electrostatic 
stabilization of the MNPs, a high zeta potential above -30.0 mV is required; accordingly, 
under the copolymerization conditions utilized for MNPs in DMF the reaction did not give 
the desired colloidally stable nanocomposite, and polymer coated nanoparticles precipitated 
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Figure 5.8 Size distribution of in situ encapsulated Fe3O4-68 by thermoresponsive PVCL-b-PAA 
5.5 Functionalization of Fe3O4-68 by PVCL-b-PAA Corresponding to “Grafting to” 
Method  
Since also in situ polymerization did not afford the desired product, we made another 
attempt using a covalent “grafting to” approach between PVCL-b-PAA copolymer and 
amine-surface functionalized Fe3O4-68 to stabilize nanoparticles. For this purpose, as shown 
in Scheme (5.2, a), aqueous suspension of Fe3O4-68@6-AHPA (preparation procedure is 
described in Appendix A.9.2) was mixed with a methanolic solution containing              
PVCL-b-PAA2, (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), and 
N-hydroxysuccinimide (NHS) as carboxylic group activators, and the obtained functionalized 
Fe3O4-68 MNPs were dispersed in 10.0 mL buffer phosphate 10 mM, pH = 7.4. The same 
procedure was also repeated in ethanol using 4-(dimethylamino) pyridine (DMAP), and      
N,N'-Dicyclohexylcarbodiimide (DCC) as coupling reagents, to facilitate amide bond 
formation between acrylic acid units of copolymer and amine group on the surface of       
Fe3O4-68 (Scheme 5.2, b), and similarly the obtained MNPs were dispersed in 10.0 mL buffer 
phosphate 10 mM, pH = 7.4. Notwithstanding the fact that there are many publications 
concerning functionalization of MNPs by thermoresponsive polymer via amide bond 
formation, in our case, this approach was not suitable enough to give highly stable smart 
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modification of Fe3O4-68 by temperature sensitive PVCL-b-PAA2 via strong coordinate 
bonding (this type of interaction is central to lewis acid-base theory) between carboxylic acid 
units as an anchor to iron oxide surface without addition of any crosslinker as displayed in 













































Scheme 5.2 Surface functionalization of Fe3O4-68 by thermoresponsive copolymer 
In this way, encapsulation of Fe3O4-68 was performed by simply mixing aqueous copolymer 
solution with Fe3O4-68 nanoparticles under sonication for 1 h and agitation at room 
temperature overnight. Full experimental details of the synthesis procedure are given in 
Appendix A.10. The obtained nanoparticles were dialyzed by dialysis bag                    
(MWCO ~ 14 KDa) against distilled water, and directly utilized for DLS and ICP 
characterization. ICP analysis indicated mean concentration of magnetic nanocomposite 
dispersed in 20.0 mL solution was about 0.14 wt % respect to the Fe3O4 nanoparticles 
The average size of Fe3O4-68 coated PVCL-b-PAA2 was found ca. 99.0 nm by DLS 
analysis according to 15 measurements based on four independent runs on 1.0 mL of 
suspension as exhibited in Figure 5.9. A uniform dispersion of nanocomposite with the 
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In order to consider stability of surface modified MNPs suspension and effectiveness 
of surface modification method, zeta potential was measured. According to the measurement 
for the smart nanohybrid suspension the zeta potential value was -36.0 mV, confirming the 
suspension was highly stable in neutral pH, and the negative surface charge evidenced the 
presence of acrylic acid block grafted strongly on the iron oxide nanoparticles surface.  




























Figure 5.10 Zeta potential as a function of pH measured by dispersion the smart 
nanocomposite in buffer phosphate solution and then adjusting the pH with NaOH 
0.1M  
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In order to check the pH responsive behavior of the nanosystem, the zeta potential of 
suspension was measured as a function of pH at room temperature, and results are reported in 
Figure 5.10. 
Smart nanohybrids are highly stable from pH 5.5 to 12 with large negative surface 
charge (from -38.0 to -33.0 mV) due to the deprotonation of carboxylic acid units. As pH 
reduced below 5, the dispersion started losing the stability and complete precipitation 
occurred as a result of protonation of carboxylic groups, which caused small positive surface 
charge +4.0 mV; however, by addition of more NaOH solution, clear and stable dispersion 
can be recovered by shaking or sonication.  
The morphology of Fe3O4/PVCL-b-PAA2 nanocomposite was investigated by TEM 
as demonstrated in Figure 5.11.  
 
Figure 5.11 TEM images of PVCL-b-PAA2 (A), Fe3O4-68 encapsulated PVCL-b-PAA2 (B), polymer 
before MNP inclusion at higher resolution (C), MNPs@PVCL-b-PAA2 at higher resolution (D), 
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Figure (5.11, A) reveals the PVCL-b-PAA2 as a short chain morphology with average 
length in the 60.0-80.0 nm range. It can be seen from the Figure (5.11, B) that MNPs are well 
distributed within the polymer matrix, and from the comparison with Figures (5.11, C, D) it is 
obvious that the composite nanoparticles retained the oval shape of the polymer in their 
structure. The average diameter of nanohybrid based on statistical analysis over 500 
nanoparticles dispersed in water is 60.0 nm as shown in Figure (5.11, D), where a 
representative particles is observed. This average size value is smaller than that one found 
from DLS analysis. Indeed, this might result from the existence of a structured water layer 
adjacent to the hydrophilic surface of nanocomposite, which can enhance the hydrodynamic 












































Figure 5.12 FTIR spectra of Fe3O4-68 coated by thermo-responsive PVCL-b-PAA2 (blue line),    
PVCL-b-PAA2 (red line), and uncoated Fe3O4-68 (green line) 
Encapsulation of Fe3O4-68 with thermoresponsive PVCL-b-PAA2 was confirmed by      
FT-IR analysis, shown in Figure 5.12. For copolymer functionalized Fe3O4-68 (blue line) two 
peaks are observed at 1700 cm
-1
 and 1619 cm
-1
, which are characteristic of stretching 
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(NHC=O) in PVCL domain on the surface of MNPs that are similarly revealed in FT-IR 
spectrum of PVCL-b-PAA (red line). In the spectrum of nanocomposite (blue line) the peak 
at 1450 cm
-1
 is representative of C-OH groups and that one at 1262 cm
-1
 is assigned to the    
C-O groups in consequence of polymer coating. The broad band centered around 3438 cm
-1
 is 
attributed to the absorption of water from the air. The characteristic Fe–O stretching vibration 
bands are also observed at 620 cm
-1
 and 584 cm
-1
 as seen clearly in FT-IR spectrum of 
uncoated Fe3O4 (green line). Moreover, two peaks at 2846 cm
-1
 and 2919 cm
-1
, corresponding 
to aliphatic C-H groups of polymer shell, confirm polymer grafted on the surface of MNPs 
successfully. 
The amount of PVCL-b-PAA2 bound on the Fe3O4-68 surface was assessed by TG 
analysis. As shown in Figure 5.13, TGA curve of smart nanocomposite (red line) revealed 
two steps in weight loss: the first significant weight loss at 95 

C can be attributed to the 
evaporation of residual water on the surface, and then the sharp mass loss observed around 
230 C to 576 C corresponds to the thermal decomposition of PVCL-b-PAA2. Above 576 °C 














Figure 5.13 TG curve of smart nanocomposite made up of Fe3O4-68 core and PVCL-b-PAA2 shell 
(red line), uncoated Fe3O4-68 (blue line) 
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Moreover, according to the TGA curve of uncoated MNPs (blue line), in the absence of a 
polymeric shell, the weight loss is about 4.0 wt % for the whole temperature range, 
corresponding to the desorption of water and combustion of DEG from the surface of       
Fe3O4-68. Therefore, the weight ratio estimated by TGA analysis (40.0 wt % MNPs and                      
60.0 wt % PVCL-b-PAA2) proves that MNPs are effectively incorporated in the polymer 
matrix. 
Subsequently, we determined the temperature-responsive property of the smart 
nanocomposite at pH 7.4 and 5.5, using DLS measurement on 1.0 mL suspension containing                
6.0 mg mL
-1
 copolymer and 0.14 wt % MNPs, as discussed in chapter 4. The expected phase 




C with a rate of 5 

C/min and 











Figure 5.14 Hydrodynamic size variation of Fe3O4-68@copolymer as a function of temperature, 
evaluated by DLS 
 
Below 35 °C (      ) at pH 7.4, the particle size of the suspension was almost constant, 
indicating that the polymer adhered strongly on the MNPs surface, and prevented aggregation 
formation. From 35 °C to 45 °C the size of the magnetic nanohybrids gradually grew and           
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at    45 C particle size strongly enhanced, indicating that LCST was reached. Indeed, at 
temperature below 45 

C, the hydrophilic copolymer chains stretched into water and 
separated every particle from its neighbors by steric and electrostatic force. When the 
temperature increased above 45 

C, the hydrophilic structure transformed into hydrophobic, 
and due to the loss of steric force, composite nanoparticles formed big aggregates, resulting 
in the increase of the particle size. We, likewise, observed the same temperature responsive 
behavior of Fe3O4-68@PVCL-b-PAA2 at pH 5.5 although the LCST was shifted to lower 
temperature ~ 40 

C as a consequence of protonation of the carboxylate groups. The obtained 
results confirmed that the smart nanocomposite is dual pH and temperature-sensitive, as 
extensively discussed in chapter 4. It is worth pointing out that LCST of copolymer solution 
with concentration of 6.0 mg mL
-1
 after grafting on the surface of MNPs at neutral pH     
(LCST ~ 45 

C) and acidic pH (LCST ~ 40 

C) is 5 

C larger than LCST of copolymer 
solution without MNPs at the same pH and concentration (LCST ~ 40 

C at pH 7.4 and 
LCST ~ 35 

C at pH 5.5) because introduction of MNPs in polymer matrix increases LCST 
value significantly; indeed, introduction of magnetic nanoparticles provides additional steric 
hindrances inside the polymer matrix, which could hamper the aggregation of the 
hydrophobic polymer segments that takes place above LCST. Consequently, higher thermal 
energy is required to overcome this barrier, and the collapse of the copolymer occurs at 
higher temperature [27-29]. 
. 
In order to have a complete characterization of the obtained nanohybrids, magnetic 
behavior of functionalized Fe3O4-68 at 10 K and 300 K was investigated. The magnetometric 
study was performed on dried powder of sample and the principal magnetic parameters 
obtained, and summarized in table 5.1 along with parameters relevant to uncoated iron oxide 
magnetic nanoparticles. As displayed in Figure 5.15, the saturation magnetization (Ms) and 
the remanence (Mr) of uncoated Fe3O4 and copolymer coated Fe3O4 at 300 K and 10 K are 
nearly equal for two samples. A small difference is observed in the coercivities, which can be 
ascribed to lower magnetic dipolar interaction between the magnetite cores in the coated 
samples as a consequence of the copolymer shell shielding [30,31]. Moreover, the magnetic 
remanence values at room temperature are ca. zero for magnetite nanoparticles before and 
after polymer coating, while at 10 K magnetic irreversibility occurs. Thus, thermoresponsive 
coated MNPs at room temperature exhibit magnetization properties similar to uncoated 
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                 Figure 5.15 Hysteresis loops of copolymer coated and uncoated MNPs at 10 K, (a) and 300K (b), 
enlargement of the low field region of the four loops, showing the transition from blocked to 
superparamagnetic state (c) 
   
 Table 5.1 Magnetic properties of Fe3O4-68 after and before polymer coating. Data are normalized for 
the amount of inorganic material 
The hyperthermic efficiency was evaluated on 1.0 mL of aqueous suspension of      
Fe3O4-68@PVCL-b-PAA2 at two different concentrations of magnetite 0.4 wt % (A) and 
0.14 wt % (B) under applying an AMF with frequency of 183 kHz and amplitude of               
17 kA m
-1 
for 5 min. The heating generated by samples under the AMF led to an increase in 
the temperature of suspension, and the temperature variation as a function of time is shown in 
Figures 5.16.  
As seen in Figure 5.16, a large temperature increase for both samples is observed, and 
the two suspensions reaching 60 

C (A) and 43 

C (B) after 5 min of field application. From 
the initial slope of the heating curves, SAR values of two samples were estimated to be        
183.0 W g(Fe3O4)
-1
 and 253.0 Wg(Fe)
-1 
for sample (A), and 150.0 W g(Fe3O4)
-1
 and 206.0 Wg(Fe)
-1 
for sample (B). In both cases, the heating power generated by the sample is sufficient to 
induce in vivo drug release. 
Sample Ms (emu g-1) 
300 K 








Fe3O4 76 84 18.0 28 300 
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It should be pointed out that the magnetic field strength and frequency used in the 
present work are lower than those reported in many other works in literature [18–20], and is 
below the threshold for clinical applications. Hence, a further enhancement of heating ability 

















Figure 5.16 Temperature vs time curves of the Fe3O4-68 functionalized PVCL-b-PAA2 
 
In conclusion, the Fe3O4-68/PVCL-b-PAA2 magnetic nanohybrids were successfully 
prepared by “grafting to” method without applying any crosslinker. The ability of this 
temperature and pH-responsive block copolymer to stabilize MNPs suspension in aqueous 
media was studied by TEM, DLS, and zeta potential measurements. FTIR and TG analyses 
also confirmed the polymer is effectively grafted on the surface of MNPs. The remarkable 
advantage of this system is that it is solely made of iron oxide MNPs and hydrophilic 
polymers such as poly N-vinylcaprolactam and poly acrylic acid, which are non-toxic and 
biodegradable, and thus can be used for biological application. Most importantly the polymer 
preserves pH and temperature responsive properties, resulting in a stimuli-responsive 
biocompatible nanohybrid, which has potential to produce high quantity of heat in response 
to harmless alternating magnetic field. 
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Chapter 6 
Drug Loading & Drug Release 
Chapter 5 described the development of magnetic nanocomposites (MNCs) 
constituted by an iron oxide magnetic nanoparticles core and a pH- and thermo-responsive 
poly (vinylcaprolactam-b-acrylic acid) (PVCL-b-PAA) shell, that have potential to be used as 
both hyperthermic agent and drug carrier. In the following, we will outline the conjugation of 
the anticancer drug doxorubicin (DOX), a potent chemotherapeutic drug used clinically for 
the treatment of a broad spectrum of cancers, to the pH- and thermo-responsive MNCs to 
provide advanced drug delivery system for the controlled release of DOX.  
Herein, in this chapter, the developed therapeutic nanosystem is investigated as 
multifunctional nanocarrier by measuring the percentage of doxorubicin released under the 
application of a harmless AMF (H = 17 kA m
-1
, f = 183 kHz). Cytotoxicity of                  
Fe3O4-68@PVCL-b-PAA2 before and after drug loading is also evaluated. 
6.1 Drug Loading 
The investigation of the efficiency of the processes of loading and release of DOX 
loaded-Fe3O4-68@PVCL-b-PAA2 MNCs was performed on 20.0 mL of two suspensions, 
containing different concentrations of MNPs and copolymer (0.14 wt % of Fe3O4 as well as              
6.0 mg mL
-1
 of copolymer, samples A, and 0.4 wt % of Fe3O4 as well as 10.0 mg mL
-1
 
copolymer, samples B). The approach followed for drug loading is schematically described in 
Figure 6.1, and explained completely in Appendix A.11. 
DOX was loaded on PVCL-b-PAA2 coated Fe3O4-68 in buffer phosphate with pH 
adjusted at 7.4 (samples A7.4, B7.4 similar to physiological pH) and 5.5 (samples A5.5, B5.5, 
corresponding to the mimicked tumour pH) simply by incubating at 25 

C in darkness for     
72 h. After incubation, the DOX-loaded nanocomposite suspension was dialyzed against 
buffer phosphate 10 mM, pH = 7.4 (or 5.5) using dialysis membrane bag (MWCO ~ 1 kDa) 
for 24 h to remove the non-encapsulated drug. The concentration of free DOX in dialysis 
fluid was analyzed by UV-Vis spectroscopy at a specific wavelength 480 nm to determine the 
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EE (%) =
mass of total drug-mass of unloaded Drug
mass of total Drug
DLC ( µg mg -1) =
mass of loaded Drug
mass of total Drug + mass of polymer+ mass of MNPs  
 
The loading data obtained for the six samples are summarized in table 6.1. 
 
Table 6.1 Encapsulation efficiency and drug loading capacity 
 
Figure 6.1Preparation of DOX loaded-Fe3O4-68@PVCL-b-PAA2 
 
According to the table 6.1, the results confirm the extraordinary capability of        
Fe3O4-68@PVCL-b-PAA2 MNCs to load high contents of DOX at neutral pH. This ability 
can be ascribed to the     stacking interactions between the aromatic rings of DOX, and 
Suspension in 20.0 mL buffer 











(A7.4): Fe3O4@polymer-DOX 0.14 6.0 0.225 90.0 29.0 
(B7.4): Fe3O4@polymer-DOX 0.4 10.0 0.225 92.0 18.0 
(B5.5): Fe3O4@polymer-DOX 0.4 10.0 0.225 53.0 10.0 
(A5.5): Fe3O4@polymer-DOX 0.14 6.0 0.225 45.0 14.0 
(C7.4):Fe3O4@polymer-DOX 0.4 10.0 0.375 96.0 23.0 
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the carbonyl groups in the structure of PVCL-b-PAA2 -based nanocomposite [1]. Moreover, 
the functionalization of Fe3O4-68 with PVCL-b-PAA2 leaded to a high negative surface 
charge (zeta potential values ca. -36.0 mV), which also allows electrostatic interactions with 
positively charged DOX (pKa = 8.3) at pH = 7.4. On the other hand, in acidic pH % EE and      
% DLC of samples (A5.5, B5.5) decreased as a result of the protonation of poly acrylic acid in 
the structure of copolymer shell, resulting in repulsive electrostatic force between positive 
surface charge of DOX and the copolymer shell.  
Importantly, the encapsulation efficiency (EE) of Fe3O4-68@PVCL-b-PAA2                
(C7.4 and D7.4) at neutral pH can be further enhanced by increasing the initial DOX 
concentration in the suspension. For instance, by using DOX with concentration of              
0.375 mg mL
-1 
in 20.0 mL of suspension, an outstanding encapsulation efficiency of 96.0 % 
and 98.0 % with drug loading capacity of 23.0 and 50.0 µg mL
-1 
for samples C 7.4 and D7.4 
were obtained  respectively.
 
 
6.2 Dual pH- and Temperature-Dependent In Vitro Drug Release in the Absence of AMF  
 
The pH and temperature-responsive magnetic nanohybrids developed in this work 
was designed to have a LCST of ~ 45 

C at pH ~ 7.4 and LCST ~ 40 

C at pH ~ 5.5, that can 
be specifically utilized as smart drug delivery systems to trigger the release of drug by acidic 
pH values and temperature simultaneously. 
The drug release behavior of 5 mL buffer suspension of sample A7.4 was studied by 
dialysis technique at different pH conditions (pH ~ 7.4, 5.5 and 4.5 roughly corresponding to 
the physiological pH, the pH of tumour microenvironment, and that of intracellular tumour 





C (below LCST), and 48 °C (above LCST), corresponding to ambient 
temperature, physiological temperature, and temperature that can be reached by the 
hyperthermic treatment (drug release process is fully described in Appendix A.12). Although 
48 C may seem slightly high temperature to simulate hyperthermia, we chose this value 
because the temperature at the MNPs surface can easily reach this value without necessarily 
producing a significant increase in the surrounding medium [2, 3]. 
The cumulative release of DOX was determined from the corresponding calibration 
curves of DOX at pH values of 4.5, 5.5, 7.4, and the percentage of drug release was assessed 
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Cumulated released DOX =  
       
      
   100 (%) 
Where    and     are the cumulative amounts of DOX released at time   and     , and 
       is amounts of loaded DOX in the nanocomposite. 
The obtained results are shown in Figure 6.2.  
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Figure 6.2 Release of doxorubicin (DOX) from drug loaded Fe3O4-68@PVCL-b-PAA2 under 




C, and 45 

C). Standard deviation 
of triplicate drug release tests (n=3) 
 
The drug release curves of sample A7.4 all follow the same trend: a rapid release of 
DOX is obtained within the first 7 h, followed by a slower rate of release in the next hours. 
Analysis of the curves shows that just a very low amount of DOX was released at 
physiological pH conditions (i.e. pH = 7.4) both at 25 

C and 37 

C (4.4 % and 7.2 % after     
7 h, respectively). The drug release was also low at pH = 5.5 and pH = 4.5 i.e., 4.6 % and     
7.6 % at 25 

C, 8.2 % and 9.3 % at 37 

C after 7 h. However, at pH = 7.4 the drug 
nanocarriers show an increase of the released DOX around 24.0 %, and remarkable release of 
45.0 % at pH ~ 5.5 and 4.5 at 48 

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period is considered: a maximum of 15.0 % (at 25 

C), 19.5 % (at 37 

C), and 54.0 %           
(at 48 

C) of DOX was released under physiological conditions after 72 h, when only the 
temperature stimulus triggered the drug release. At pH ~ 5.5, after 72 h a maximum drug 
release of 16.0 % and 25.0 % were achieved for 25 

C and 37 

C respectively. However, this 
value sharply increases up to 72.0 % at 48 °C, when the pH and thermoresponsive polymer 
shrinks, squeezing drug out from the nanocomposite as exhibited in Figure 6.3. Finally, at   
pH = 4.5 an almost complete release of the encapsulated drug (98.8 %) is observed at 48 

C 
after 72 h, when the DOX-MNCs were exposed to both pH and temperature stimuli, which 
rupture the nanocomposite. It should also be noted that at acidic pH, the primary amine group 
of free DOX is protonated (pKa = 8.3), therefore, increasing its solubility in aqueous 
medium, facilitating its expulsion out of the polymer layer.  
These data, thus, demonstrate that by combining both effect of the pH and the 
temperature, a controlled release of the DOX can be obtained. Other important reasons 
behind this promising pH/temperature-responsive drug release behavior of the                
Fe3O4-68@PVCL-b-PAA2 material comes from the fact that the     stacking interaction 
between the carbonyl groups of nanocomposite and the aromatic moieties of DOX molecules 

















 Figure 6.3 Scheme of the drug release mechanisms operating in our MNCs. Gentle release caused by 
shrinkage of temperature-responsive polymer under heating at neutral pH and intense release at pH 
4.5-5.5 due to additional ruptures of the nanocomposite [5] 
 
This pH-dependent controlled release phenomenon can be also ascribed to the increased 
protonation of the carboxylic acid unites of PVCL-b-PAA2 nanocarrier surface as the pH of 
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charge. This will lead to a reduction of the electrostatic attraction between PVCL-b-PAA2 and 
DOX protonated molecules, increasing the progressive drug release.  
Overall, the pH- and temperature-responsive drug release results obtained in this 
work, suggest the great ability of the designed PVCL-b-PAA-based magnetic nanocarriers to 
be applied as efficient drug encapsulation and delivery systems with an extremely good pH 
and temperature sensitivities for an intelligent and on-demand drug release on acidic tumour 
microenvironments with combination of hyperthermia performance. 
 
6.3 Drug Release under the Application of an AMF 
The observed pH- and temperature-dependence drug delivery profiles highlight the 
convenience of exploiting the magnetic properties of the magnetite cores to induce a 
temperature increase by external application of an AMF. Thus, in addition to an endogenous 
stimuli (pH) that boosts the localized drug release on the tumour site, we can externally 
enhance this effect by inducing a temperature increase through magnetic hyperthermia. 
 









































Figure 6.4 Magnetically induced thermal response curve of Fe3O4-68@PVCL-b-PAA2-DOX                 
(0.14 wt % of MNPs at pH ~ 7.4 (red plot) and pH ~ 5.5 (blue plot) for dual pH- and thermal-
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For this purpose, 5 mL of samples A7.4 (pH = 7.4 and LCST ~ 45 

C) or A5.5 (pH = 5.5 and 
LCST ~ 40 







 of loaded-DOX respectively, 
were exposed to the AMF (f = 183 kHz and H = 17 kA m
-1
) at initial temperature (37 

C) 
similar to physiological temperature. As displayed in Figure 6.4, a suitable temperature for 
hyperthermia treatment (48 

C) was reached within 6’ min for sample (A7.4) and 11’ min for 
sample (A5.5), and SAR values of both samples (A7.4 ~ 276.0 W g (Fe)
-1
 and                            
A5.5 ~ 427.0 W g (Fe)
-1
) were estimated based on the initial slope of the heating curve vs time. 
Cumulative DOX release of samples (A7.4, A5.5) as a function of time was estimated at 
different time interval (30, 40, 50, and 60 min) under applying the AFM and results are 
plotted in Figure 6.5. In contrast, the drug release without application of AMF was also 
carried out on 5.0 mL of both samples (A7.4, A5.5) at 37 

C, and treated in the same way for 
comparison. Experimental details of drug release are completely given in Appendix A.13. 
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Figure 6.5 Cumulative DOX released from Fe3O4-68@PVCL-b-PAA2-DOX NPs (0.14 wt % MNPs) 
for different exposure time to the AMF. Standard deviation of triplicate drug release tests (n=3) 
 
After each drug release experiment with and without AMF, samples were centrifuged, 
and the supernatants analyzed by UV-Vis spectroscopy to determine the amount of DOX 
released. As revealed in Figure 6.5, for samples kept at 37 

C without application of the 
AMF, low drug release percentage was estimated after 60 min at both pH (~ 10.0 % at            
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nanosystem was observed at hyperthermia temperature for both samples (A7.4, A5.5) after      
30 min under AMF. Indeed, 23 % of DOX at pH ~ 7.4 and 40.2 % at pH ~ 5.5 were released. 
After one hour, the maximal drug release percentage at pH = 7.4 was 47.0 %, while almost 
total percentage of DOX (~ 99.98 %) was noticeably released at pH ~ 5.5 after 60 min under 
applying AMF by enhancing temperature of samples up to 55 

C during heating cycle; 
consequently, these promising results confirm that in addition to an endogenous stimuli (pH) 
that could boost the localized drug release on the tumour site, this effect could be externally 
enhanced by inducing a temperature increase through localized magnetic hyperthermia by 
applying external magnetic field.  
 
6.4 A Smart Hyperthermia with Switchable Drug Release  
AMF-triggered drug release behaviors of the DOX-loaded nanocomposite particles 
were performed under continuous’ application of the AMF. Comparison of the release 
patterns of DOX in Figure 6.5 and 6.2 shows that the drug release can be accelerated by 
application of an external magnetic field. It is speculated that the higher temperature (55 

C) 
obtained with the application of the AMF, is responsible for the enhancement in release rates 
due to increased drug diffusivity. To go one step further, we verified the possibility to have a 






















Figure 6.6 On-off switching cycle of AMF and DOX release profile corresponding to reversible   
swell-shrink property of Fe3O4-68@PVCL-b-PAA2-DOX nanocomposite in response to field 
application  
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To this aim, AMF was introduced under ‘‘intermittent’’ condition (10’ steps) for overall time 
of 60 min, and results were compared with the ones obtained by applying the field 
continuously for the same amount of time. Hyperthermia switchable drug release was 
performed on 5.0 mL of samples B7.4 (MNPs 0.4 wt %, LCST ~ 45 

C,                                 
SAR ~ 453.0 W g(Fe)
-1
) and B5.5 (MNPs 0.4 wt %, LCST ~ 40 

C, SAR~ 427.0 W g (Fe)
-1
), 
containing 0.21 mg mL
-1
 and 0.12 mg mL
-1
 DOX, respectively. Drug release process is 
explained in Appendix A.14 with more details. 
The field was first applied for 10 min, a time long enough for both samples B7.4 and 
B5.5, to reach 50 

C. The AMF was then turned ‘off’ for 10 min, allowing cooling them down 
to 25 

C. This process was repeated 6 times. After each cycle samples were centrifuged, and 
supernatant was analyzed by UV-Vis spectroscopy to evaluate amount of drug release, and 
results are reported in Figure 6.6. 
According to Figure 6.6, from first to sixth cycles of AMF application DOX is 
released up to ca. 40.0 % at pH = 7.4 and 63.0 % at pH = 5.5, and no release occurs when the 
AMF is switched off. In other words, almost more than half amount of DOX was released 
after 6 cycles in acidic pH, whereas less than 50.0 % of DOX was released at physiological 
pH during the heating ‘on’ process. The result at pH 7.4 is in good agreement with that 
obtained by continuous AMF application, while at pH = 5.5 the drug release is ca. 33.0 % 
less than one measured under continuous AMF application. 
Thus, at ‘on’ state and pH = 7.4, the MNCs deformed only under influence of 
temperature changes, triggering the release of the drug molecules. However, in acidic pH the 
additional pH stimulus boosts drug release, and magnetic hyperthermia can extremely 
enhance the effect. On the other hand, when the magnetic field is off, the DOX release does 
not change at each cycle. In fact, the polymer absorbs water and re-swells, thus, strongly 
slowing down the drug release. We, therefore, can conclude that this composite nanoparticles 
are also feasible for application in ‘‘on/off’’ drug delivery systems for in vivo application by 
exploiting the triggering induced by application of the AMF.  
 
6.5 Cytotoxicity Study 
Nanoparticles used as a therapeutic agent in drug delivery system must be preferably 
nontoxic. Hence, the cell biocompatibility of Fe3O4-68@PVCL-b-PAA2 MNCs were 
investigated by WST-1 assay in triplet at different MNPs concentrations before DOX 
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demonstrated in Figure 6.7 (conducting cell viability studies with more details are described 
in Appendix A.15). Moreover, cytotoxicological effect of Fe3O4-68@PVCL-b-PAA2-DOX 
containing 14.0 µg mL
-1
 DOX with different concentrations of MNPs was assessed by      
WST-1 assay with the same incubation time according to the same procedure explained in 


















Figure 6.7 Cell viability (%) assessed by WST-1 assay after 24 h of incubation with                      














Figure 6.8 Cell viability (%) assessed by WST-1 assay after 24 h of incubation with                      
Fe3O4-68@PVCL-b-PAA2-DOX containing 14.0 µg mL
-1
 DOX with respect to a cell control sample 
0.0625 wt % NPs-DOX 0.01 wt % NPs-DOX 0.008 wt % NPs-DOX
Concentration of Fe3O4 in MNCS-DOX
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Cell viability studies revealed that there is no difference in viability percentage of 
A375 human melanoma cells incubated for 24 h with polymer coated nanoparticles and 
control for all samples considered, even after DOX conjugation. These data indicate that the 
MNCs are not cytotoxic, and the amount of drug released at physiological pH and body 
temperature is so low to have any effect on cell viability of A375 human melanoma cells, so 
these results verify the possibility of using these nanosystems as efficient cargo carrier for 
controlled drug delivery.    
 
To conclude, in this study, MNPs grafted with copolymer PVCL-b-PAA, were 
successfully developed as multifunctional nanocarriers for therapeutic applications. This 
hybrid nanomaterial was found to be an efficient nanoheater at relatively low concentrations, 
with exceptional drug loading capacity and controlled drug release, triggered by the acidic 
tumour microenvironment in combination with hyperthermia performance. Significantly, the 
external application of an AMF (magnetic hyperthermia) was observed to further induce the 
drug release. The dual pH- and temperature-responsive drug delivery behavior observed in 
these nanosystems showed a burst release of the drug at mimicked acidic tumour 
environment, whereas at physiological pH and temperature, negligible amount of drug was 















1. M. Gisbert-Garzarán.; M. Manzano.; M. Vallet-Regí. Bioeng. 2017, 4, 1. 
2. M. Creixell.; A. C. Bohorquez.; M. Torres-Lugo.; C. Rinaldi. ACS Nano. 2011, 5, 7124. 
3. B. Kozissnik.; A. C. Bohorquez.; J. Dobson.; C. Rinaldi. Int. J. Hyperth. 2013, 29, 706. 
4. X. Yu.; Y. Zhu. Sc. Tech. Adv. Mater. 2016, 17, 229. 





136 Smart Nanocomposite for Drug Delivery and Hyperthermia Performance 
Chapter 7 
Conclusions and Perspectives 
The experimental work, presented here was focused on the design of a novel smart 
magnetic nanocomposite, composed of iron oxide magnetic nanoparticles enclosed in a dual 
pH and temperature responsive poly (N-vinylcaprolactam-b-acrylic acid) polymer for 
controlled drug delivery in combination with hyperthermia performance for therapeutic 
application. To realize this goal, magnetic nanoparticles with suitable magnetic 
characteristics for efficient conversion of magnetic energy into heat were prepared, and 
embedded in a multi stimuli responsive polymer, optimized for drug encapsulation and 
controlled release under the application of an external alternating field with frequency and 
amplitude suitable for application in human being. 
 
Although thermal decomposition and co-precipitation approaches are the most 
commonly synthetic methods, employed for MNPs preparation, here we focused on the 
polyol synthetic procedure since MNPs synthesized by this approach exhibit excellent 
heating performance for hyperthermia due to their specific morphology. By this technique 
flower-like shaped, monodisperse, spinel ferrite Fe3O4 nanoparticles in the form of stable 
dispersion in diethylen glycol, were prepared. X-ray diffraction and TEM analyses confirmed 
MNPs have a good crystallinity, with crystallite size of 14 nm and average particle diameter 
of 18.0 nm. Due to the optimal particle size and specific morphology, nanoparticles exhibited 
superparamagnetic behavior with high magnetization saturation (Ms ~ 76 emu g
-1
), high 
capability of heat generation potential, and huge specific absorption rate value                   
(SAR ~ 357.0 W g
-1
 (Fe)) under application of an AC magnetic field with f = 183 kHz and         
H = 17 kA m
-1
 even at relatively low concentration of ~ 1.0 mg mL
-1
. These properties are 
extremely promising in view of the clinical application of this nanomaterial as heat mediator 
for magnetic fluid hyperthermia.  
Second, pH and temperature responsive poly (N-vinylcaprolactam-b-acrylic acid) 
(PVCL-b-PAA) was prepared by free-radical polymerization approach. PVCL-based 
copolymer was selected as a smart polymer owing to the high biocompatibility, lower 
toxicity, and proper thermal sensitivity that PVCL shows with respect to PNIPAM, which is 
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presence of PAA blocks in polymer backbone, the copolymer is sensitive to pH as well. 
PVCL-b-PAA was synthesized successfully, and buffer solution of this copolymer (0.1 wt %) 





C, above physiological temperature (~ 37
 
C) and close to that which can 
be easily achieved by hyperthermia treatment, depending on pH of the media and 
concentration of polymer solution. 
As a third step, surface modification of superparamagnetic iron oxide nanoparticles by 
stimuli responsive PVCL-b-PAA was performed for the first time using a ’’grafting to’’ 
approach, exploiting the PAA units in the structure of copolymer, which act as proper anchor 
for surface functionalization of MNPs. The final suspension was highly stable and 
monodispersed with negative surface charge, as indicated by zeta potential measurement, 
confirming strong adherence of polymer on the surface of MNPs. Then, Doxorubicin, a 
positive-charge anticancer drug, widely used as chemotherapeutic drug, was loaded on the 
magnetic nanocomposites. Thanks to the strong electrostatic interaction with the negative 
surface charge arising from the presence of carboxylate in the polymer, very high 
encapsulation efficiency ( > 92.0 %) at neutral pH was obtained.  
The dual pH- and temperature-responsive nature of the nanocarrier allowed for a burst 
release of the drug at mimicked acidic tumour environment upon application of an external 
alternating magnetic field, whereas at physiological pH and body temperature negligible 
amount of drug was released, confirming that the drug was efficiently retained in the 
nanocarrier. Smart nanocomposite, besides, demonstrated reversibly switchable behavior in 
response to self-generated heat from the incorporated MNPs upon the magnetic field 
application; consequently, Fe3O4@PVCL-b-PAA2 exhibited the dynamically and reversibly 
tunable structures of smart nanohybrids, that have the potential to be utilized as a device for 
hyperthermia treatment of tumour as well as a switchable drug release platform by simple 
switching an AMF ‘on’ and ‘off’. Furthermore, the developed nanocarriers showed low 
cytotoxicity during 24 h incubation on A375 human melanoma cells. Therefore, the presented 
strategy and findings can represent a new way to design and synthesize stable smart magnetic 
nanocomposite materials with novel structures for targeted combinatorial thermo-
chemotherapy triggered by abnormal acidic cell microenvironments on tumour site, with the 
subsequent minimization of side effects on the healthy cells. 
 
 




Materials and Methods 
A.1 Starting Materials  
All chemicals of analytical quality were purchased from Sigma-Aldrich Co. with the 
exception of O-ethyl xanthic acid potassium salt, purchased from Alfa Aesar Co. Water was 
deionized and filtered with a Milli-Q System (Merck Millipore Co., Germany). 2,2ˊ-Azobis 
(2-methylpropionitrile) (AIBN) was recrystallized from methanol before use.                        
N-vinylcaprolactam, N-vinylpyrrolidone, and acrylic acid were distilled under low pressure 
before copolymerization. 1,4-Dioxane was dried by sodium before use. All the other reactants 
and solvents were used with no further purification. Dialysis bag with molecular weight      
cut-off (MWCO) of 14 kDa, dialysis kit with MWCO of 1 KDa, Dulbecco's Modified Eagle 
Medium (DMEM), a culture medium used for A375 cells, Fetal Bovine Serum (FBS), and 
A375 human melanoma cell line were purchased from Sigma Aldrich Co.  
 
A.2 Synthesis of Iron Oxide Superparamagnetic Nanoparticles (Fe3O4-68) 
Fe3O4-68 NPs were prepared by polyol method. First, iron (III) acetate was prepared 
by mixing Fe
0
 (10.024 g, 0.179 mol) and 100.0 g of CH3COOH (1.67 mol) in the presence of 
H2O2 (11.73 mL, 0.5 mol) in 400.0 mL of DEG. Then, Fe (CH3COO)3 (46.6 g, 0.2 mol) was 
added to a solution of FeCl2 (12.675 g, 0.1 mol) in 130.0 mL of DEG under N2 flow. 
Afterward, precursors were mixed together under mechanical stirring for 10 minutes, and 
temperature was increased with a heating rate of 2 °C/min up to 150 °C for one hour, and 
then kept under refluxing at 170 °C for 19 h. At about 170 °C formation of magnetic 
nanoparticles started. Subsequently the dark brown dispersion was air cooled to room 
temperature, and stored under N2 atmosphere to prevent any oxidation to maghemite,             
- Fe2O3. The dark brown dispersion contains about 1.33 wt % of Fe3O4 according to ICP 
measurement. In order to increase the particle size of Fe3O4-68 to provide flower-like 
nanoparticles, the half quantity of prepared magnetic nanoparticles in DEG, containing      
1.33 wt % MNPs, was used as seeds and reaction was similarly repeated with half amount of 
precursors during 5 h at 170 

C.  
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A.3 Synthesis of Methyl 2-[(Ethoxycarbonothioyl) Sulfanyl] Propanoate  
The RAFT CTA (Methyl 2-[(ethoxycarbonothioyl)sulfanyl]propanoate) was prepared 
according to the procedure as shown in Scheme A.1. First, methyl-2-bromopropionate            
(5.0 g, 30 mmol) was dissolved in 50.0 mL of methanol in a flask on ice bath, and then         
O-ethyl xanthic acid potassium salt (5.3 g, 33.0 mmol) was added to the solution and reacted 
for a day. Afterward, ethyl ether and hexane mixture (200.0 mL, ether/hexane 50/50) was 
used to extract the product from the solution. The extraction solution was washed with 
deionized water several times and dried with 26.0 wt % NaCl aqueous solution. After solvent 





HNMR (400 MHz, CDCl3): δ= 1.41 (t, 3H), 1.57 (d, 3H), 3.75       

















Chain Transfer Agent (CTA)
SK
 
Scheme A.1 Synthesis of Chain Transfer Agent 
 
A.4 RAFT Synthesis of PVCL  
Scheme A.2 displays synthesis process of PVCL by RFT polymerization. Firstly, a 
Schlenk tube containing N-vinylcaprolactam (NVCL) (5.0 g, 35.92 mmol), CTA                  
(34.4 mg, 0.1 mmol), AIBN (13.5 mg, 0.05 mmol), and dioxane (16.0 mL) was degassed by 
four freeze–pump–thaw cycles, kept under nitrogen flow, and heated at 60 C under stirring 
for 20 h in an oil bath. The reaction mixture was then cooled down with liquid nitrogen to 
stop the polymerization. Finally, a sample was withdrawn and analyzed by 
1
HNMR and FTIR 
to access the molecular structure of PVCL as shown in Figure A.1 and Figure A.2 
respectively, while the remaining solution was precipitated in hexane. The precipitated 
polymer was filtered off, dried under vacuum, and purified by dialysis bag with MWCO of    
1 kDa against distilled water for three days. After lyophilization, polymer was obtained as 
powder and kept at 4 

C.  





















Scheme A.2 Synthesis of PVCL by RAFT polymerization 
 
1
HNMR (400 MHz, CDCl3): δ= 4.39 ppm (Ha,−NCH−of the α position), 3.18 ppm          
(OCH3 –O=COCH3−of CTA), 3.1 ppm (Hb,−NCH2−), 2.4 ppm (Hc, −COCH2−) and 1.76 




HNMR of PVCL 
The IR spectrum of PVCL is depicted in Figure A.2. As it is seen from the spectrum, 
the polymer reveals a broad absorption in the 3507 cm
-1
 region due to O-H stretching from 
absorbed water molecules since PVCL absorbs moisture from the air easily. Furthermore, two 
stretching peaks at 2932 cm
-1
 and 2853 cm
-1 
can be representative for absorption of
 
aliphatic 
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peak of amide carbonyl groups (NH-C=O) in PVCL domain at 1623 cm
-1
, while the peaks at 
1479 cm
-1
 and 1200 cm
-1
 are assigned to the characteristic absorptions of its C-N and C-O 
groups respectively. The more characteristic bands in the spectrum of the PVCL correspond 
to the moiety C=S at 1081 cm
-1





presence of chain transfer agent in polymeric backbone. 







































Figure A.2 FTIR spectrum of PVCL 
 
A.5 RAFT Synthesis of PVCL-b-PVPON  
As displayed in Scheme A.3, RAFT polymerization of PVCL-b-PVPON was 
performed following the same procedure used for PVCL, reported in section A.4, and started 
from a mixture of NVCL (8.7 g, 62.0 mmol), N-vinylpyrrolidone (NVPON)                           
(1.3 g, 11.69 mmol), CTA (0.092 g, 0.44 mmol), AIBN (0.036 g, 0.22 mmol), and dioxane 
(15.0 mL). Purification of copolymer was performed by dialysis bag with MWCO ~ 1 KDa 
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against distilled water for three days. 
1
HNMR and FTIR characterization were performed to 



















Scheme A.3 Synthesis of PVCL-b-PVPON by RAFT polymerization
 
1
HNMR (400 MHz, CDCl3): δ= 4.38 ppm (Ha,−NCH−of the α position), 3.69 ppm                 
(1Haˊ,–NCH–of the the α position), 3.21 ppm (2Hb, –NCH2– of the caprolactam ring and 
2Hb,ˊ-COCH2– of the pyrrolidone ring), 2.5-2.4 ppm (2Hc, –COCH2– of the caprolactam ring 
and 2Hcˊ, –NCH2– of the pyrrolidone ring), 2.0 ppm (2Hdˊ, –CH2–of the backbone), and           
1.68-1.48 ppm (2Hd, –CH2–of the backbone, 6He,–CH2– of the caprolactam ring, 2Heˊ,–CH2–













HNMR of PVCL-b-PVPON 
Figure A.4 exhibits broad peak in the IR spectrum of the copolymer at 3500 cm
-1
, 
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Figure A.2, the PVCL homopolymer has a single absorption band at 1623 cm
-1
 associated 
with the stretching vibration of the carbonyl group in the caprolactam ring; however, the 
additional absorption band at 1661 cm
-1
 appears when the PVPON segment is grown in the 
structure of copolymer as shown in Figure A.4. According to the IR spectrum of              
PVCL-b-PVPON, the aliphatic C-H stretching peaks are assigned at 2928 cm
-1
 and            
2858 cm
-1









are attributed to the C-N and C-O groups in the structure
 
of copolymer. In addition, 





 respectively.  












































Figure A.4 FTIR spectrum of PVCL-b-PVPON 
 
A.6 Synthesis of PVCL-b-PAA by Free Radical Polymerization 
The PVCL-b-PAA copolymer was prepared by free radical copolymerization of 
NVCL with acrylic acid (AA) in the presence of AIBN as initiator as displayed in Scheme 
A.4. The procedure used 1.0 g (80.0 mol %) of NVCL, 0.123 mL (20.0 mol %) of AA, and             
2.0 mol % of AIBN dissolved in 12.0 mL of solvent (DMF, polymer AA1, dioxane, polymer 
   
144 
 
AA2, and isopropanol, polymer AA3). The mixture was purged with nitrogen for 30 min and 
let to react in an oil bath at 70 

C for 24 h under nitrogen flow. Afterward, the solution was 
cooled to room temperature, and the copolymer was precipitated in diethyl ether at low 
temperature. The precipitation was carried out three times to remove unreacted materials, and 
the product dried in vacuum at room temperature for 48 h. Further purification was 
performed by dialysis technique using dialysis bag with MWCO of 14 kDa against distilled 
water for 24 h, and then after lyophilization, polymer was stored at 4 

C. Formation of three 
copolymers was confirmed by 
1
HNMR and FTIR characterization as revealed in Figures A.5 

























HNMR of copolymer  




HNMR spectroscopy was performed using a NMR spectrometer (400 MHz) with CDCl3 as 




 spectra of copolymers AA1, AA2, and AA3 exhibited peaks at 4.38 
ppm (1Ha, –NCH–of the α position), 3.20 ppm (2Hb,–NCH2–), 2.48 ppm (1Haˊ, –HCO2CH– 
of the α position), 2.34 ppm (2Hc, –COCH2– of the caprolactam ring), 1.78 ppm               
(2Hdˊ, –CH2– of the backbone), 1.53 ppm (2Hd, -CH2-of the backbone), 1.44 ppm              
(6He, –CH2–of the caprolactam ring). 
Corresponding to Figure A.6, IR spectrum of copolymer shows an absorption typical 
peak of amide carbonyl group (-CON-) in PVCL domain at 1637 cm
-1
. The IR also reveals a 
peak at 1724 cm
-1
 caused by the stretching vibration of -COOH (carboxylic) groups in AA 
domain, while the peak at 1260 cm
-1
 can be assigned to the characteristic absorptions of its  
C-O groups. Moreover, a wide peak at 3538 cm
-1
 is attributed to the absorptions of OH 
groups of absorbed water from the air. The peaks at 2856 cm
-1
 and 2928 cm
-1
 reveal the 
presence of aliphatic C-H groups in the structure of polymers. A specific peak at 2510 cm
-1
, 
besides, is assigned to the internal hydrogen bond formation between carboxylic acid groups 
in polymeric chain. 

















































Figure A.6 FTIR spectrum of PVCL-b-PAA 
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A.7 Encapsulation of Magnetic Nanoparticles by PVCL Corresponding to Post 
Modification Method 
DEG-stabilized nanoparticles (Fe3O4-68) (13.5 mg, 0.0581 mmol) were added to         
4.0 mL DEG containing PVCL (10.0 mg, 0.92 µmol, Mn ~ 10857 g mol
-1
). Once the mixture 
was complete, the resulting suspension was sonicated for an hour at 0 

C and stirred for two 
hours at room temperature. The obtained nanocomposite was precipitated by addition of 
acetone and recovered by magnet decantation. The resulting nanoparticles were washed 
thoroughly with ethanol/acetone three times to remove excess of polymer. Final 
nanocomposite was dispersed into 20.0 mL phosphate buffer (10 mM, pH = 7.4), and ICP-
AES analysis indicated a mean concentration of magnetic nanocomposite dispersed in 
solution of 0.11 wt %. 
A.8 Encapsulation of Magnetic Nanoparticles by PVCL-b-PVPON by Post Modification 
Method 
DEG-stabilized magnetic nanoparticles (13.5 mg, 0.0581 mmol) was added to 4.0 mL 
DEG containing PVCL-b-PVPON (10.0 mg, 0.5 µmol, Mn ~ 20857 g mol
-1
) under sonication 
for an hour at 0 

C and stirred for two hours at room temperature. Acetone was added to the 
suspension to precipitate the nanocomposite, which was subsequently recovered by magnet 
decantation. The resulting NPs were washed thoroughly with ethanol/acetone three times to 
remove excess of polymer and redispersed in buffer phosphate (10 mM, pH = 7.4). 
Concentration of magnetic nanocomposite suspended in solution was 0.1066 wt % as 
obtained by ICP analysis. 
A.9 Coating of MNPs by Capping Ligands  
A.9.1 Functionalization of MNPs by PAA 
100.0 mL of acetone was added to 5.0 mL of Fe3O4-68 suspended in DEG (66.5 mg, 
0.286 mmol Fe3O4). The precipitate was washed 3 times with ethanol/acetone to remove 
DEG completely. Afterward, 15.0 mL aqueous solution containing PAA (1.0 mg mL
-1
) was 
mixed with Fe3O4-68 NPs and sonicated for one hour. Then, the resulting nanoparticles 
suspension was stirred vigorously at 25
 
C for 2 h. Finally, MNPs were separated via 
magnetic decantation, washed with ethanol three times and redispersed in 15.0 mL distilled 
water. 
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A.9.2 Functionalization of MNPs by 6-AHPA 
Surface functionalization of Fe3O4-68 with 6-aminohexylphosphonic acid (6-AHPA) 
was performed using 6-aminohexylphosphonic acid (6-AHPA) ligand that permits both a 
strong covalent bond between the MNPs and itself to give a free amino group on the surface 
of MNPs for the further functionalization. Typically, 5.0 mL of MNPs suspended in DEG    
(66.5 mg, 0.286 mmol) was precipitated by addition of 100.0 mL acetone before surface 
modification. Precipitate washed three times with ethanol/acetone to remove DEG 
completely. Afterward, 15.0 mL ethanol contained 6-AHPA (1.0 mg mL
-1
) was mixed with 
MNPs precipitate and sonicated for one hour. Then, the resulting nanoparticles suspension 
was stirred vigorously at 25 

C for 2 h. Finally, MNPs were washed with ethanol three times 
via magnetic decantation and redispersed in 10.0 mL distilled water. 
A.10 Encapsulation of Fe3O4-68 by PVCL-b-PAA2 
Firstly, 1.5 mL of Fe3O4-68 suspended in DEG (19.95 mg, 0.086 mmol Fe3O4) was 
precipitated by addition of 50.0 mL acetone and then nanoparticles were washed 3 times with 
ethanol/acetone to completely remove DEG. Secondly, PVCL-b-PAA2 (0.1178 g, 0.43 µmol, 
Mn ~ 271890 g mol
-1
)  was dissolved in 20.0 mL Milli-Q water by addition of 15.0 µL NaOH      
0.1 M up to pH ~ 9 (the solubility of copolymer at neutral pH is too low due to the internal 
hydrogen bonds between acrylic acid groups in polymeric backbone); afterward, pH was 
adjusted to 7.4 by addition of HCL 0.1 M. Fe3O4-68 NPs precipitate was added to the 
polymer solution, sonicated for one hour, and then kept under shaker at room temperature 
overnight. Finally, functionalized MNPs were dialyzed with dialysis bag                        
(MWCO of 14 KDa) against Milli-Q water for 24 h. According to the ICP analysis, final 
suspension contains 0.14 wt % MNPs. The same procedure was used to prepare 
functionalized MNPs contains 0.4 wt % iron oxide nanoparticles just by properly modifying 
the initial quantities of Fe3O4-68 NPs (4.5 mL of the MNPs suspended in DEG with            
1.33 wt % respect to Fe3O4 ~ 59.85 mg, 0.258 mol Fe3O4) and copolymer (0.2 g, 0.735 µmol).  
A.11 Doxorubicin Loading on Fe3O4 Coated PVCL-b-PAA2  
PVCL-b-PAA2 coated Fe3O4-68 NPs were dispersed in 15.0 mL buffer phosphate          
10 mM, (pH = 8.5), and then pH was adjusted to 7.4 (samples A7.4, B7.4 and C7.4, D 7.4) or 5.5           
(samples A5.5 and B5.5) by addition of HCL 0.1 M to provide smart nanocomposite 




for sample A and 0.4 wt % 
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of MNPs and 10.0 mg mL
-1 
copolymer for sample B by following the same procedure, which 
was reported in section A.10. Afterward, 5.0 mL aqueous solution of doxorubicin (DOX)               
(0.9 mg mL
-1 
for samples A, B and 1.5 mg mL
-1 
for samples C, D) was added to the 
suspension and the mixture was incubated at 25 °C at darkness for 72 h. After incubation the 
DOX-loaded nanocomposite suspension was dialyzed against buffer phosphate 10 mM,       
pH = 7.4 or 5.5 using dialysis membrane bag (MWCO ~ 1 kDa) for 24 h to remove the non-
encapsulated drug. The concentration of free DOX in dialysis fluid was analyzed by UV-Vis 
spectroscopy at a specific wavelength 480 nm to determine the drug encapsulation efficiency 
(EE), and Drug Loading (DLC) Contents. A calibration curve of DOX in buffer phosphate     
10 mM, pH ~ 7.4 or pH ~ 5.5 was made as the reference.  
A.12 In Vitro Drug Release Behavior in the Absence of Alternating Magnetic Field (AMF) 
In order to study the pH and temperature dependence of the drug release kinetics in 
the absence of an AMF, 6 sets of experiments were performed. That means, the drug release 
was studied at 25 °C, 37 °C (physiological temperature, < LCST), and 48 °C (hyperthermia 
temperature, > LCST), and for each temperature, samples were held at pH = 7.4, the 
physiological pH, pH = 5.5, and pH = 4.5 to mimic acidic tumour pH values. Typically,        
5.0 mL of Fe3O4-68@PVCL-b-PAA2@DOX dispersed in buffer phosphate with the selected 
pH (7.4, 5.5 or 4.5) were inserted in a dialysis bag (MWCO ~ 14 kDa) and dialyzed against 
50.0 mL of buffer phosphate with the same pH value, under mild stirring. A dialysate volume 
of 10 times that of the dialysis bag was chosen to ensure sink conditions for the DOX. 
Moreover, this volume was required for the dialysis bag to be fully immersed in the medium. 
Dialysis set up were either maintained to room temperature, or placed into preheated water 
baths at 37 °C and 48 °C. At predetermined time points (i.e. 30 min, 1, 2, 3, 4, 5, 6,7, 24, 30, 
48, and 72 h), whole dialysate (50.0 mL) was taken out, and 50.0 mL of fresh buffer 
phosphate with the appropriate pH was added to preserve sink conditions. Afterward, the 
volume of 50.0 mL extracted dialysate was decreased to 5.0 mL by rotary evaporation at      
25 

C, so that the absorbance of DOX released in the dialysis fluid became in the detectable 
range of UV-Vis spectroscopy.  
 
A.13 Drug Release Under an Alternating Magnetic Field 
5.0 mL of sample A7.4 with an iron concentration of 0.14 wt % was placed in the 
magnetic coil of the instrument and then after the suspension was stabilized at the 
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physiological body temperature (37 °C), the AMF with f = 183 kHz and H = 17 kA m
-1
 was 
applied for different time interval (30, 40, 50, and 60 min). The sample, then, was taken out 
of the instrument after selected time interval, and centrifuged 15 min to separate the 
nanoparticles from supernatant. Nanoparticles were collected and redispersed in 5.0 mL fresh 
buffer phosphate 10 mM, pH = 7.4, and supernatant was analyzed by UV-Vis absorption 
spectroscopy at wavelength 480 nm for the evaluation of the amount of drug released. The 
amount of DOX released from sample A5.5 under the AMF was evaluated following the same 
procedure.  
 
A.14 Smart Hyperthermia with Switchable Drug Release 
5.0 mL of suspension of Fe3O4-68@PVCL-b-PAA2-DOX in buffer phosphate 10 mM, 
pH = 7.4 contains 0.4 wt % MNPs (B7.4) was placed in the copper coil. The AMF with 
frequency of 183 kHz and intensity of 17 kA m
-1 
was turned on for 10 min, allowing the 
nanocomposite suspension to be heated up to 50 

C. The AMF was then turned off, and 
allowed cooling down to 25 

C. This process was repeated for 6 times. The released DOX 
during each cycle was collected by centrifugation and its absorbance at 480 nm was measured 
by UV-Vis spectroscopy. The cumulated released DOX was calculated using the following 
equation, 
Cumulated released DOX = 
           
      
  100 (%) 
where              is the cumulative amount of released DOX at   cycle of AMF application 
and        is the total amount of incorporated DOX in the nanocomposite. 
Switchable drug release of sample (B5.5) was assessed by following the same procedure as 
sample (B7.4). 
 
A.15 Cytotoxicity Assay 
Cell viability against DOX loaded magnetic nanoparticles was investigated by WST-1 
assay on melanoma cancer cells (A375). Briefly, A375 human melanoma cells were seeded 
in 96-well plates in complete culture medium composed of Dulbecco's Modified Eagle's 
(DMEM) medium supplemented with 10.0 % fetal bovine serum (FBS), 10.0 mg mL
-1
 
penicillin G sodium and 10.0 mg mL
-1
 streptomycin sulfate. Indeed, about 5000 viable cells 
were added to each well of a 96-well culture plate and incubated at 37 

C under 5.0 % CO2 
atmosphere overnight to allow cells to attach to wells of cell culture plates. Then, the medium 
from A375 cells were replaced with 100.0 µL of fresh complete culture medium, containing 
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Fe3O4-68@PVCL-b-PAA2-DOX composed of 14.0 µg mL
-1
 DOX with different 
concentration of MNPs (0.065, 0.01, and 0.008 wt % Fe3O4) in triplet. Afterward, 100.0 µL 
of the crude toxin in addition to 10.0 µL of cell proliferation reagent WST-1 (Roche) were 
added to each well and incubated at 37 C under 5.0 % CO2 in a humidified incubator for 24 
h. Negative controls (medium culture) and positive controls (medium culture and cells) were 
also included in every experiment. After 24 h incubation, the absorbance of samples was 
measured in a microplate reader (Bio-Rad) at 450 nm. The percent cytotoxicity was 
calculated from the following equation:  
 
(A Experimental value−A negative control) / (A positive control−A negative control) ×100 
 
Where A Experimental value is the absorbance with the sample, A negative control is the 
absorbance with media control, and A positive control is the absorbance with cells control. 
 
Cytotoxicity of Fe3O4-68@PVCL-b-PAA2 MNCPs contains 0.25, 0.125, 0.0625, 0.01, 
and 0.008 wt % of Fe3O4 in 100.0 µL complete medium before drug loading was measured 
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Appendix B 
Instrumentations 
This section describes the instruments used for the characterization of magnetic 
nanoparticles, thermoresponsive polymers, and smart magnetic nanocomposite investigated 
in this study. These involve mainly the facilities for determination of particles size, 
morphology, and structure of magnetic nanoparticles, thermoresponsive polymers as well as 
smart nanocomposite. The instruments including DLS, ICP, DSC-TG, FTIR used in this work 
are located at Colorobbia Consulting S.r.l, while UV spectrometer, NMR, SQUID, XRD, and 
TEM are located at LAMM, Chemistry Department, University of Florence. Gel permeation 
chromatography analysis of polymers was performed at the Department of Industrial 
Chemistry of University of Pisa from the research group of Prof. F. Chiellini.  
B.1 GEL Permeation Chromatography 
The GPC apparatus used to determine the molecular weight of PVCL and            
PVCL-b-PVPON, consisted of a Waters™ 600 Controller equipped with a Waters 410 
Differential Refractometer and a Waters™ 600 Pump, managed by ChromNAV software 
(Jasco Europe, Lecco, Italy). A Plgel guard column and two PLgel Mixed D 5 μm columns 
(7.5   300 mm) (Agilent, CA, USA) were employed. The eluent was tetrahydrofuran 
CHROMASOLV
®
 Plus (THF) and the flow rate was maintained at 1.0 mL min
-1
. Polystyrene 
standards (Sigma-Aldrich) were used to obtain a calibration curve (2-1000 kDa). Prior to 
analysis the samples were dissolved in the eluent at a concentration of 5.0 mg mL
-1
 and 
filtered by using cellulose ester filters (0.2 μm). 
GPC analysis of PVCL-b-PAA was carried out with a Waters 600 model equipped 
with a Waters 410 Differential Refractometer and two Ultrahydrogel TM linear 6–13 μm 
columns (7.8 × 300 mm) (Fluka Analytical) at room temperature. Mobile phase constituted 
by water (HPLC grade) was eluted at a flow rate of 1.0 mL min
-1
. Polyethylene oxide 
standards (Polymer Laboratories, UK) were used to obtain a calibration curve                     
(Mn range 560–879000 g mol
-1
). Prior to analysis, the samples were dissolved in water at a 
concentration of 5.0 mg mL
-1
 and filtered by using cellulose ester filters (0.2 μm). 
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B.2 Dynamic Light Scattering 
DLS measurement was performed on 1.0-2.0 mL of dispersions of MNPs, polymers, 
or magnetic nanocomposite in water or buffer phosphate 10 mM at different pH, in a quartz 
cuvette. DLS was performed using a Nano-ZS Zetasizer (ZEN 3600-Malvern) equipped with 
a He–Ne laser (633 nm) at an angle of 173

.  
B.3 Zeta Potential Measurements 
Zeta potential measurements were carried out using a Nano-ZS Zetasizer (ZEN 3600-
Malvern) instrument. An equilibration time of 2 min was allowed before each measurement 
and at least five replicate measurements were made for each sample. 
B.4 Fourier Transform Infrared Spectroscopy 
The FT-IR spectra of the products were recorded with a double-beam Agilent 
Technology Cary 640 Series FTIR spectrometer in range of 4000–500 cm
-1
 using KBr pellets. 
B.5 ICP-AES 
The quantitative analysis of iron content was carried out with an Atomic Emission 
Spectrometer coupled with an Inductively Coupled Plasma torch (ICP-AES, Varian 710-ES). 
To analyze iron content, powder samples were digested with 2.0 mL of HNO3 and 2.0 mL of 
HCL. The calibration standard was prepared by serial dilution of a commercial standard 
solution of Fe 1000 mg mL
-1
. The wavelength used for the determination of Fe is 238 nm. 
The operating conditions were optimized to obtain maximum signal strength. 
B.6 DSC-TG 
 
TGA analyses have been performed using a NETZSCH STA 449C Jupiter instrument. 
Measurements were performed on about 50.0 mg of dried magnetic nanocomposite deposited 
into an alumina sample-holder. The scanning temperature range was set from room 




) and measurements were carried 
out under N2 flux. Results were elaborated with a Proteus Analysis (Netzsch) software. 
B.7 Turbidimetric Analysis 
 
UV-Vis spectroscopy (UV-Vis) measurements were performed at the Department of 
Organic Chemistry of the University of Florence (Prof. S. Cicchi) by recording the 
transmittance of 1.0 mL polymer aqueous solutions with a Varian Carry 4000 UV 
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spectrophotometer at a wavelength ranging from 200 nm to 800 nm. The measurements were 
carried out by monitoring change in transmittance as a function of temperature at 500 nm 
wavelength for PVCL, PVCL-b-PVPON, and 570 nm wavelength for PVCL-b-PAA. Before 
each measurement, the sample was left to equilibrate at the desired temperature for 5 min. 
 
B.8 Nuclear Magnetic Resonace (NMR)  
1
HNMR spectra of the copolymers were recorded on a Bruker 400 MHz NMR 
spectrometer. The copolymer solutions with concentrations of 1.0 mg mL
-1
 were prepared in 
CDCl3 or D2O, and measured at 25 





B.9 Transmission Electron Microscopy (TEM) 
The average diameter and size distribution of MNPs, polymers, and smart magnetic 
nanocomposite (MNCs) were determined by Transmission Electron Microscopy (TEM) 
images recorded using a CM12 PHILIPS transmission electron microscope operating at 100 
kV using a LaF6 source. Samples were prepared by drop drying a dilute aqueous suspension 
of MNPs, smart magnetic nanocomposite, or polymer solution (1.0 mg mL
-1
) onto 200 mesh 
carbon-coated copper grids. The recorded micrographs were processed by means of the iTEM 
TEM Imaging Platform software (Olympus), and were further analysed with the FIJI open 
software.  
B.10 XRD 
Powder X-ray diffraction (XRD) measurements were carried out using a Bruker D8 
Advance diffractometer equipped with Cu Kα (1.54178 Å) radiation and operating in θ−θ 
Bragg−Brentano geometry at 40 kV and 40 mA. Lattice parameters were evaluated on 
averaging over (400), (511) and (440) peaks. The determination of the mean crystallite 
diameter, d, was performed using the Scherrer equation, d = (0.9λ)/(β cosθ), where λ is the 
wavelength of the incident X-ray (1.54178 Å), θ the diffraction angle, and β the full-width at 
half-maximum. The quantification of the phase percentage was obtained analyzing the 
diffraction pattern by the Rietveld method with TOPAS software.  
B.11 Magnetic Characterization and SAR evaluation  
Magnetic measurements were performed using a Quantum Design MPMS SQUID 
magnetometer operating in the 1.8–350 K temperature range and with an applied field up to 
50 kOe. Measurements were performed on pressed powder of sample. All data were 
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corrected for the diamagnetic contribution of the sample holder, and were normalized to the 
amount of magnetic material as evaluated from elemental analysis. Zero Field Cooled–Field 
Cooled (ZFC/FC) curves were obtained by measuring the temperature dependence of the 
magnetization applying a probe magnetic field (50 Oe), after cooling the sample in the 
absence (ZFC) or in the presence (FC) of the field. A rough estimate of TB value accuracy is 
given by the half interval between the temperatures of two subsequent acquisition points, i.e., 
2.5 K. The field dependence of the magnetic moment (M vs. H) was measured cycling the 
field between ±50 kOe at 2.5 K and 300 K. The accuracy of HC, MR, and MS evaluation can 
be estimated as low as 3%. 
The evaluation of Specific Absorption Rate (SAR) was performed through 
calorimetric measurements by recording temperature kinetics of samples exposed to an 
alternating magnetic field. The instrument is adapted from a commercial setup, composed by 
a 6 kW Fives Celes power supply, a water-cooled induction coil and a series of variable 
capacitors (420 nF to 4.8 μF) for setting the required frequency. Such resonant RLC circuit is 
able to produce an alternating magnetic field in the range of 50–400 kHz and with amplitude 
up to 19.1 kA m
−1
 (Figure B.1) The frequency and field amplitude values used in this work 
(183 kHz, 17.0 kA m
−1
) were chosen in order to operate under the physiological limit,          






, beyond which deleterious responses of living tissues are observed. 
The sample was placed in the middle of the induction coil, inside a polystyrene sample holder 
placed in a glass Dewar connected to a glycol thermal bath in order to isolate the sample bath 
from the thermal gradient of the coils and from the environment (Figure B.2). The real 
amplitude of the magnetic field was determined by an AMF Life Systems high frequency 
probe. Measurements of the sample temperature were performed by an optical fiber 
thermometer connected to a digital temperature recorder (Fotemp).  
 
     Figure B.1 Power supply MP6-400 6kW®, Fives Celes Inc. and FoTemp optical fiber thermometer 
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Figure B.2 Detail of the Ethylene glycol thermostated system 
 
 
 
 
